BOARD OF TRUSTEES Public Meeting Agenda

HARRISHEALTH

Thursday, February 27, 2025 9:00 A.M.

BOARD ROOM

4800 Fournace Place, Bellaire, TX 77401

The meeting may be viewed online: http://harrishealthtx.swagit.com/live.

*Notice: Some Board Members may participate by videoconference.

Mission

Harris Health is a community-focused academic healthcare system dedicated to improving the health of those most in need in Harris County through quality care delivery, coordination of care and education.

AGENDA

I. Cal	ll to Order and Record of Attendance	Dr. Andrea Caracostis	2 min
II. Ap	proval of the Minutes of Previous Meeting	Dr. Andrea Caracostis	1 min
	Board Meeting – January 30, 2025		
	wayne and A Consider Decountations	Du Andrea Consessio	45
III. An	nouncements / Special Presentations	Dr. Andrea Caracostis	15 min
A.	CEO Report Including Special Announcements – Dr. Esmaeil Porsa		(10 min)
В.	Board Member Announcements Regarding Board Member Advocacy and Community Engagements		(5 min)
IV. <u>Pu</u>	blic Comment	Dr. Andrea Caracostis	3 min
V. Exe	ecutive Session	Dr. Andrea Caracostis	30 min
A. B.	Report Regarding Quality of Medical and Healthcare, Pursuant to Tex. Occ. Code Ann. §§151.002, 160.007 and Tex. Health & Safety Code Ann. §161.032 to Receive Peer Review and/or Medical Committee Report, Including Report of the Medical Executive Board in Connection with the Evaluation of the Quality of Medical and Healthcare Services, and also the Harris Health Quality, Safety Performance Measures, Good Catch Recipients, Centers for Medicare and Medicaid Services Quality Reporting with Possible Action Regarding this Matter Upon Return to Open Session — Dr. Andrea Caracostis, Dr. Steven Brass and Dr. Yashwant Chathampally Medical Executive Board Report and Credentialing Discussion, Pursuant to Tex. Occ. Code Ann. §§151.002, 160.007 and Tex. Health & Safety Code Ann. §161.032 to Receive Peer Review and/or Medical Committee Report, Including Consideration of Approval of Credentialing Changes for Members of Harris Health Medical Staff Upon Return to Open Session		(10 min)
	- Dr. Kunal Sharma and Dr. Asim Shah		

Board of Trustees I Board Meeting Agenda

February 27, 2025

Page **2** of **5**

C. Report Regarding Harris Health Correctional Health Quality of Medical and Healthcare, Including Credentialing Discussion and Operational Updates, Pursuant to Tex. Occ. Code Ann. §\$151.002, 160.007, Tex. Health & Safety Code Ann. §161.032 and Tex. Gov't Code Ann. §551.071 to Receive Peer Review and/or Medical Committee Report with Possible Action Upon Return to Open Session – Dr. O. Regaie Eains

(10 min)

VI. Reconvene to Open Meeting

Dr. Andrea Caracostis 2 min

VII. General Action Item(s)

Dr. Andrea Caracostis 4 min

- A. General Action Item(s) Related to Quality: Medical Staff
 - Consideration of Approval of Credentialing Changes for Members of Harris Health Medical Staff – Dr. Kunal Sharma

(2 min)

- B. General Action Item(s) Related to Quality: Correctional Health Medical Staff
 - 1. <u>Consideration of Approval of Credentialing Changes for Members of</u> Harris Health Correctional Health Medical Staff – *Dr. O. Reggie Egins*

(2 min)

VIII. Executive Session

Dr. Andrea Caracostis 45 min

D. Consultation with Attorney Regarding Expansion of Oncology Service Line on the LBJ Campus, to Include Radiation Therapy and Infusion Services, Pursuant to Tex. Gov't Code Ann. §§551.071, 551.085, and Possible Action Upon Return to Open Session – Ms. Sara Thomas and Dr. Esmaeil Porsa (20 min)

E. Consultation with Attorney Regarding Executive Orders, State and Federal Legislative Updates Impacting Harris Health, Pursuant to Tex. Gov't Code Ann. §551.071, and Possible Action Upon Return to Open Session

(15 min)

- Ms. Sara Thomas

(10 min)

F. Consultation with Attorney Regarding Interlocal Agreement with Harris County for Correctional Healthcare Services Between Harris County and Harris County Hospital District d/b/a Harris Health for Correctional Healthcare, Pursuant to Tex. Gov't Code Ann. §551.071, and Possible Action Upon Return to Open Session – Ms. Sara Thomas

IX. Reconvene to Open Meeting

Dr. Andrea Caracostis 5 min

X. Strategic Discussion

Dr. Andrea Caracostis 30 min

- A. Harris Health Strategic Plan Initiatives
 - Presentation Regarding Board Update on the 2025 Bond Issuance <u>Process – Mr. Christopher</u> <u>J. Janning, Hilltop Securities Inc. and</u> Masterson Advisors LLC

(10 min)

2. <u>Presentation Regarding the Harris Health 2026-2030 Strategic Plan</u>
<u>Update – *Ms. Maria Cowles and BRG*</u>

(10 min)

B. Committee Reports

(10 min)

- February 11, 2025 Quality Committee Dr. Andrea Caracostis
- February 13, 2025 Budget & Finance Committee *Mr. Jim Robinson*
- February 13, 2025 Compliance & Audit Committee Ms. Carol Paret

Board of Trustees I Board Meeting Agenda

February 27, 2025

Page **3** of **5**

XI. New Items for Board Consideration

Dr. Andrea Caracostis 11 min

n Harris

(1 min)

A. Consideration of Approval of the Interlocal Agreement between Harris County and Harris Health for Correctional Health Care Services

- Ms. Sara Thomas

B. Consideration of Approval of a Resolution Authorizing Proceedings to Issue and Sell Harris County Hospital District, Limited Tax Bonds, Series 2025; Authorizing the Preparation of all Financing and Offering Documents; Approving the Engagement of Professionals in Connection with the Issuance and Sale of the Bonds; and Making Other Provisions Regarding Such Bonds and Matters Incident Thereto – Ms. Victoria Nikitin

(5 min)

C. Consideration of Approval of Reimbursement Resolution Declaring Intent to Reimburse Certain Capital Expenditures – *Ms. Victoria Nikitin*

(5 min)

XII. Consent Agenda Items

Dr. Andrea Caracostis 5 min

- A. Consent Purchasing Recommendations
 - Consideration of Approval of Purchasing Recommendations
 (Items A1 through A3 of the Purchasing Matrix) Ms. Paige McInnis and
 Mr. Jack Adger, Harris County Purchasing Office

(See Attached Expenditure Summary: February 27, 2025)

2. <u>Harris Health Fourth Quarter of Fiscal Year 2024 Premier Spend Report</u> for Information Only – *Ms. Paige McInnis and Mr. Jack Adger, Harris*County Purchasing Office

B. Consent Committee Recommendations

- Consideration of Acceptance of the Harris Health First Quarter Fiscal Year 2025 Investment Report – Ms. Victoria Nikitin [Budget & Finance Committee]
- Consideration of Acceptance of the Harris Health Fourth Quarter Calendar Year 2024 Pension Plan Report – Ms. Victoria Nikitin [Budget & Finance Committee]
- Consideration of Acceptance of the Harris Health December 2024
 Financial Report Subject to Audit Ms. Victoria Nikitin

 [Budget & Finance Committee]
- Consideration of Acceptance of the Harris Health Single Audit Report of Federal and State Award Programs for the Year Ended September 30, 2024 – Mr. Chris Clark, FORVIS MAZARS, LLC [Compliance & Audit Committee]
- Consideration of Acceptance of the Harris Health Independent Auditor's Report and Financial Statements for the Year Ended September 30, 2024

 Mr. Chris Clark, FORVIS MAZARS, LLC

 [Compliance & Audit Committee]

C. Consent Contract Recommendations

1. Consideration of Approval of Contract Recommendations (Items C1 through C2 of the Contract Matrix)

- Dr. Amy Smith, Mr. Christopher Okezie and Mr. Jon Hallaway

(See Attached Expenditure Summary: February 27, 2025)

- D. New Consent Items for Board Approval
 - 1. Consideration of Acceptance of the Harris Health January 2025 Financial Report Subject to Audit - Ms. Victoria Nikitin
 - 2. Consideration of Approval to Acquire McGee, Troost, and LBJ Hospital Loop Streets in Exchange for Consideration and the Conveyance of **Easements to the City of Houston** - Mr. Louis Smith and Mr. Patrick Casey
 - 3. Consideration of Approval of the Revised Harris Health 2025 Board of Trustees Calendar - Ms. Sara Thomas
- E. Consent Reports and Updates to the Board
 - 1. Updates Regarding Pending State and Federal Legislative and Policy Issues Impacting Harris Health - Mr. R. King Hillier

{End of Consent Agenda}

XIII. Item(s) Related to the Health Care for the Homeless Program

- A. Review and Acceptance of the Following Reports for the Health Care for the Homeless Program (HCHP) as Required by the United States Department of Health and Human Services, which Provides Funding to the Harris County Hospital District d/b/a/Harris Health to Provide Health Services to Persons Experiencing Homelessness under Section 330(h) of the Public Health Service Act - Dr. Jennifer Small and Ms. Tracey Burdine
 - HCHP February 2025 Operational Update
- **B.** Consideration of Approval of the HCHP 2025 Sliding Fee Scale – Dr. Jennifer Small and Ms. Tracey Burdine

XIV. Executive Session **Dr. Andrea Caracostis** 50 min

- G. Review of the Health Care for the Homeless Program Director's Performance Evaluation, Pursuant to Tex. Gov't Code Ann. §551.085, Including Consideration of Approval of the Performance Evaluation Upon Return to Open Session - Dr. Jennifer Small and Ms. Tracey Burdine
- H. Review of the Community Health Choice, Inc. and Community Health Choice Texas, Inc. Unaudited, Financial Performance for the 12-month Year Ending December 31, 2024, Pursuant to Tex. Gov't Code Ann. §551.085 - Ms. Lisa Wright, CEO and Ms. Anna Mateja, CFO, Community Health Choice

Dr. Andrea Caracostis 10 min

(9 min)

(1 min)

(5 min)

(10 min)

Board of Trustees I Board Meeting Agenda

February 27, 2025

Page **5** of **5**

I. Consultation with Attorney Regarding Community Health Choice Litigation Settlement, Pursuant to Tex. Gov't Code Ann. §§551.071, 551.085, and Possible Action Upon Return to Open Session, Including Settlement of Litigation – Ms. Sara Thomas and Mr. Chris Buley, CLO, Community Health Choice (10 min)

J. Deliberation Regarding the Purchase, Exchange, Lease, or Value of Real Property, Pursuant to Tex. Gov't Code Ann. §551.072 – *Dr. Esmaeil Porsa*

(15 min)

K. Report by the Executive Vice President, Chief Compliance and Risk Officer, Regarding Compliance with Medicare, Medicaid, HIPAA and Other Federal and State Health Care Program Requirements, Including Status of Fraud and Abuse Investigations, Pursuant to Pursuant to Tex. Gov't Code Ann. §551.071 and Tex. Health & Safety Code Ann. §161.032, and Possible Action Regarding this Matter Upon Return to Open Session – Ms. Carolynn Jones

(10 min)

- XV. Reconvene Dr. Andrea Caracostis 2 min
- XVI. Adjournment Dr. Andrea Caracostis 1 min



MINUTES OF THE HARRIS HEALTH SYSTEM BOARD OF TRUSTEES

Board Meeting Thursday, January 30, 2025 9:00 A.M.

AGENDA ITEM	DISCUSSION	ACTION/RECOMMENDATION
I. Call to Order and Record of Attendance	The meeting was called to order at 9:00 a.m. by Dr. Caracostis, Chair. It was noted that a quorum was present and the attendance was recorded. Dr. Caracostis stated while some of Board members are in the room with us today, others will participate by videoconference as permissible by state law and the Harris Health Videoconferencing Policy. Only participants scheduled to speak have been provided dial in information for the meeting. All others who wish to view the meeting may access the meeting online through the Harris Health website: http://harrishealthtx.swagit.com/live .	* *
II. Approval of the Minutes of Previous Meeting	Board Meeting – December 12, 2024	Motion No. 25.01-01 Moved by Mr. Jim Robinson, seconded by Ms. Carol Paret, and unanimously passed that the Board approve the minutes of December 12, 2024 Board meeting. Motion carried.
III. Announcements/ Special Presentations	A. CEO Report Including Special Announcements Dr. Esmaeil Porsa, President and Chief Executive Officer (CEO), recognized Ms. Patricia Darnauer, Executive Vice President and Administrator of Lyndon B. Johnson (LBJ) Hospital, for her exceptional dedication and hard work throughout her tenure at Harris Health. He also announced her upcoming retirement. The Board joined in expressing their sincere appreciation for her valuable contributions.	As Presented.
	 B. Board Member Announcements Regarding Board Member Advocacy and Community Engagements Mr. Paul Puente attended the First Friday tour on January 10, 2025, which included a visit to the Settegast Health Center and the LBJ outpatient facility, where he engaged with the team and learned about the infrastructure. Mr. Jim Robinson stated that he also serves as the Chair of the Harris Central Appraisal District Board. He cautioned that there may be a serious attempt to reduce the operating funds hospital districts receive next year, potentially lowering the tax rate from 10% to 5%, which could significantly impact Harris Health. 	As Presented.
IV. Public Comment	Ms. Cynthia Cole, Executive Director of Local #1550 – AFSCME (American Federation of State, County, and Municipal Employees), spoke to the Board about employee concerns and issues.	As Presented.

	Ms. Sheila Taylor, a Council at Large (CAL) member, addressed the Board about changes to the CAL bylaws.	
	Ms. Alicia Reyes, a former Board member and current CAL member, also spoke to the Board regarding the CAL bylaws. Ms. Clarita Oliver, a CAL member, addressed the Board on the topic of the CAL bylaws. Mr. Josh Mica, a CAL member, also spoke to the Board regarding the CAL bylaws. Mr. Daniel Bustamante, a CAL member, addressed the Board regarding changes to the CAL bylaws.	
V. Executive Session	At 9:32 a.m., Dr. Caracostis stated that the Board would enter into Executive Session for Items V. 'A through C' as permitted by law under Tex. Health & Safety Code Ann. §161.032, Tex. Occ. Code Ann. §§151.002, 160.007 and Tex. Gov't Code Ann. §551.071.	
	A. Report Regarding Quality of Medical and Healthcare, Pursuant to Tex. Health & Safety Code Ann. §161.032, Tex. Occ. Code Ann. §\$160.007 and 151.002 to Receive Peer Review and/or Medical Committee Report, Including Report of the Medical Executive Board in Connection with the Evaluation of the Quality of Medical and Healthcare Services, and also the Harris Health Quality, Safety Performance Measures, Good Catch Recipients, Centers for Medicare and Medicaid Services Quality Reporting with Possible Action Regarding this Matter Upon Return to Open Session	No Action Taken.
	B. Medical Executive Board Report and Credentialing Discussion, Pursuant to Tex. Occ. Code Ann. §§151.002, 160.007 and Tex. Health & Safety Code Ann. §161.032 to Receive Peer Review and/or Medical Committee Report, Including Consideration of Approval of Credentialing Changes for Members of Harris Health Medical Staff Upon Return to Open Session	No Action Taken.
	C. Report Regarding Harris Health Correctional Health Quality of Medical and Healthcare, Including Credentialing Discussion and Operational Updates, Pursuant to Tex. Occ. Code Ann. §§151.002, 160.007, Tex. Health & Safety Code Ann. §161.032 and Tex. Gov't Code Ann. §551.071 to Receive Peer Review and/or Medical Committee Report with Possible Action Upon Return to Open Session	No Action Taken.
VI. Reconvene to Open Meeting	At 9:50 a.m., Dr. Caracostis reconvened the meeting in open session; she noted that a quorum was present, and that no action was taken in Executive Session.	

VII. General Action Item(s)		
	A. General Action Item(s) Related to Quality: Medical Staff	
	 Approval of Credentialing Changes for Members of the Harris Health System Medical Staff Dr. Kunal Sharma, Chair, Medical Executive Board, presented the credentialing changes for members of the Harris Health System Medical Staff. In December 2024, there were eighteen (18) initial appointments, thirteen (13) reappointments, five (5) changes/additions of privileges, and thirty-six (36) resignations. In January 2025, there were twenty-three (23) initial appointments, one hundred seventeen (117) reappointments, thirteen (13) changes/additions of privileges, and twenty-five (25) resignations. A copy of the credentialing report is available in the permanent record. 	Motion No. 25.01-02 Moved by Dr. Cody Pyke, seconded by Ms. Afsheen Davis, and unanimously passed that the Board approve agenda item VII.A.1. Motion carried.
	B. General Action Item(s) Related to Quality: Correctional Health Medical Staff	
	Medical Staff Dr. Otis Egins, Chief Medical Officer, Harris Health Correctional Health, presented the	Motion No. 25.01-03 Moved by Ms. Libby Viera - Bland, seconded by Dr. Cody Pyke, and unanimously passed that the Board approve agenda item VII.B.1. Motion carried.
	C. General Action Item(s) Related to Community Health Choice	
	Approval of the Reappointment of Members to the Community Health Choice, Inc. (CHC) and Community Health Choice Texas, Inc. (CHCT), Collectively "Community", Board of Directors	Motion No. 25.01-04 Moved by Dr. Cody Pyke, seconded by Mr. Jim Robinson, and unanimously passed that the Board approve agenda item VII.C.1. Motion carried.
	2. Approval of the Appointment of Members to the Community Health Choice, Inc. (CHC) and Community Health Choice Texas, Inc. (CHCT), Collectively "Community", Board of Directors	Motion No. 25.01-05 Moved by Ms. Libby Viera - Bland, seconded by Ms. Afsheen Davis, and unanimously passed that the Board approve agenda item VII.C.2. Motion carried.
	3. Community Health Choice Retirement Notification of Board Member, Raymond Khoury	For Information Only

		T
VIII. Executive Session	At 9:55 a.m., Dr. Caracostis stated that the Board would enter into Executive Session for Item VIII. 'D' as permitted by law under Tex. Gov't Code Ann. §§551.071 and 551.085.	
	D. Consultation with Attorney Regarding Expansion of Oncology Service Line on the LBJ Campus, to	Motion No. 25.01-06
	Include Radiation Therapy and Infusion Services, Pursuant to Tex. Gov't Code Ann. §§551.071, 551.085, and Possible Action Upon Return to Open Session	Moved by Dr. Andrea Caracostis, seconded by Dr. Cody Pyke, and unanimously passed that the
	Motion: to direct Administration to take necessary actions towards planning the expansion of Infusion Services and creation of Radiation Oncology Services at the Legacy Facility on LBJ Campus?	Board approve agenda item
IX. Reconvene to Open Meeting	At 10:36 a.m., Dr. Andrea Caracostis reconvened the meeting in open session; she noted that a quorum was present. The Board then took action on item VIII. "D" of the Executive Session agenda.	
X. Strategic Discussion		
	A. Harris Health Strategic Plan Initiatives	
	1. Presentation Regarding Governance Structure of the Patient and Family Advisory Council (PFAC)	As Presented.
	Mr. David Riddle, Administrative Director, Patient Experience, delivered a presentation	
	regarding Governance Structure of the Patient and Family Advisory Council (PFAC). He discussed	
	the PFAC model, current strategy, and governance, as well as the addition of Ambulatory Care	
	Services (ACS) to the PFAC governance. Ms. Ellen Aspinall, a member of the Ben Taub PFAC, and	
	Ms. Courtney Darton, a member of the LBJ PFAC, highlighted the contributions of their respective hospital PFACs for each pavilion. Dr. Jennifer Small, Executive Vice President of	
	Ambulatory Care Services, provided an update on the system-wide PFAC strategy. A discussion	
	followed regarding the PFAC model, which is endorsed by The Centers for Medicare & Medicaid	
	Services (CMS) and other organizations and will bring compliance across all platforms at Harris	
	Health. It was noted that CAL members could apply to join the PFAC. A copy of the presentation is available in the permanent record.	
	2. Presentation Regarding Harris Health's 2024 Employee Experience and Culture Survey Results	As Presented.
	Ms. Ashley Smith, Manager, Employee Experience & Culture, presented the results of Harris	
	Health's 2024 Employee Experience and Culture Survey. She highlighted a response rate of 72%,	
	with a target of 75%, and an engagement score of 79, with all pavilions scoring at or above the	
	benchmark for engagement. She also shared the top strengths of Harris Health and the major themes for 2024. A copy of the presentation is available in the permanent record.	

3. Presentation Regarding Harris Health's 2024 Medical Staff Engagement Summary Survey Results	As Presented.
Ms. Jessey Thomas, Senior Vice President, Medical Affairs, delivered a presentation on Harris Health's 2024 Medical Staff Engagement Summary Survey Results. She reported a response rate of 50.3%, compared to the NRC Health average response rate of 51.8%. She discussed the workplace experience loyalty measure, pavilion comparisons, and key drivers for 2024 related to the overall rating as a place to practice. She also covered the top strengths and opportunities, as well as the highest workplace experience score for 2024. A copy of the presentation is available in the permanent record.	
4. Presentation Regarding the Harris Health 2026-2030 Strategic Plan Update	As Presented.
Mr. Faisal Amin, Director, BRG, presented an update on the Harris Health 2026-2030 Strategic Plan. He touched upon the following topics: the Strategic Planning Process, Timing and the Board as a Key Stakeholder, Stakeholder Engagement, the Strategic Planning Structure, BRG's Rocket Strategy Model, and an update on Retreat Takeaways.	
Mr. Sam Moskowitz, Managing Director, BRG, provided an overview of the 2021–2025 Strategic Plan, highlighting the Mission, Vision, and Values. He reviewed the Board Retreat themes, compared Harris Health's mission and vision with those of similar systems, and Mr. Moskowitz discussed the current and proposed changes for the 2026-2030 Strategic Plan.	
Dr. Caracostis recommended allowing the board time to review the information and revisit it for feedback at a future meeting. She also requested that BRG contact each board member individually for their input. A copy of the presentation is available in the permanent record.	
B. January Committee Reports	As Presented.
 DEI Committee Ms. Libby Viera – Bland shared that the Diversity, Equity and Inclusion (DEI) Committee met on January 7, 2025 to discuss the following topics: 	
Ms. Ashley Smith, Manager Employee Experience & Culture, delivered a presentation on Harris Health's 2024 Employee Experience and Culture Survey results, which included the Safety Culture Survey. With a 72% response rate, 7,772 employees provided feedback. She covered key topics such as compensation, workplace safety, and change management (communication). She also highlighted the top strengths and opportunities for Harris Health, focusing on psychological safety, the major themes for 2024, engagement key performance indicators, and the next steps moving forward.	

Or. Chethan Bachireddy, Senior Vice President and Chief Health Officer, delivered a presentation on updates regarding Harris Health's population health, including efforts to accelerate health equity by addressing Health-Related Social Needs (HRSNs), the Health Equity Strategic Playbook, raising awareness through a systemwide campaign, HRSN screening in the inpatient setting, and empowering patients and staff through the Harris Health Cares initiative to connect with community resources.

• Quality Committee

Dr. Caracostis stated that the Quality Committee convened on January 7, 2025, and discussed the following topic:

 The monthly High Reliability Organization (HRO) video titled "Post Operative Infection Prevention" was viewed.

Joint Conference Committee

Dr. Caracostis stated that the Joint Conference Committee met on January 9, 2025 to discuss the following topics:

- Dr. Kunal Sharma, Chair of the Medical Executive Board, and Dr. Asim Shah, Vice Chair of the MEB, provided the Committee with an update on the activities of the MEB.
- o Dr. Tien Ko, Chief of Staff at LBJ, and Dr. Sandeep Markan, Chief of Staff at BT, shared updates on the system pavilions.
- Dr. Mohammad Zare, Assistant Chief of Staff at UT, provided an update on ambulatory care services, while Dr. Fareed Khan, Assistant Chief of Staff at BCM, updated the Committee on activities at the ACS.
- Ms. Jessey Thomas, Senior Vice President of Medical Affairs, and Ms. Maxia Webb, Customer Service Manager at NRC Health, presented Harris Health's 2024 Medical Staff Engagement Summary. During the presentation, Ms. Webb discussed the Workplace Experience Loyalty Measure, pavilion comparison charts, key drivers for 2024—such as the overall rating as a place to practice, comments from 2024, and themes for improvement opportunities.

XI. Consent Agenda Items		
	A. Consent Purchasing Recommendations	
	 Approval of Purchasing Recommendations (Items A1 through A7 of the Purchasing Matrix) A copy of the purchasing agenda is available in the permanent record. 	Motion No. 25.01-07 Moved by Mr. Jim Robinson, seconded by Ms. Libby Viera - Bland, and unanimously passed that the Board approve agenda item XI.A.1. Motion carried.
	B. Consent Grant Recommendations	
	Approval of Grant Recommendations (Items B1 through B2 of the Grant Matrix)	Motion No. 25.01-08 Moved by Dr. Cody Pyke, seconded by Ms. Ingrid
	A copy of the grant matrix is available in the permanent record.	Robinson, and unanimously passed that the Board approve agenda items XI.B. through XI.D. Motion carried.
	C. Consent Contract Recommendations	
	Approval of Contract Recommendations (Items C1 through C2 of the Contract Matrix)	Motion No. 25.01-08 Moved by Dr. Cody Pyke, seconded by Ms. Ingrid Robinson, and unanimously passed that the Board approve agenda items XI.B. through XI.D. Motion carried.
	D. New Consent Items for Board Approval	
	Acceptance of the Harris Health November 2024 Financial Report Subject to Audit	Motion No. 25.01-08 Moved by Dr. Cody Pyke, seconded by Ms. Ingrid Robinson, and unanimously passed that the Board approve agenda items XI.B. through XI.D. Motion carried.

	Houston Electric, LLC, at Lyndon B. Johnson Hospital, 5656 Kelley St., Houston, Harris County, Texas	Motion No. 25.01-08 Moved by Dr. Cody Pyke, seconded by Ms. Ingrid Robinson, and unanimously passed that the Board approve agenda items XI.B. through XI.D. Motion carried.
	E. Consent Reports and Updates to the Board	
	Updates Regarding Pending State and Federal Legislative and Policy Issues Impacting Harris Health System	For Information Only
	{End of Consent Agenda}	
XII. Item(s) Related to the Health Care for the Homeless Program		
	 (HCHP) as Required by the United States Department of Health and Human Services, which Provides Funding to the Harris County Hospital District d/b/a/Harris Health System to Provide Health Services to Persons Experiencing Homelessness under Section 330(h) of the Public Health Service Act HCHP January 2025 Operational Update 	Motion No. 25.01-09 Moved by Ms. Afsheen Davis, seconded by Ms. Ingrid Robinson, and unanimously passed that the Board approve agenda item XII.A. Motion carried.

	Ms. Burdine also presented the HCHP Patient Satisfaction Trending Data for Q3 and Q4, noting a slight decrease in scores. She attributed this decline to missed opportunities caused by provider vacancies, extended wait times, and a lack of a consistent provider community. However, she mentioned that the vacancies have been filled and they expect these issues to be resolved. Dr. LaResa Ridge, Medical Director for HCHP, presented the Q3 Quality Management Report, stating that HCHP met Health Resources and Services Administration (HRSA) benchmarks, as well as its internal benchmarks, for 13 out of 17 quality standards. The four areas needing improvement are childhood immunization status, diabetes A1c >9, maternal care (early entry into prenatal care), and HIV linkage to care. Action plans have been implemented to assess the effectiveness of these measures. A copy of the presentation is available in the permanent record.	
	B. Approval of the HCHP Consumer Advisory Council Report	Motion No. 25.01-10 Moved by Ms. Carol Paret, seconded by Mr. Jim Robinson, and unanimously passed that the Board approve agenda item XII.B. Motion carried.
	C. Approval of the HCHP Patient Satisfaction Report	Motion No. 25.01-11 Moved by Dr. Cody Pyke, seconded by Mr. Paul Puente, and unanimously passed that the Board approve agenda item XII.C. Motion carried.
	D. Approval of the HCHP Quality Management Report	Motion No. 25.01-12 Moved by Ms. Carol Paret, seconded by Ms. Ingrid Robinson, and unanimously passed that the Board approve agenda item XII.D. Motion carried.
XIII. Executive Session	At 12:12 p.m., Dr. Andrea Caracostis stated that the Board would enter into Executive Session for Items XIII. 'E and F' as permitted by law under Tex. Gov't Code Ann. §551.071 and Tex. Health & Safety Code Ann. §161.032.	

Minutes of the Board of Trustees Board Meeting – January 30, 2025 Page 10 of 10

	E. Consultation with Attorney Regarding Interlocal Agreement with Harris County for Correctional Healthcare Services Between Harris County and Harris County Hospital District D/B/A Harris Health for Correctional Healthcare, Pursuant to Tex. Gov't Code Ann. §551.071, and Possible Action Upon Return to Open Session	
	F. Report by the Executive Vice President, Chief Compliance and Risk Officer, Regarding Compliance with Medicare, Medicaid, HIPAA and Other Federal and State Health Care Program Requirements, Including Status of Fraud and Abuse Investigations, Pursuant to Pursuant to Tex. Gov't Code Ann. §551.071 and Tex. Health & Safety Code Ann. §161.032, and Possible Action Regarding this Matter Upon Return to Open Session	No Action Taken.
XIV. Reconvene	At 1:14 p.m., Dr. Cody Pyke, Vice-Chair, in lieu of Dr. Andrea Caracostis, reconvened the meeting in open session; she noted that a quorum was present, and that no action was taken in Executive Session.	
XV. Adjournment	There being no further business to come before the Board, the meeting adjourned at 1:14 p.m.	

I certify that the foregoing are the Minutes of the Harris Health System Board of Trustees Meeting held on January 30, 2025.

Respectfully Submitted,

Andrea Caracostis, MD, MPH, Chair

Carol Paret, BS, Secretary

Minutes transcribed by Cherry A. Pierson, MBA



Thursday, January 30, 2025 Harris Health Board of Trustees Board Meeting Attendance

BOARD MEMBERS PRESENT	BOARD MEMBERS ABSENT
Afsheen Davis	Sima Ladjevardian
Dr. Andrea Caracostis (Chair)	
Carol Paret (Secretary)	
Dr. Cody Pyke (Vice Chair)	
Ingrid Robinson	
Jim Robinson	
Libby Viera-Bland	
Paul Puente	

EXECUTIVE LEADERSHIP/STAFF/ SPECIAL INVITED GUESTS		
Alexander Barrie	Derek Curtis	
Alicia Reyes (Public Speaker)	Ebon Swofford (Harris County Attorney's Office)	
Amber Olig (BRG)	Elizabeth Hanshaw Winn (Harris County Attorney's Office)	
Amna Abbasi (BRG)	Ellen Aspinall	
Dr. Amy Smith	Dr. Esmaeil Porsa (Harris Health System, President & CEO)	
Anthony Williams	Esperanza "Hope" Galvan	
Ashley Smith	Faisal Amin (BRG)	
Carolyn Bartley	Dr. Glorimar Medina	
Carolynn Jones	Holly Gummert (Harris County Attorney's Office)	
Cathy Johnson	Jack Adger (Harris County Purchasing Office)	
Cherry Pierson	Dr. Jennifer Small	
Clarita Oliver (Public Speaker)	Jennifer Zarate	
Concepcion Espinosa	Jerald "Jerry" Summers	
Courtney Dalton	Jessey Thomas	
Cynthia Cole (Public Speaker: AFSME 1550)	John Matcek	
Daniel Bustamante (Public Speaker)	Jonathan Fombonne (Harris County Attorney's Office)	
Daniel Smith	Dr. Joseph Kunisch	
David Riddle	Josh Mica (Public Speaker)	

Virtual Attendee Notice: If you joined as a group and would like to be counted as present, please submit an email to: BoardofTrustees@harrishealth.org before close of business the day of the meeting.

HARRISHEALTH

EXECUTIVE LEADERSHIP/STAFF/ SPECIAL INVITED GUESTS							
Kiki Teal	Patricia Darnauer						
Dr. Kunal Sharma	Patrick Casey						
Dr. LaResa Ridge	Randy Manarang						
Lindsey "Katie" Rutherford (Harris County Attorney's Office)	Sam Karim						
Louis Smith	Sam Moskowitz (BRG)						
Maria Cowles	Dr. Sandeep Markan						
Dr. Matasha Russell	Sara Thomas (Harris County's Attorney's Office)						
Matthew Schlueter	Shawn DeCosta						
Dr. Maureen Padilla	Sheila Taylor (Public Speaker)						
Micah Rodriguez	Dr. Steven Brass						
Michael Fritz (Harris County Attorney's Office)	Taylor McMillan						
Michael Hill	Tekhesia Phillips						
Dr. Michael Nnadi	Teresa Recio						
Dr. O. Reggie Egins	Dr. Tien Ko						
Obdulia Ramirez	Tracey Burdine						
Olga Rodriguez	Victoria Nikitin						
Omar Reid							

Virtual Attendee Notice: If you joined as a group and would like to be counted as present, please submit an email to: BoardofTrustees@harrishealth.org before close of business the day of the meeting.

17



Public Comment Registration Process

Pursuant to Texas Government Code Ann. §551.007, members of the public are invited to attend the regular meetings of the Harris Health Board of Trustees and may address the Board during the public comment segment regarding an official agenda item or a subject related to healthcare/patient care rendered at Harris Health. Public comment will occur prior to the consideration of all agenda items.

If you have signed up to attend as a public speaker attending virtually, a meeting link will be provided within 24-48 hours of the scheduled meeting. Notice: Virtual public speakers will be removed from the meeting after speaking and have the option to join the meeting live via http://harrishealthtx.swagit.com/live. You must click the "Watch Live" hyperlink in the blue bar, located

How to Request to Address the Board of Trustees

on the top left of the screen.

Members of the public must register in advance to speak at the Harris Health Board of Trustees Board meetings. Members of the public can contact the Board of Trustees Office during core business hours, Monday through Friday between 8:00 a.m. to 4:00 p.m. To register, members of the public must submit registration no later than 4:00 p.m. on the day before the scheduled meeting using one of the following manners:

- 1. Providing the requested information located in the "Speak to the Board" tile found at https://www.harrishealth.org/about-us-hh/board/Pages/registerForm.aspx
- Printing and completing the downloadable registration form found at https://www.harrishealth.org/about-us-hh/board/Documents/Public%20Comment%20Registration%20Form.pdf
- 3. Emailing a hard-copy of the completed registration form to BoardofTrustees@harrishealth.org
- 4. Mailing a completed registration form to 4800 Fournace Pl., Ste. E618, Bellaire, TX 77401
- 5. Contacting a Board of Trustees staff member at (346) 426-1524 to register verbally or by leaving a voicemail with the required information denoted on the registration form

Prior to submitting a request to address the Harris Health Board of Trustees, please take a moment to review the rules to be observed during the Public Comment Period.

Rules During Public Comment Period

The presiding officer of the Board of Trustees or the Board Secretary shall keep the time for speakers.

Three Minutes

A speaker, whose subject matter, as submitted, relates to an identifiable item of business on the agenda, will be requested by the presiding officer to come to the podium where they will be provided three (3) minutes to speak. A speaker, whose subject matter, as submitted, does not relate to an identifiable item of business on the agenda, will also be provided three (3) minutes to speak. A member of the public who addresses the body through a translator will be given at least twice the amount of time as a member of the public who does not require the assistance of a translator.

harrishealth.org

HARRISHEALTH

Meeting of the Board of Trustees

- Page 19 Was Intentionally Left Blank -

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Executive Session

Report Regarding Quality of Medical and Healthcare, Pursuant to Tex. Occ. Code Ann. §151.002, 160.007 and Tex. Health & Safety Code Ann. §161.032 to Receive Peer Review and/or Medical Committee Report, Including Report of the Medical Executive Board in Connection with the Evaluation of the Quality of Medical and Healthcare Services, and also the Harris Health Quality, Safety Performance Measures, Good Catch Recipients, Centers for Medicare and Medicaid Services Quality Reporting with Possible Action Regarding this Matter Upon Return to Open Session.

Dr. Yashwant Chathampally

Associate Chief Medical Officer, Senior Vice President – Quality & Patient Safety

HARRISHEALTH

Meeting of the Board of Trustees

- Page 21 Was Intentionally Left Blank -

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Executive Session

Medical Executive Board Report and Credentialing Discussion, Pursuant to Tex. Occ. Code Ann. §\$151.002, 160.007 and Tex. Health & Safety Code Ann. §161.032 to Receive Peer Review and/or Medical Committee Report, Including Consideration of Approval of Credentialing Changes for Members of Harris Health Medical Staff Upon Return to Open Session.

Dr. Yashwant Chathampally

Associate Chief Medical Officer, Senior Vice President – Quality & Patient Safety

HARRISHEALTH

Meeting of the Board of Trustees

- Pages 23 - 38 Were Intentionally Left Blank -

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Executive Session

Report Regarding Harris Health Correctional Health Quality of Medical and Healthcare, Including Credentialing Discussion and Operational Updates, Pursuant to Tex. Occ. Code Ann. §151.002, 160.007, Tex. Health & Safety Code Ann. §161.032 and Tex. Gov't Code Ann. §551.071 to Receive Peer Review and/or Medical Committee Report with Possible Action Upon Return to Open Session.

O. Reggie Egins, MD, CCHP-CP

Chief Medical Officer - Correctional Health

HARRISHEALTH

Meeting of the Board of Trustees

- Pages 40 - 43 Were Intentionally Left Blank -

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Consideration of Approval Regarding Credentialing Changes for Members of the Harris Health Medical Staff

The Harris Health Medical Executive Board approved the attached credentialing changes for the members of the Harris Health Medical Staff on February 11, 2025.

The Harris Health Medical Executive Board requests the approval of the Board of Trustees.

Thank you.

Dr. Yashwant Chathampally

Associate Chief Medical Officer, Senior Vice President – Quality & Patient Safety

Board of Trustees



February 2025 Medical Staff Credentials Report

Medical Staff Initial Appointments: 21
BCM Medical Staff Initial Appointments - 10
UT Medical Staff Initial Appointments - 9
HCHD Medical Staff Initial Appointments - 2
Medical Staff Reappointments: 54
BCM Medical Staff Reappointments - 21
UT Medical Staff Reappointments - 31
HCHD Medical Staff Reappointments - 2
BCM/UT/Harris County Hospital District (Harris Health) Medical Staff Changes in Clinical Privileges: 2
BCM/UT/HCHD Medical Staff Resignations: 15
Other Business
For Information
Temporary Privileges Awaiting Board Approval - 14
Urgent Patient Care Need Privileges Awaiting Board Approval - o
organic rations care reconstructions and approval-to
BCM/UT/Harris County Hospital District (Harris Health) Medical Staff Files for Discussion: 2
Medical Staff Initial Appointment Files for Discussion - 2
Medical Staff Reappointment Files for Discussion - 0

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Consideration of Approval of Credentialing Changes for Members of the Harris Health Correctional Health Medical Staff

The Harris Health Correctional Health Medical Executive Committee approved the attached credentialing changes for the members of the Harris Health Correctional Health Medical Staff on February 10, 2025.

The Harris Health Correctional Health Medical Executive Committee requests the approval of the Board of Trustees.

O. Reggie Egins, MD, CCHP-P

Chief Medical Officer of Correctional Health

Board of Trustees



February 2025 Correctional Health Credentials Report

Medical Staff Initial Appointments: 2	
Medical Staff Reappointments: 10	
Medical Staff Resignations: 1	
Medical Staff Files for Discussion: o	

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Executive Session

Consultation with Attorney Regarding Interlocal Agreement with Harris County for Correctional Healthcare Services Between Harris County and Harris County Hospital District D/B/A Harris Health for Correctional Healthcare, Pursuant to Tex. Gov't Code Ann. §551.071, and Possible Action Upon Return to Open Session.

Sara Thomas

Chief Legal Officer/Division Director Harris County Attorney's Office Harris Health

imas

HARRISHEALTH

Meeting of the Board of Trustees

- Pages 49 - 155 Were Intentionally Left Blank -

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Board of Trustees Update on the 2025 Bond Issuance Process

Representatives from the financial advisory firm Hilltop Securities Inc. will provide a presentation updating the Board of Trustees on to the 2025 bond issuance process.

Victoria Nikitin

EVP - Chief Financial Officer



Harris County Hospital District

Limited Tax Bonds, Series 2025

February 27, 2025

Executive Summary



Harris Health in collaboration with Harris County is seeking to issue its first tranche of voter-approved hospital district bonds in May 2025

- November 2023, Harris County voters approved \$2.5 billion to fund facility improvements including renovations at the Lyndon B. Johnson (LBJ) Hospital, Ben Taub Hospital, and district clinics and health centers and levying a tax to repay the bonds.
- Since January 2024, the Harris Health/County finance working group has worked to refine appropriation and cash flow requirements to finance the LBJ Expansion Project
- May 2025, Harris Health is undertaking the first issuance of voter approved bonds in an amount not to exceed \$850 million, the amount of which has been determined by projected cash flow requirements through March 2026
- Timing of the expected future issuances to be determined in consultation with the County, tentatively
 March 2026 and June 2027
- As required by state statute, Harris County Commissioners Court must approve the issuance of the bonds in addition to Harris Health's approval

Preliminary Timeline



Feb-25											
S	М	Т	W	Th	F	S					
						1					
2	3 10	4	5	6	7	8					
9	10	11	12	13	14	15					
16	17	18	19	20	21	22					
23	24	25	26	27	28						

Mar-25					Apr-25								May-25									
S	М	Т	W	Th	F	S		S	М	Т	W	Th	F	S		S	М	Т	W	Th	F	S
						1				1	2	3	4	5						1	2	3
2	3	4	5	6	7	8		6	7	8	9	10	11	12		4	5	6	7	8	9	10
9	10	11	12	13	14	15		13	14	15	16	17	18	19		11	12	13	14	15	16	17
16	17	18	19	20	21	22		20	21	22	23	24	25	26		18	19	20	21	22	23	24
23	24	25	26	27	28	29		27	28	29	30					25	26	27	28	29	30	31
30	31			-		issic ess C			ourl	t			Н	lolid	ay				FON	MC I	Vlee	eting

Date	Action
	Harris Health Board Meeting
Thu - Feb 27	 HH Board requests Commissioners Court to approve "Go Forward" order
	 HH Board Considers Adoption of Reimbursement Resolution for Routine Capital Costs
	Harris County - Business Court Meeting - Consider "Go Forward" Order
Wed - Mar 5	 Allows for HH Finance Working Group to initiate the formal issuance process, including appointing
	all firms necessary to execute transaction, including legal and underwriting firms
Thu - Mar 27	Harris Health Board Meeting – Consider Adoption of Bond Order and other bond documents, including the Preliminary Official Statement "POS"
Thu - Apr 10	Commissioners Court - Considers approval of the sale of the bonds via "Parameter Sale" and approving other bond related documents, including the POS
Tue – May 13	Bond Pricing – Bond Sale Date locks in interest rates and repayment structure
Tue - May 27	Closing – District received bond proceeds
Thu - Jun 12	Commissioners Court - Ratification

Plan of Finance



- The Plan of Finance for the total Project consists of Harris Health cash flow from operations and three bond issuances, with the first issuance occurring in 2025 and subsequent issuances tentatively in 2026 and 2027
- The initial debt issuance consists of up to \$850 million of Limited Tax Bonds, Series 2025 for the purpose of funding the following <u>estimated</u> uses of bond proceeds:
 - ~\$300 million to reimburse cash outlays for Project costs funded by District cash
 - \$543 million deposit into Project Fund to fund future construction draws through March 2026
 - Remaining amounts to fund financing costs


Calendar Year	Beg. Balance	Expenses	Bond Funding (1)	Cash Funding (1)	End Balance
2022	-	(5,721,416)	-	-	(5,721,416)
2023	(5,721,416)	(29,189,919)	-	-	(34,911,335) -
2024	(34,911,335)	(122,779,497)	-	-	(157,690,832) -
2025	(157,690,832)	(545,959,882)	840,000,000	-	136,349,286
2026	136,349,286	(648,026,038)	830,000,000	-	318,323,248
2027	318,323,248	(694,575,173)	830,000,000	-	453,748,075
2028	453,748,075	(591,400,061)	-	137,651,986	-
2029	-	(202,545,191)	-	202,545,191	-
2030	-	(226,883,970)	-	226,883,970	-
2031	-	(147,485,971)	-	147,485,971	-
2032	-	(33,770,834)	-	33,770,834	-
2033	-	(28,179,165)	-	28,179,165	-
2034	-	(19,091,667)	-	19,091,667	-
_		(3,295,608,784)	2,500,000,000	795,608,784	

Initially, funded from District cash – to be reimbursed by a portion of bond proceeds

⁽¹⁾ For purposes of illustration. Excludes interest earnings

Pro Forma Debt Service – 2025 Bonds





¹ Preliminary, subject to change. Assumes "Aa1/AA" rated market interest rates as of January 13, 2025 + 25 bps

Contacts



Christopher J. Janning

Hilltop Securities Inc.

Managing Director | Investment Banker
717 N Harwood St, Suite 3400 | Dallas, TX 75201
direct: 214.953.4042 | work mobile: 214.225.6653
christopher.janning@hilltopsecurities.com | HilltopSecurities.com

Mario Hernandez

Hilltop Securities Inc.

Vice President | Investment Banker
717 N Harwood St, Suite 3400 | Dallas, TX 75201
direct: 214.953.4182 | work mobile: 469.830.2178

Mario.Hernandez@hilltopsecurities.com | HilltopSecurities.com

Tina Arias Peterman Managing Director

Masterson Advisors LLC 3 Greenway Plaza, Suite 1100 Houston, TX 77046 Phone & Text 713-814-0564 | Tina.Peterman@MastersonAdvisors.com

Jonathan Church Director

Masterson Advisors LLC
P 713-814-0562 (Voice and Text)
Email Jonathan.Church@MastersonAdvisors.com

BOARD OF TRUSTEES

HARRISHEALTH

Meeting of the Board of Trustees

- Pages 163 - 172 Were Intentionally Left Blank -

BOARD OF TRUSTEES

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Presentation Regarding the Harris Health 2026-2030 Strategic Plan Update

Maria M. Cowles

EVP, Chief Strategy Officer and Chief of Staff



THINKBRG.COM



Update & Discussion with the Board of Trustees Harris Health's 2026 - 2030 Strategic Plan

February 27, 2025



Milestone:

Create Harris Health

Roadmap with Leadership

Sign-Off; Development &

Implementation of an Initial

Communications Plan



Strategic Planning Approach

Phases 1 & 2 Merged:
Approach, Process, Design and Data Analytics
Active Stakeholder Engagement to Develop Plan

Phase 3:
Preliminary Plan
Development

Phase 4: Development of Final Strategic Plan Optional Phase 5: Development/ Activation of Implementation Plan

November 2024-January 2025

Milestone:

Develop & Present Leadership with Initial Engagement Findings with Early Recommendations on the Direction of the Strategic Plan February 2025-May 2025

Milestones:

1st and 2nd Drafts of Strategic Plan to Leadership & Stakeholders **June 2025- October 2025**

Milestones:

Gain Leadership and Board Approval of Strategic Plan; Development and Roll-out of Communication October 2025-Forward

Milestone:

Creation and
Implementation of Plan with
Designated Performance
Metrics Identified and
Tracked







Stakeholder Engagement

30+ 9====

15+ Presentations

100+
Artifacts Received & Produced



Focus Groups
Completed

2+ Surveys & Questionnaires 1000+



Survey Feedback







Extensive Stakeholder Engagement Continues







Common Themes | Internal Stakeholders

Expanding Access to Care

- Increased focus on ambulatory network.
- Addressing appointment availability.
- Enhancing care pathways from acute to ambulatory.
- Strengthen health promotion & disease management efforts.
- Expand mobile & community-based services.

Workforce & Operational Resilience

- Recruitment & retention challenges.
- Addressing healthcare worker shortages.
- Leadership development & agility.

Financial & Strategic Growth

- Opportunities in valuebased care models.
- Financial headwinds.
- Need for improved cost efficiency & supply chain strategies.

Digital Transformation

- Technology gaps & data availability remain concerns.
- Need for a data-driven organization.
- Opportunities to leverage system-wide integration.





Common Themes | External Stakeholders

Community Access & Health Equity

- Improve access to primary & specialty care.
- Address disparities in underserved communities.
- Expand mobile & community-based services.
- Improve access to food security, housing, and transportation resources.
- Foster stronger collaboration with local organizations & policymakers.

Collaboration & Strategic Partnerships

- Strengthen alliances with community health providers.
- Integrate with hospitals, academia, & public agencies.
- Expand public-private partnerships.
- Enhance collaboration with local partners to drive impact.

Patient Experience, Engagement & Trust

- Improve communication
 & patient engagement.
- Build trust through culturally competent care.
- Reduce wait times & enhance coordination.
- Promote proactive care & long-term health management.

Innovation & Financial Sustainability

- Develop sustainable funding models.
- Advocate for state & federal support.
- Explore innovative financial & operational strategies.
- Leverage technology & data for smarter decision-making.






BRG



Board of Trustees Engagement Moving Forward







Milestone:

Create Harris Health

Roadmap with Leadership

Sign-Off; Development &

Implementation of an Initial

Communications Plan



Strategic Planning Approach

Phases 1 & 2 Merged:
Approach, Process, Design and Data Analytics
Active Stakeholder Engagement to Develop Plan

Phase 3:
Preliminary Plan
Development

Phase 4: Development of Final Strategic Plan Optional Phase 5: Development/ Activation of Implementation Plan

November 2024-January 2025

Milestone:

Develop & Present Leadership with Initial Engagement Findings with Early Recommendations on the Direction of the Strategic Plan February 2025-May 2025

Milestones:

1st and 2nd Drafts of Strategic Plan to Leadership & Stakeholders **June 2025- October 2025**

Milestones:

Gain Leadership and Board Approval of Strategic Plan; Development and Roll-out of Communication October 2025-Forward

Milestone:

Creation and
Implementation of Plan with
Designated Performance
Metrics Identified and
Tracked







Questions & Feedback





BOARD OF TRUSTEES

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Committee Reports

Committee Meetings:

- Quality Committee February 11, 2025
 - A summary was attached for your review.
 - Harris Health Safety Message: Minute for Medicine Video
 - Ventilator Associated Pneumonia (VAP)
- Budget & Finance Committee February 13, 2025
 - o Harris Health First Quarter Fiscal Year 2025 Investment Report
 - o Harris Health Fourth Quarter Calendar Year 2024 Pension Plan Report
 - o Harris Health December 2024 Financial Report Subject to Audit
 - o Brief Update Regarding Upcoming Bond-related Items
- Compliance & Audit Committee February 13, 2025
 - Presentation Regarding the Harris Health Independent Auditor's Report and Overview for the Year Ended September 30, 2024
 - Harris Health Single Audit Report of Federal and State Award Programs for the Year Ended September 30, 2024
 - Harris Health Independent Auditor's Report and Financial Statements for the Year Ended September 30, 2024
 - Presentation Regarding the Harris Health Quarterly Internal Audit Update as of February 13, 2025



Board of Trustees – Executive Summary
Patient Safety & Quality Programs – Open Session Presentation
February 27, 2025

Please refer to the reports presented at the Quality Committee Meeting Open Session on February 11, 2025 for additional details.

HRO Safety Message - Video: Ventilator Associated Pneumonia

High-reliability Organizations (HROs) are those that successfully complete their missions despite massive complexity and high risk. Examples include the Federal Aviation Administration's Air Traffic Control system, aircraft carriers, and nuclear power plants. In each case, even a minor error could have catastrophic consequences. Yet, adverse outcomes in these organizations are rare. Five principles of a High Reliability Organization (HRO) are: (1) Preoccupation with failure; (2) Reluctance to simplify interpretations; (3) Sensitivity to operations; (4) Commitment to resilience; and (5) Deference to expertise.

Meeting of the Board of Trustees

Thursday, February 27, 2025

Consideration of Approval of a Resolution Authorizing Proceedings to Issue and Sell Harris

County Hospital District, Limited Tax Bonds, Series 2025; Authorizing the Preparation of
all Financing and Offering Documents; Approving the Engagement of Professionals in

Connection with the Issuance and Sale of the Bonds; and Making Other Provisions

Regarding Such Bonds and Matters Incident Thereto

Overview:

Board approval of the proposed Resolution is necessary for Harris Health Finance Working Group to initiate the formal bond issuance process, including appointing all firms necessary to execute transaction, including legal and underwriting firms.

Background and Specifics:

- November 2003, Harris County voters approved \$2.5 billion to fund facility improvements including renovations at the Lyndon B. Johnson (LBJ) Hospital, Ben Taub Hospital, and district clinics and health centers and levying a tax to repay the bonds.
- Since January 2024, the Harris Health/County finance working group has worked to refine appropriation and cash flow requirements to finance the LBJ Expansion Project.
- May 2025, Harris Health is undertaking the first issuance of voter approved bonds in an amount not to exceed \$850 million, the amount of which has been determined by projected cash flow requirements through March 2026.
- Expected future issuances to occur in March 2006 and June 2027.
- As required by state statute, Harris County Commissioners Court must approve the issuance of the bonds in addition to Harris Health's approval.

Request:

Administration requests the Board's Approval of the Resolution Authorizing Proceedings to Issue and Sell Harris County Hospital District, Limited Tax Bonds, Series 2025; Authorizing the Preparation of all Financing and Offering Documents; Approving the Engagement of Professionals in Connection with the Issuance and Sale of the Bonds; and Making Other Provisions Regarding Such Bonds and Matters Incident Thereto prior to submission to the Harris County Commissioners Court for its approval.

Victoria Nikitin

EVP - Chief Financial Officer

RESOLUTION AUTHORIZING PROCEEDINGS TO ISSUE AND SELL HARRIS COUNTY HOSPITAL DISTRICT, LIMITED TAX BONDS, SERIES 2025; AUTHORIZING THE PREPARATION OF ALL FINANCING AND OFFERING DOCUMENTS; APPROVING THE ENGAGEMENT OF PROFESSIONALS IN CONNECTION WITH THE ISSUANCE AND SALE OF THE BONDS; AND MAKING OTHER PROVISIONS REGARDING SUCH BONDS AND MATTERS INCIDENT THERETO

WHEREAS, the Harris County Hospital District, d/b/a Harris Health System (the "District"), is a duly constituted hospital district operating pursuant to Article IX, Section 4 of the Texas Constitution, Chapter 281, Texas Health and Safety Code, as amended ("Chapter 281"), and an election held on November 20, 1965;

WHEREAS, pursuant to the laws of the State of Texas (the "State"), including particularly Chapter 281 and Chapter 1371, Texas Government Code, as amended, and an election held within the District on November 7, 2023, the Commissioners Court of Harris County, Texas (the "Commissioners Court") is authorized and has to the power to issue limited tax bonds, in the District's name on the District's faith and credit, to acquire, construct, equip, or enlarge District hospitals or the hospital system;

WHERAS, the Board of Trustees of the District (the "Board") has determined that it is in its best interest to request that the Commissioners Court authorize the issuance of Harris County Hospital District, Limited Tax Bonds, Series 2025 (the "Bonds"), for the purpose of financing the acquisition, construction, equipment, and/or enlargement of the District hospitals or the hospital system;

WHEREAS, to proceed with the issuance of the Bonds, the Board hereby acknowledges and affirms that (i) such legal services require specialized expertise and experience in municipal finance, federal tax law and federal and state securities laws and therefore cannot be adequately performed by the attorneys and supporting personnel of the District, (ii) such legal services cannot be reasonably obtained from attorneys in private practice under a contract providing for the payment of hourly fees without contingency because the District will not be obligated to pay any legal fees until the successful closing of the contemplated transaction, and (iii) entering into a contingent fee contract for legal services is in the best interest of the residents of the District because Co-Bond Counsel (defined herein) and Co-Disclosure Counsel (defined herein) will only be paid in the event that the contemplated transaction is completed and the Bonds successfully issued and delivered; and

WHEREAS, the Board further wishes to approve (1) the preparation of all financing, authorizing and offering documents, as required or appropriate, to be used in the public offering of the Bonds, (2) the engagement of Co-Bond Counsel, Co-Disclosure Counsel and the underwriting syndicate, all in connection with the issuance and sale of the Bonds, and (3) request the County's approval of such actions.

NOW, THEREFORE, BE IT RESOLVED, BY THE BOARD OF TRUSTEES OF HARRIS COUNTY HOSPITAL DISTRICT THAT:

ARTICLE I

AUTHORIZING PREPARATION OF FINANCING DOCUMENTS AND OFFERING DOCUMENTS

Section 1.1: The Board hereby authorizes the preparation of all necessary agreements, certificates, instruments and other documents, including without limitation, authorizing orders, resolutions, and a preliminary official statement, together with all ancillary, financing and offering documents that may be necessary or desirable for the issuance and sale of one or more series of Bonds in an aggregate amount not to exceed Eight Hundred Fifty Million Dollars (\$850,000,000). The Board reserves the right to amend such amounts in the order authorizing such Bonds, and to include in such orders the right to tax any and all administrative or judicial measures to ensure the sale, issuance and delivery of the Bonds.

ARTICLE II

ENGAGEMENT OF PROFESSIONALS

Section 2.1: Engagement of Professionals. The Board hereby approves the engagement of (1) Bracewell LLP and Bratton & Associates, PLLC, as Co-Bond Counsel ("Co-Bond Counsel"), and (2) Norton Rose Fulbright US LLP and Leon Alcala, PLLC, as Co-Disclosure Counsel ("Co-Disclosure Counsel"). The District hereby waives all conflicts of interest it may have to legal representation by these firms under the terms to be set out by the Harris County Attorney. The Chief Executive Officer of the District or any designee thereof is hereby authorized to enter into letter agreements with Co-Bond Counsel and Co-Disclosure Counsel in substantially the forms attached hereto as Exhibit A and Exhibit B. The prior engagement of Hilltop Securities Inc. and Masterson Advisors LLC, as Co-Financial Advisors to the District in connection with the Bonds, is hereby recognized and confirmed.

<u>Section 2.2</u>: <u>Approval of Underwriting Syndicate</u>. The District hereby approves the engagement of the underwriting syndicate in connection with the sale of the Bonds, as set forth in <u>Exhibit C</u>.

ARTICLE III

MISCELLANEOUS

Section 3.1: Authorization of Other Matters Relating Thereto. The Chief Executive Officer and Chief Financial Officer, or any one or more of such officials of the District (the "Officials") are hereby authorized and directed by the Board to do and perform all acts and things and to execute, acknowledge and deliver in the name, under the seal and on behalf of the District, all certificates, financing statements, instruments and other documents, whether or not herein mentioned, as are necessary or desirable to carry out the terms and provisions of this Resolution.

The Officials and such other officials and employees of the District as may be designated by the Officials are authorized to incur reasonable and necessary expenses in connection with the sale and delivery of the Bonds (and all other matters described herein), and for presentations to rating agencies, bond insurance companies, any other credit providers and prospective purchasers of the Bonds, if any. Necessary travel of the Officials and such other officials and employees of the District is hereby affirmed and approved. The expenditure of a portion of the proceeds of the Bonds for travel expenditures of the aforementioned is hereby affirmed and approved. All such persons shall be entitled to reimbursement by the District, as appropriate.

- Section 3.2: Further Proceedings. The Officials are hereby authorized and directed to do any and all things necessary and/or convenient to carry out the terms of this Resolution and any other related documents. During the term of the Bonds, the Officials are further authorized to act on behalf of the District in exercising any and all rights and options provided to the District and performing all obligations of the District pursuant to the terms of the Bonds.
- <u>Section 3.3:</u> <u>Severability.</u> If any section, paragraph, clause or provision of this Resolution shall for any reason be held to be invalid or unenforceable, the invalidity or unenforceability of such section, paragraph, clause or provision shall not affect any of the remaining provisions of this Resolution.
- Section 3.4: Open Meeting. It is hereby found, determined and declared that a sufficient written notice of the date, hour, place and subject of the meeting of the Commissioners Court at which this Order was adopted was posted at a place convenient and readily accessible at all times to the general public for the time required by law preceding this meeting, as required by the Open Meetings Law, Chapter 551, Texas Government Code, and that this meeting has been open to the public as required by law at all times during which this Order and the subject matter thereof has been discussed, considered and formally acted upon. The Commissioners Court further ratifies, approves and confirms such written notice and the contents and posting thereof.
- <u>Section 3.5:</u> <u>Repealer.</u> All orders, resolutions and ordinances, or parts thereof, inconsistent herewith are hereby repealed to the extent of such inconsistency.
- <u>Section 3.6:</u> <u>Effective Date</u>. This Resolution shall be in force and effect upon ratification and approval by the Commissioners Court.

	PASSED AND APPROVED this _	day of	, 2025.
		HARRIS CO DISTRICT	UNTY HOSPITAI
ATTEST:		Chair, Board o	of Trustees
Secretary, l	Board of Trustees		
(SEAL) At	tachments:		
	Co-Bond Counsel Professional Servi Co-Disclosure Counsel Professional Underwriting Syndicate		nent

EXHIBIT A

CO-BOND COUNSEL PROFESSIONAL SERVICES AGREEMENT

EXHIBIT B

CO-DISCLOSURE COUNSEL PROFESSIONAL SERVICES AGREEMENT

EXHIBIT C

UNDERWRITING SYNDICATE

Jefferies LLC

Siebert Williams Shank & Co., LLC

Stern Brothers

DA Davidson

Estrada Hinojosa

Piper Sandler & Co.

SWBC

Wells Fargo Securities LLP

CERTIFICATE OF SECRETARY

THE STATE OF TEXAS	§
COUNTY OF HARRIS	§
HARRIS COUNTY HOSPITAL DISTRICT	8

I, the undersigned Secretary of the Board of Trustees of the Harris County Hospital District, hereby certify as follows:

1. The Board of Trustees of the Harris County Hospital District, convened in a regular meeting on February 27, 2025, at the regular meeting place thereof, and the roll was called of the duly constituted officers and members of said Board, to wit:

Andrea Caracostis	Board Chair
Cody M. Pyke	Vice Chair
Carol Paret	Secretary
Afsheen Davis	Trustee
Sima Ladjevardian	Trustee
Paul J. Puente	Trustee
Ingrid Robinson	Trustee
Jim Robinson	Trustee
Libby Viera-Bland	Trustee

and all of said persons were present, except the following absentee(s): _____, thus constituting a quorum. Whereupon, among other business, the following was transacted at said meeting: a written

RESOLUTION AUTHORIZING PROCEEDINGS TO ISSUE AND SELL HARRIS COUNTY HOSPITAL DISTRICT, LIMITED TAX BONDS, SERIES 2025; AUTHORIZING THE PREPARATION OF ALL FINANCING AND OFFERING DOCUMENTS; APPROVING THE ENGAGEMENT OF PROFESSIONALS IN CONNECTION WITH THE ISSUANCE AND SALE OF THE BONDS; AND MAKING OTHER PROVISIONS REGARDING SUCH BONDS AND MATTERS INCIDENT THERETO

was duly introduced for the consideration of said Board. It was then duly moved and seconded that said resolution be adopted; and, after due discussion, said motion, carrying with it the adoption of said resolution prevailed and carried by the following vote:

	Member(s) shown present voted Member(s) shown present absta	
described in the said ordinance hand foregoing preeting pertain foregoing parage Board as indicas sufficiently notiche aforesaid meeting, said meeting for that public notice Chapter 551, Telegal or the said meeting for the public notice Chapter 551, Telegal or the said meeting for the public notice Chapter 551, Telegal or the said meeting for the public notice Chapter 551, Telegal or the said meeting for the public notice Chapter 551, Telegal or the said meeting for the said ordinance had not said meeting for the said meeting fo	e above and foregoing paragraph is has been duly recorded in said Bobaragraph is a true, full and correcting to the adoption of said ordinal graph are the duly chosen, qualified ted therein; that each of the office ified officially and personally, in a seeting, and that said ordinance wo, and each of said officers and ment r such purpose; that said meeting	
[SEAL]		Secretary, Board of Trustees Harris County Hospital District

Member(s) shown present voted "Aye."

THE STATE OF TEXAS	\$ \$ \$			
COUNTY OF HARRIS	\$ \$			
The Commissioners Court of Harcourt at the Harris County Administra 2025, and the roll was called of the du wit:	tion Building	in the City o	of Houston, Te	exas, on March 5,
Lina Hidalgo		County Judg	e	
Rodney Ellis			er, Precinct No	o. 1
Adrian Garcia			er, Precinct No	
Tom Ramsey, P.E.		Commission	er, Precinct No	o. 3
Lesley Briones		Commission	er, Precinct No	o. 4
and all of such persons were present, except,				
ORDER AUTHORIZING IS COUNTY HOSPITAL DISTRICT, IN THE PREPARATION OF ALL FINAND THE ENGAGEMENT OF IT ISSUANCE AND SALE OF THE REGARDING SUCH BONDS AND	ected: PROCEEDIN LIMITED TA ANCING DO PROFESSION BONDS; A MATTERS I	AX BONDS, CUMENTS, NALS IN C AND MAKI NCIDENT T	SERIES 2025 , OFFERING CONNECTIO NG OTHER THERETO	5; APPROVING DOCUMENTS, ON WITH THE PROVISIONS
ORDER AUTHORIZING IS COUNTY HOSPITAL DISTRICT, IN THE PREPARATION OF ALL FINAND THE ENGAGEMENT OF ISSUANCE AND SALE OF THE REGARDING SUCH BONDS AND Commissioner	PROCEEDIN LIMITED TA ANCING DO PROFESSION BONDS; A MATTERS I	AX BONDS, CUMENTS, NALS IN (AND MAKI NCIDENT 1 d the order ar seconded the	SERIES 2025 OFFERING CONNECTIO NG OTHER THERETO and made a mote motion for	5; APPROVING DOCUMENTS, ON WITH THE PROVISIONS tion that the same adoption of the
ORDER AUTHORIZING IS COUNTY HOSPITAL DISTRICT, IN THE PREPARATION OF ALL FINAND THE ENGAGEMENT OF ITSSUANCE AND SALE OF THE REGARDING SUCH BONDS AND Commissioner	PROCEEDIN LIMITED TA ANCING DO PROFESSION BONDS; A MATTERS I	AX BONDS, CUMENTS, NALS IN C AND MAKI NCIDENT T d the order as seconded the e order, prev	SERIES 2025 OFFERING CONNECTIO NG OTHER THERETO and made a mote motion for	5; APPROVING DOCUMENTS, ON WITH THE PROVISIONS tion that the same adoption of the
ORDER AUTHORIZING IS COUNTY HOSPITAL DISTRICT, IN THE PREPARATION OF ALL FINAND THE ENGAGEMENT OF ITSSUANCE AND SALE OF THE REGARDING SUCH BONDS AND Commissioner	PROCEEDIN LIMITED TA ANCING DO PROFESSION BONDS; A MATTERS I introduced adoption of the	AX BONDS, CUMENTS, NALS IN C AND MAKI NCIDENT T d the order as seconded the e order, prev	SERIES 2025 OFFERING CONNECTIO NG OTHER THERETO and made a mote motion for ailed by the fo	5; APPROVING DOCUMENTS, ON WITH THE PROVISIONS tion that the same adoption of the
ORDER AUTHORIZING IS COUNTY HOSPITAL DISTRICT, IN THE PREPARATION OF ALL FINAND THE ENGAGEMENT OF IT ISSUANCE AND SALE OF THE REGARDING SUCH BONDS AND Commissioner be adopted. Commissioner order. The motion, carrying with it the	PROCEEDIN LIMITED TA ANCING DO PROFESSION BONDS; A MATTERS I introduced adoption of th	AX BONDS, CUMENTS, NALS IN C AND MAKI NCIDENT T d the order ar seconded the e order, prev	SERIES 2025 OFFERING CONNECTIO NG OTHER THERETO and made a mote motion for ailed by the fo	5; APPROVING DOCUMENTS, ON WITH THE PROVISIONS tion that the same adoption of the
ORDER AUTHORIZING IS COUNTY HOSPITAL DISTRICT, IN THE PREPARATION OF ALL FINAND THE ENGAGEMENT OF ITSSUANCE AND SALE OF THE REGARDING SUCH BONDS AND Commissioner be adopted. Commissioner order. The motion, carrying with it the	PROCEEDIN LIMITED TA ANCING DO PROFESSION BONDS; A MATTERS I introduce adoption of th	AX BONDS, CUMENTS, NALS IN C AND MAKI NCIDENT T d the order ar seconded the e order, prev	SERIES 2025 OFFERING CONNECTIO NG OTHER THERETO and made a mote motion for ailed by the fo	5; APPROVING DOCUMENTS, ON WITH THE PROVISIONS tion that the same adoption of the
ORDER AUTHORIZING IS COUNTY HOSPITAL DISTRICT, IN THE PREPARATION OF ALL FINAND THE ENGAGEMENT OF IT ISSUANCE AND SALE OF THE REGARDING SUCH BONDS AND Commissioner be adopted. Commissioner order. The motion, carrying with it the Judge Lina Hidalgo Comm. Rodney Elli	PROCEEDIN LIMITED TA ANCING DO PROFESSION BONDS; A MATTERS I introduced adoption of the Year S Etia	AX BONDS, CUMENTS, NALS IN C AND MAKI NCIDENT T d the order ar seconded the e order, prev	SERIES 2025 OFFERING CONNECTIO NG OTHER THERETO and made a mote motion for ailed by the fo	5; APPROVING DOCUMENTS, ON WITH THE PROVISIONS tion that the same adoption of the

The County Judge thereupon announced that the motion had duly and lawfully carried and that the order had been duly and lawfully adopted. The order thus adopted follows:

ORDER AUTHORIZING PROCEEDINGS TO ISSUE AND SELL HARRIS COUNTY HOSPITAL DISTRICT, LIMITED TAX BONDS, SERIES 2025; APPROVING THE PREPARATION OF ALL FINANCING DOCUMENTS, OFFERING DOCUMENTS, AND THE ENGAGEMENT OF PROFESSIONALS IN CONNECTION WITH THE ISSUANCE AND SALE OF THE BONDS; AND MAKING OTHER PROVISIONS REGARDING SUCH BONDS AND MATTERS INCIDENT THERETO

WHEREAS, the Harris County Hospital District, d/b/a Harris Health System (the "District") has requested, pursuant to a resolution of its Board of Trustees (the "Board") passed on February 27, 2025, which is attached hereto as <u>Exhibit A</u>, that the Commissioners Court issue limited tax bonds in the name of the District and on the faith and credit of the District;

WHEREAS, pursuant to the laws of the State of Texas (the "State"), including particularly Chapter 281, Texas Health and Safety Code, as amended ("Chapter 281"), Chapter 1371, Texas Government Code, as amended ("Chapter 1371"), and an election held within the District on November 7, 2023 (the "Election"), the Commissioners Court of Harris County, Texas (the "Commissioners Court") is the appropriate entity to, is authorized, and has to the power to issue limited tax bonds, in the name and on the faith and credit of the District, to acquire, construct, equip, or enlarge District hospitals or the hospital system;

WHEREAS, the Commissioners Court has determined that the issuance of the limited tax bonds for the purpose of financing the acquisition, construction, equipment, and/or enlargement of the District facilities is in the best interests of the citizens of the District; and

WHEREAS, the Commissioners Court now proposes to issue Harris County Hospital District, Limited Tax Bonds, Series 2025 (the "Bonds"), pursuant to the provisions of Chapter 281, Chapter 1371, and the Election, to accomplish all or part of the purpose described in the preceding recital.

NOW, THEREFORE, BE IT ORDERED, ADJUDGED AND DECREED BY THE COMMISSIONERS COURT OF HARRIS COUNTY, TEXAS THAT:

ARTICLE I

APPROVAL AND RATIFICATION OF DISTRICT RESOLUTION

<u>Section 1.1:</u> The Commissioners Court hereby ratifies and approves the resolution of the Board of the District passed on February 27, 2025, which is attached hereto as <u>Exhibit A</u>, and such approval hereby authorizes the preparation of the financing documents, offering document and the selection of professionals to carry out the sale, issuance and delivery of the Bonds.

ARTICLE II

MISCELLANEOUS

<u>Section 2.1:</u> <u>Authorization of Other Matters Relating Thereto</u>. The County Judge, the County Clerk, the County Budget Officer, the Deputy Executive Director, Office of Management

and Budget, or any one or more of such officials of the County (the "Officials") are hereby authorized and directed by the Commissioners Court to do and perform all acts and things and to execute, acknowledge and deliver in the name, under the seal and on behalf of the County, all certificates, financing statements, instruments and other documents, whether or not herein mentioned, as are necessary or desirable to carry out the terms and provisions of this Order in coordination and conjunction with any authorized District officials.

The Officials and such other officials and employees of the County as may be designated by the Officials are authorized to incur reasonable and necessary expenses in connection with the sale and delivery of the Bonds (and all other matters described herein), and for presentations to rating agencies, bond insurance companies, any other credit providers, if any, and prospective purchasers of the Bonds. Necessary travel of the Officials and such other officials and employees of the County is hereby affirmed and approved. The expenditure of a portion of the proceeds of the Bonds for travel expenditures of the aforementioned is hereby affirmed and approved. All such persons shall be entitled to reimbursement by the County or the District, as appropriate.

- Section 2.2: Further Proceedings. The Officials are hereby authorized and directed to do any and all things necessary and/or convenient to carry out the terms of this Order and the exhibit attached hereto. During the term of the Bonds, the Officials are further authorized to act on behalf of the County and, if appropriate, the District, in exercising any and all rights and options provided to the County and performing all obligations of the County pursuant to the terms of the Bonds.
- <u>Section 2.3:</u> <u>Severability.</u> If any section, paragraph, clause or provision of this Order shall for any reason be held to be invalid or unenforceable, the invalidity or unenforceability of such section, paragraph, clause or provision shall not affect any of the remaining provisions of this Order.
- Section 2.4: Open Meeting. It is hereby found, determined and declared that a sufficient written notice of the date, hour, place and subject of the meeting of the Commissioners Court at which this Order was adopted was posted at a place convenient and readily accessible at all times to the general public for the time required by law preceding this meeting, as required by the Open Meetings Law, Chapter 551, Texas Government Code, and that this meeting has been open to the public as required by law at all times during which this Order and the subject matter thereof has been discussed, considered and formally acted upon. The Commissioners Court further ratifies, approves and confirms such written notice and the contents and posting thereof.
- <u>Section 2.5:</u> <u>Repealer</u>. All orders, resolutions and ordinances, or parts thereof, inconsistent herewith are hereby repealed to the extent of such inconsistency.
- <u>Section 2.6:</u> <u>Effective Date</u>. This Order shall be in force and effect from and after its passage on the date shown below, and the Resolution of the District, attached hereto as <u>Exhibit A</u>, shall take contemporaneous effect with the passage of this Order.

[Remainder of Page Intentionally Left Blank]

DOPTED this day of, 2025.
HARRIS COUNTY, TEXAS
County Judge Lina Hidalgo
h
oard of Trustees of the Harris County Hospital District

EXHIBIT A

RESOLUTION OF THE BOARD OF TRUSTEES OF THE HARRIS COUNTY HOSPITAL DISTRICT

THE STATE OF TEXAS §

COUNTY OF HARRIS §

I, the undersigned, the duly elected, qualified and acting County Clerk and Ex Officio Clerk of the Commissioners Court of Harris County, Texas, do hereby specify that the attached and foregoing is a true and correct copy of an order entitled:

ORDER AUTHORIZING PROCEEDINGS TO ISSUE AND SELL HARRIS COUNTY HOSPITAL DISTRICT, LIMITED TAX BONDS, SERIES 2025; AUTHORIZING THE PREPARATION OF ALL FINANCING AND OFFERING DOCUMENTS; APPROVING THE ENGAGEMENT OF PROFESSIONALS IN CONNECTION WITH THE ISSUANCE AND SALE OF THE BONDS; AND MAKING OTHER PROVISIONS REGARDING SUCH BONDS AND MATTERS INCIDENT THERETO

adopted by such Commissioners Court at a regular meeting, open to the public, held on March 5, 2025, together with an excerpt from the minutes of such meeting showing the adoption thereof, as same appears of record in the official minutes of such Commissioners Court on file in my office.

I further certify that the written notice of the date, hour, place and subject of the meeting of the Commissioners Court of Harris County, Texas, at which the foregoing order was adopted, was posted on a bulletin board located at a place convenient to the public in the Harris County Administration Building and readily accessible to the general public at the earliest possible time, pursuant to Chapter 551, Texas Government Code, as amended.

WITNESS MY HAND AND THE OFFICIAL SEAL OF SUCH COURT, this March 5, 2025.

TENESHIA HUDSPETH, County Clerk and Ex Officio Clerk of the Commissioners Court of Harris County, Texas

County Clerk Teneshia Hudspeth

[SEAL]

BOARD OF TRUSTEES

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Consideration of Approval of Reimbursement Resolution Declaring Intent to Reimburse Certain Capital Expenditures

Proposed Reimbursement Resolution

- ➤ Harris Health will make, or has made not more than 60 days prior to the date hereof, payments in the maximum principal amount of \$50,000,000 with respect to the certain capital maintenance for facilities, including the acquisitions of medical capital equipment, building improvements, information technology, and the purchase of other materials, land and rights of way, along with other related professional services, as further described in Exhibit A of the attached Resolution hereto (collectively, the "Financed Project").
- ➤ Harris Health desires to be reimbursed for the costs associated with the Financed Projects from the proceeds of obligations to be issued after the approval of this Reimbursement Resolution.
- Adopting the proposed reimbursement resolution allows Harris Health to reimburse itself for expenditures paid prior to the issuance of such obligations for such expenditures from proceeds of such obligations. In order for Harris Health to reimburse itself for these expenditures, IRS rules require adopting a resolution establishing the intent to reimburse such expenditures.

Victoria Nikitin

EVP - Chief Financial Officer

RESOLUTION DECLARING INTENT TO

REIMBURSE CERTAIN EXPENDITURES

WHEREAS, Harris County Hospital District d/b/a Harris Health System (the "Issuer") is a political subdivision of the State of Texas authorized to finance its activities by issuing obligations, including certificates of obligations pursuant to Section 271.041 et. seq. of the Texas Local Government Code, as amended and other applicable Texas law; and

WHEREAS, the Issuer will make, or has made not more than 60 days prior to the date hereof, payments with respect to the certain capital maintenance for facilities, including the acquisitions of medical capital equipment, building improvements, information technology, and the purchase of other materials, land and rights of way, along with other related professional services, as further described in Exhibit A hereto (collectively, the "Financed Project"); and

WHEREAS, in certain circumstances, federal and/or state law requires that the Issuer express its official intent to issue obligations to reimburse itself for expenditures paid prior to the issuance of such obligations for such expenditures to be eligible for reimbursement from proceeds of such obligations; and

WHEREAS, the Issuer desires to reimburse itself for the costs associated with the Financed Projects from the proceeds of obligations to be issued after the date hereof; and

WHEREAS, the Issuer reasonably expects to issue obligations to reimburse itself for the costs associated with the Financed Projects; and

WHEREAS, Section 1.150-2(d)(2) of the Treasury Regulations sets forth limitations regarding the timing of reimbursements made from the proceeds of certain obligations.

NOW, THEREFORE, be it resolved that:

- Section 1. The Issuer reasonably expects to reimburse itself for costs that have been or will be paid after the date that is 60 days prior to the date hereof and that are to be paid in connection with the acquisition, construction, rehabilitation, reconstruction or renovation of the Financed Projects from the proceeds of obligations to be issued subsequent to the date hereof.
- Section 2. The Issuer reasonably expects that the maximum principal amount of obligations issued to reimburse the Issuer for the costs associated with the Financed Projects will be \$50,000,000. Such obligations may be issued in one or more series.
- Section 3. Unless otherwise advised by bond counsel, any reimbursement allocation will be made not later than 18 months after the later of (1) the date the original expenditure is paid or (2) the date on which the Financed Project to which the expenditure relates is placed in service or abandoned, but in no event more than three years after the original expenditure is paid.

IM-#10617621.3

ADOPTED THIS	DAY OF	, 2025.
	By:	
	Name:	
Approved as to Legal Form Only:		
Christian D. Menefee Harris County Attorney		
, , ,		
By: Elizabeth Hanston Winn Title: Assistant County Attorney		

EXHIBIT A

DESCRIPTION OF FINANCED PROJECTS

<u>Description</u> <u>Amount</u>

Facilities and related capital maintenance \$47,574,000

Medical capital equipment \$2,426,000



Harris County Purchasing Agent

February 11, 2025

Board of Trustees Office Harris Health

RE: Board of Trustees Meeting – February 27, 2025 **Budget and Finance Agenda Items**

The Office of the Harris County Purchasing Agent recommends review of the attached procurement actions:

- A. Approvals
- B. Harris Health Premier Spend Report for Q4 FY2024 (information only, no action requested)

All recommendations are within the guidelines established by Harris County and Harris Health.

Sincerely,

Paige MoInnis

Paige McInnis Purchasing Agent

JA/ea

Attachments

Budget and Finance Agenda Items for the Harris County Hospital District dba Harris Health System - Board of Trustees Report Expenditure Summary: February 27, 2025 (Approvals)

No.	Vendor	Description Justification Contract	Action Basis of Recommendation Term	Project Owner	Previous Amount	E	Current Estimated Cost
A1		Service and Maintenance of Siemens Brand Equipment for Harris Health - To provide service and maintenance for Siemens brand equipment located throughout Harris Health. Sole Source Exemption	Purchase Sole Source Exemption One (1) year initial term with five (5) one-year renewal options	James Young		\$	1,983,217
A2	_	Service and Maintenance of Steris Brand Equipment for Harris Health - To provide service and maintenance for Steris brand sterilizers and operation room equipment located throughout Harris Health. Sole Source Exemption	Purchase Sole Source Exemption Three-year initial term	James Young		\$	1,024,507
A3	PROLIM Global Corporation PROLIM Global Corporation MWBE Goal: 16%	Information Technology Consulting and Staff Augmentation Services - A contract was previously awarded to Protiviti Inc. at the September 26, 2024 Board Meeting for Information Technology Consulting and Staff Augmentation Services. Protiviti Inc. was not able to contract with Harris Health, therefore the award to Protiviti Inc. is requested to be rescinded and awarded to the next highest scored vendor through the RFP process, PROLIM Global Corporation. Job No. 240174	Best proposal meeting requirements One (1) year initial term with four (4) one-year renewal options	Ronald Fuschillo		\$	840,000
			•		Total Expenditures	\$	3,847,724
					Total Revenue	\$	(0)

BOARD OF TRUSTEES

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Harris Health Fourth Quarter of Fiscal Year 2024 Premier Spend Report for Information Only

HARRIS HEALTH PREMIER Q4 SPEND FY2024	
SUPPLIER	Q4 SPEND FY2024
AMN HEALTHCARE, INC.	\$8,729,109
CARDINAL HEALTH 200, LLC	\$5,566,278
PHILIPS HEALTHCARE	\$4,854,057
MCKESSON PHARMACEUTICAL	\$3,748,973
CAREFUSION 303, INC.	\$3,336,840
US FOODS, INC.	\$3,292,943
MORRIS & DICKSON CO., LTD.	\$2,054,028
JOHNSON & JOHNSON HEALTH CARE SYSTEMS INC.	\$1,895,750
BOSTON SCIENTIFIC CORPORATION	\$1,335,827
BECTON, DICKINSON AND COMPANY	\$1,291,549
MEDLINE INDUSTRIES, LP	\$1,241,847
INSIGHT DIRECT USA, INC.	\$1,151,405
BAXTER HEALTHCARE CORPORATION	\$969,920
LABORATORY CORPORATION OF AMERICA HOLDINGS	\$763,751
GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC.	\$696,829
BECKMAN COULTER, INC.	\$692,312
AESCULAP, INC.	\$687,883
MASIMO AMERICAS, INC.	\$644,327
PARTSSOURCE, INC.	\$522,783
COVIDIEN SALES LLC	\$458,366
ABBVIE INC. DBA ABBVIE US LLC	\$446,566
FFF ENTERPRISES, INC.	\$432,962
SMITH & NEPHEW INC - ORTHOPAEDIC DIVISION	\$430,190
CLEAN HARBORS ENVIRONMENTAL SERVICES, INC.	\$412,776
CSL BEHRING	\$409,965
HILL-ROM COMPANY, INC.	\$393,033
AMGEN INC.	\$372,455
BAYER HEALTHCARE LLC	\$369,540
OLYMPUS AMERICA, INC.	\$369,413
ODP BUSINESS SOLUTIONS, LLC	\$369,303
BOEHRINGER LABORATORIES, LLC	\$366,085
ICU MEDICAL SALES, INC.	\$357,102
W.W. GRAINGER, INC.	\$353,205
MEDTRONIC, INC.	\$352,700
LSL INDUSTRIES, LLC DBA LSL HEALTHCARE	\$320,947
DRAEGER, INC.	\$309,041
CAREFUSION SOLUTIONS, LLC	\$306,348
SAGE PRODUCTS, LLC	\$298,640
STRYKER SALES, LLC DBA STRYKER ENDOSCOPY	\$289,034
FRESENIUS KABI USA, LLC	\$283,902
SYSMEX AMERICA, INC.	\$271,799
INARI MEDICAL, INC.	\$266,500
LEICA MICROSYSTEMS INC.	\$265,078
3M HEALTHCARE US OPCO LLC	\$240,905
ABBOTT LABORATORIES INC.	\$239,088
STERIS CORPORATION	\$238,633
NETWORK SERVICES COMPANY DBA NETWORK DISTRIBUTION	\$237,194
INC. I AND UK DELIVICED COINTENING DOWN NET MOUNT DISTRIBUTION	۶۷۵۱,194

HARRIS HEALTH PREMIER Q4 SPEND FY2024	
SUPPLIER	Q4 SPEND FY2024
FUJIFILM SONOSITE, INC.	\$215,820
S2S GLOBAL	\$202,914
PFIZER (GENERIC)	\$197,769
COOK MEDICAL LLC	\$194,820
KARL STORZ ENDOSCOPY-AMERICA, INC.	\$191,247
KCI USA, INC. DBA 3M MEDICAL SOLUTIONS	\$189,256
STRYKER SALES, LLC DBA STRYKER INSTRUMENTS	\$184,072
CARLISLE FOODSERVICE PRODUCTS	\$179,868
MUSCULOSKELETAL TRANSPLANT FOUNDATION	\$178,204
CDW	\$166,033
HENRY SCHEIN, INC.	\$164,140
EDWARDS LIFESCIENCES LLC	\$159,538
WELLS PHARMA OF HOUSTON, LLC	\$156,829
NOVA BIOMEDICAL CORPORATION	\$154,786
TELEFLEX LLC	\$151,525
GETINGE USA SALES, LLC	\$149,803
B. BRAUN MEDICAL INC.	\$145,632
GEORGIA-PACIFIC CONSUMER PRODUCTS LP	\$145,200
JUBILANT DRAXIMAGE INC.	\$143,624
PENUMBRA INC	\$139,195
ARAMARK UNIFORM AND CAREER APPAREL	\$138,365
MERIT MEDICAL SYSTEMS, INC.	\$135,497
MYLAN INSTITUTIONAL	\$130,747
FAGRON COMPOUNDING SERVICES, LLC DBA FAGRON STERILE SERVICES	\$129,746
GE HEALTHCARE INC.	\$126,850
FISHER SCIENTIFIC HEALTHCARE	\$122,673
GE PRECISION HEALTHCARE LLC	\$122,143
ECOLAB USA, INC.	\$116,776
BIOMERIEUX, INC.	\$111,701
LINDE GAS & EQUIPMENT INC.	\$110,459
SHARED IMAGING, LLC	\$109,950
CHIESI USA, INC	\$109,637
SUNMED GROUP HOLDINGS, LLC DBA AIRLIFE	\$108,704
MIDMARK SALES CORPORATION	\$107,952
PACTIV LLC	\$106,315
3M COMPANY	\$104,450
PDC HEALTHCARE (PRECISION DYNAMICS CORPORATION)	\$103,965
BAUSCH HEALTH US, LLC	\$103,115
NIHON KOHDEN AMERICA, LLC	\$100,836
ADVANCED STERILIZATION PRODUCTS SERVICES INC.	\$98,852
SHOCKWAVE MEDICAL, INC.	\$96,450
BARD PERIPHERAL VASCULAR, INC.	\$95,651
I.B.S. SOLUTIONS CORPORATION	\$95,475
PC CONNECTION, INC.	\$95,410
INTEGRA LIFESCIENCES CORPORATION	\$94,613
STANDARD TEXTILE CO., INC.	\$94,345
SOFIE CO.	\$93,060
JOHNE CO.	\$33,000

HARRIS HEALTH PREMIER Q4 SPEND FY2024	
SUPPLIER	Q4 SPEND FY2024
COUNTRY PURE FOODS, INC.	\$87,962
KIMBALL INTERNATIONAL BRANDS, INC.	\$87,256
RADIOMETER AMERICA INC.	\$85,904
BARD MEDICAL DIVISION	\$85,178
AT&T MOBILITY NATIONAL ACCOUNTS, LLC	\$83,119
HAMILTON MEDICAL, INC.	\$80,301
STRYKER SALES, LLC DBA STRYKER CRANIOMAXILLOFACIAL	\$79,724
LYFT	\$78,709
MCKESSON MEDICAL-SURGICAL INC.	\$78,572
VERATHON INC.	\$77,536
ANDWELL LLC	\$77,415
ASTELLAS PHARMA US, INC.	\$74,686
ENCOMPASS GROUP, LLC	\$72,738
TEVA PHARMACEUTICALS USA (BRAND)	\$70,321
DAVOL INC.	\$70,164
MERCK SHARP & DOHME LLC	\$69,953
VERITIV CORPORATION	\$69,643
TIDI PRODUCTS, LLC	\$68,351
GLOBAL HEALTHCARE EXCHANGE (GHX)	\$67,305
FISHER & PAYKEL HEALTHCARE, INC.	\$66,277
DIAGNOSTICA STAGO, INC.	\$64,274
ORTHO-CLINICAL DIAGNOSTICS, INC.	\$63,014
TENNANT SALES AND SERVICE COMPANY	\$63,006
CAPITAL INVENTORY, INC.	\$62,500
WELCH ALLYN, INC.	\$60,404
DOLE PACKAGED FOODS COMPANY	\$57,941
TAYLOR HEALTHCARE	\$57,649
AGILITI HEALTH, INC.	\$56,969
SOLAIRE MEDICAL STORAGE, LLC DBA INNERSPACE H.C.	\$55,653
AMERICAN HEALTH PACKAGING	\$55,232
THE J. M. SMUCKER COMPANY	\$54,116
TYSON FOODS, INC.	\$53,806
EXEMPLIS LLC	\$52,798
WNA INC	\$52,767
NESTLE HEALTH SCIENCES	\$52,758
PERFORMANCE HEALTH SUPPLY, LLC	\$52,722
PEPSICO FOODSERVICE	\$52,693
HIKMA PHARMACEUTICALS USA INC.	\$52,651
ACUMED LLC	\$50,841
AMPHASTAR PHARMACEUTICALS, INC.	\$50,303
US MED-EQUIP, LLC	\$50,053
MICHAEL FOODS, INC.	\$48,805
HOLOGIC SALES AND SERVICE, LLC	\$48,783
SMITH & NEPHEW INC - WOUND MANAGEMENT DIVISION	\$47,663
SABERT CORPORATION	\$47,334
CONVATEC INC	\$47,089
SANOFI-AVENTIS U.S. LLC	\$47,022
STATES TO THE PROPERTY OF THE	777,022

HARRIS HEALTH PREMIER Q4 SPEND FY2024	
SUPPLIER	Q4 SPEND FY2024
ZIMMER BIOMET	\$46,279
KIMBERLY CLARK GLOBAL SALES LLC	\$45,706
KURIN, INC.	\$45,500
AMERICAN REGENT, INC.	\$44,615
REMEL INC.	\$43,291
BIO-RAD LABORATORIES, INC.	\$42,063
ARUP LABORATORIES, INC.	\$42,039
THE CLOROX SALES COMPANY	\$41,846
HORMEL FOODS CORPORATION	\$41,533
QUVA PHARMA, INC.	\$41,482
HEALTHMARK INDUSTRIES CO., INC.	\$39,946
MOLNLYCKE HEALTH CARE US, LLC	\$39,161
SCA PHARMACEUTICALS, LLC	\$38,723
CARCO GROUP, INC. DBA PRECHECK	\$38,228
SUN PHARMACEUTICAL LABORATORIES, LTD.	\$38,227
LEICA BIOSYSTEMS A DIVISION OF LEICA MICROSYSTEMS INC.	\$37,768
EHOB INC	\$35,941
PROFESSIONAL DISPOSABLES INTERNATIONAL, INC.	\$35,296
ELI LILLY AND COMPANY	\$34,430
INTEGRA LIFESCIENCES SALES, LLC	\$34,302
SAGENT PHARMACEUTICALS, INC.	\$34,117
STANCE HEALTHCARE INC.	\$33,981
HEALTH CARE LOGISTICS, INC.	\$33,616
ADVANCE MEDICAL DESIGNS, INC.	\$32,422
ASTRAZENECA PHARMACEUTICALS LP	\$31,962
LUMINEX CORPORATION	\$31,752
AVKARE, LLC.	\$31,077
KRAFT HEINZ FOODS COMPANY, FOODSERVICE DIVISION	\$30,694
US FOODS CULINARY EQUIPMENT & SUPPLIES	\$29,851
TRI-ANIM HEALTH SERVICES, INC.	\$29,828
MAJOR PHARMACEUTICALS	\$29,390
SMITH & NEPHEW INC - BIOTHERAPEUTICS	\$29,336
STERIS INSTRUMENT MANAGEMENT SERVICES, INC.	\$29,149
HELMER SCIENTIFIC, LLC	\$28,792
PEPSICO INC.	\$28,369
DART CONTAINER CORPORATION	\$27,839
GLAXOSMITHKLINE INC.	\$27,495
PACIRA PHARMACEUTICALS, INC.	\$26,876
DEROYAL INDUSTRIES, INC.	\$26,378
PAI HOLDINGS, LLC DBA PAI PHARMA	\$25,981
APPLIED MEDICAL RESOURCES CORPORATION	\$25,913
OWENS & MINOR DISTRIBUTION, INC.	\$25,727
EXELA PHARMA SCIENCES, LLC	\$25,221
GLOBUS MEDICAL, INC.	\$24,227
ZYDUS PHARMACEUTICALS USA INC	\$23,669
SMITHS MEDICAL ASD, INC.	\$23,396
RICHARD-ALLAN SCIENTIFIC	\$22,392
MONTH MENT SCIENTING	722,332

SUPPLIER Q4 SPEND FY2024 DR. REDDY'S LABORATORIES, INC. \$22,364 SLMP, LLC DBA STATLAB MEDICAL PRODUCTS \$22,267 COLOPLAST CORP. \$21,799 LABORIE MEDICAL TECHNOLOGIES CORP. \$21,380 TEVAP HARMACEUTICALS USA (GENERIC) \$20,311 GENERAL MILLS \$20,291 ANGIODYNAMICS, INC. \$20,0077 FLEXICARE INCORPORATED \$19,360 CONAGRA FOODS INC \$19,360 CONMED CORPORATION \$19,360 COMED CORPORATION \$18,963 O&M HALYARD, INC. \$18,863 THE COCA-COLA COMPANY \$18,784 SOMERSET PHARMA LLC \$17,949 MEDEGEN MEDICAL PRODUCTS, LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,661 BAUSCH & LOMB AMERICAS INC. \$16,612 BAUSCH & LOMB AMERICAS INC. \$16,572 Z-MEDICA, LLC \$16,321 KEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$15,376 KIS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,376 KOCH	HARRIS HEALTH PREMIER Q4 SPEND FY2024	
DR. REDDY'S LABORATORIES, INC. \$22,364 SLMP, LLC DBA STATLAB MEDICAL PRODUCTS \$22,267 COLOPLAST CORP. \$21,380 TEVA PHARMACEUTICALS USA (GENERIC) \$20,311 GENERAL MILLS \$20,291 ANGIODYNAMICS, INC. \$20,077 FLEXICARE INCORPORATEO \$19,909 CONAGRA FOODS INC \$19,600 CONAGRA FOODS INC \$18,963 COMMED CORPORATION \$18,963 OSM HALYARD, INC. \$18,875 THE COCA-COLA COMPANY \$18,787 SOMERSET PHARMA LLC \$17,949 KAMPBELL FOODSERVICE COMPANY \$17,749 SAURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,104 DIVERSEY, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$15,733 KICH FOODS \$15,734 KOCH FOODS \$15,734 KOCH FOODS \$15,732 KOCH FOODS \$15,732 KOCH GOODS <td< th=""><th></th><th>Q4 SPEND FY2024</th></td<>		Q4 SPEND FY2024
COLOPLAST CORP. \$21,799 LABORIE MEDICAL TECHNOLOGIES CORP. \$21,380 TEVA PHARMACEUTICALS USA (GENERIC) \$20,311 GENERAL MILLS \$20,291 ANGIODYNAMICS, INC. \$20,077 FLEXICARE INCORPORATED \$19,009 CONAGRA FOODS INC \$19,360 COMBE CORPORATION \$19,104 VAPOTHERM, INC. \$18,893 OSM HALYARD, INC. \$18,875 THE COCA-COLA COMPANY \$18,784 SOMERSET PHARMAL LC \$18,754 REDEGER MEDICAL PRODUCTS, LLC \$17,794 CAMPBELL FOODSERVICE COMPANY \$17,783 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,604 DIVERSEY, INC. \$16,572 NEGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,311 NOVO SURGICAL, INC. \$15,737 NOVO SURGICAL, INC. \$15,737 HOVERTECH INTERNATIONAL \$15,572 BSN MEDICAL, INC. \$15,512 BSN MEDICAL, INC. \$15,501 PROGRESSIVE MEDICAL, INC. <td>DR. REDDY'S LABORATORIES, INC.</td> <td>\$22,364</td>	DR. REDDY'S LABORATORIES, INC.	\$22,364
LABORIE MEDICAL TECHNOLOGIES CORP. \$21,380 TEVA PHARMACEUTICALS USA (GENERIC) \$20,311 GENERAL MILLS \$20,297 ANGIODYNAMICS, INC. \$20,077 FLEXICARE INCORPORATED \$19,909 CONAGRA FOODS INC \$19,360 COMMED CORPORATION \$18,963 O&M HALYARD, INC. \$18,875 THE COCA-COLA COMPANY \$18,875 MEDEGEN MEDICAL PRODUCTS, LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,738 AZURITY PHARMACEUTICALS, INC. \$17,616 BAUSCH & LOMB AMERICAS INC. \$17,616 DIVERSEY, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,722 Z-MEDICA, LLC \$16,321 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,542 AMBU INC. \$15,542 MOVERTECH INTERNATIONAL \$15,542 SN MEDICAL, INC. \$14,690 SOU MEDICAL CORPORATION \$14,693 ANCHOR PACKAGING \$14,691 SILE FROZEN SCORPORATION \$14,693 COLL MEDICAL CORPORATION <td>SLMP, LLC DBA STATLAB MEDICAL PRODUCTS</td> <td>\$22,267</td>	SLMP, LLC DBA STATLAB MEDICAL PRODUCTS	\$22,267
TEVA PHARMACEUTICALS USA (GENERIC) \$20,311 GENERAL MILLS \$20,271 ANGIODYNAMICS, INC. \$20,077 FLEXICARE INCORPORATED \$19,909 CONAGRA FOODS INC \$19,360 COMMED CORPORATION \$18,875 O&M HALYARD, INC. \$18,875 THE COCA-COLA COMPANY \$18,784 SOMERSET PHARMA LLC \$18,779 MEDEGEN MEDICAL PRODUCTS, LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,38 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,616 BAUSCH & LOMB AMERICAS INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$15,779 NOVO SURGICAL, INC. \$15,779 NOVO SURGICAL, INC. \$15,779 NOVO SURGICAL, INC. \$15,571 HOVERTECH INTERNATIONAL \$15,611 BSN MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,591	COLOPLAST CORP.	\$21,799
GENERAL MILLS \$20,931 ANGIODYNAMICS, INC. \$20,077 FLEXICARE INCORPORATED \$19,909 COMAGRA FOODS INC \$19,360 COMMED CORPORATION \$19,014 VAPOTHERM, INC. \$18,963 OSM HALYARD, INC. \$18,875 THE COCA-COLA COMPANY \$18,784 SOMERSET PHARMA LLC \$18,757 MEDEGEN MEDICAL PRODUCTS, LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,738 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,753 NOVO SURGICAL, INC. \$15,542 AMBU INC. \$15,542 MOVERTECH INTERNATIONAL \$15,561 BSN MEDICAL, INC. \$14,690 PROGRESSIVE MEDICAL, INC. \$14,690 SOLL MEDICAL CORPORATION \$14,591 FEDERAL EXPRESS CORPORATION <td>LABORIE MEDICAL TECHNOLOGIES CORP.</td> <td>\$21,380</td>	LABORIE MEDICAL TECHNOLOGIES CORP.	\$21,380
ANGIODYNAMICS, INC. FLEXICARE INCORPORATED 519,007 FLEXICARE INCORPORATED 519,360 CONAGRA FOODS INC 519,014 VAPOTHERM, INC. 518,963 O&M HALYARD, INC. 518,767 THE COCA-COLA COMPANY 518,784 SOMERSET PHARMA LLC 518,757 MEDEGEN MEDICAL PRODUCTS, LLC 517,949 CAMPBELL FOODSERVICE COMPANY 517,738 AZURITY PHARMACEUTICALS, INC. 517,661 BAUSCH & LOMB AMERICAS INC. 517,661 BAUSCH & LOMB AMERICAS INC. 516,822 NEOGENOMICS LABORATORIES, INC. 516,822 NEOGENOMICS LABORATORIES, INC. 516,331 KLS MARTIN LP 515,779 NOVO SURGICAL, INC. 515,737 KOCH FOODS 515,542 AMBU INC. 515,376 HOVERTECH INTERNATIONAL 515,261 BSN MEDICAL, INC. 515,376 HOVERTECH INTERNATIONAL 514,683 ANCHOR PACKAGING 514,582 KERECIS LLC 514,444 ASPEN SURGICAL CREPORATION 514,582 KERECIS LLC 513,390 ASPIRE BAKERIES LLC 513,390 ASPIRE BAKERIES LLC 513,390 ASPIRE BAKERIES LLC 513,390 ASPIRE BAKERIES LLC 513,497 ASPEN SURGICAL PRODUCTS, INC. 512,945 MXR IMAGING, INC. 512,945 MXR IMAGING, INC. 511,754 ASPEN SURGICAL PRODUCTS, INC. 511,754 ANDOZ INC. 511,754 STERICYCLE, INC. 510,900	TEVA PHARMACEUTICALS USA (GENERIC)	\$20,311
FLEXICARE INCORPORATED \$19,909 CONAGRA FOODS INC \$19,360 CONMED CORPORATION \$19,014 VAPOTHERM, INC. \$18,863 O&M HALYARD, INC. \$18,875 THE COCA-COLA COMPANY \$18,784 SOMERSET PHARMA LLC \$17,949 MEDEGEN MEDICAL PRODUCTS, LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,738 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,733 NOVO SURGICAL, INC. \$15,373 KOCH FOODS \$15,542 AMBU INC. \$15,373 HOVERTECH INTERNATIONAL \$15,512 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 20LL MEDICAL CORPORATION \$14,690 ANCHOR PACKAGING \$14,591 FEEDERAL EXPRESS CORPORATION	GENERAL MILLS	\$20,291
CONAGRA FOODS INC \$19,360 CONMED CORPORATION \$19,014 VAPOTHERM, INC. \$18,963 O&M HALYARD, INC. \$18,875 THE COCA-COLA COMPANY \$18,784 SOMERSET PHARMA LLC \$17,949 MEDEGEN MEDICAL PRODUCTS, LLC \$17,959 CAMPBELL FOODSERVICE COMPANY \$17,738 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$16,822 NEGGENOMICS LABORATORIES, INC. \$16,822 VENGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,376 NOVO SURGICAL, INC. \$15,376 HOVERTECH INTERNATIONAL \$15,362 BSN MEDICAL, INC. \$15,911 PROGRESSIVE MEDICAL, INC. \$14,693 2OLL MEDICAL CORPORATION \$14,693 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,592 KERECIS LLC \$13,300 ASPIRE BAKERIES LLC </td <td>ANGIODYNAMICS, INC.</td> <td>\$20,077</td>	ANGIODYNAMICS, INC.	\$20,077
CONMED CORPORATION \$19,014 VAPOTHERM, INC. \$18,863 O&M HALYARD, INC. \$18,875 THE COCA-COLA COMPANY \$18,784 SOMERSET PHARMA LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,738 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,104 DIVERSEY, INC. \$16,822 NEGGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,572 Z-MEDICA, LLC \$15,779 NOVO SURGICAL, INC. \$15,779 NOVO SURGICAL, INC. \$15,779 NOVO SURGICAL, INC. \$15,779 NOVO SURGICAL, INC. \$15,576 AMBU INC. \$15,576 HOVERTECH INTERNATIONAL \$15,011 BSN MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 AND LUMEDICAL CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$14,932 KERECIS LLC \$13,906 ASPIRE BAKERIES LLC \$13,906 A	FLEXICARE INCORPORATED	\$19,909
VAPOTHERM, INC. \$18,963 O&M HALYARD, INC. \$18,875 THE COCA-COLA COMPANY \$18,787 SOMERSET PHARMA LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,738 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,604 DIVERSEY, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KOCH FOODS \$15,542 AMBU INC. \$15,336 HOVERTECH INTERNATIONAL \$15,542 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,991 FEDERAL EXPRESS CORPORATION \$14,844 SILENTIA INC. \$13,306 KERECIS LLC \$13,490 ASPEN SURGICAL PRODUCTS, INC. \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945	CONAGRA FOODS INC	\$19,360
O&M HALYARD, INC. \$18,875 THE COCA-COLA COMPANY \$18,784 SOMERSET PHARMA LLC \$18,757 MEDEGEN MEDICAL PRODUCTS, LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,104 DIVERSEY, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KCCH FOODS \$15,542 AMBU INC. \$15,331 HOVERTECH INTERNATIONAL \$15,736 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 20LL MEDICAL CORPORATION \$14,690 20LL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILINIA INC. \$14,372 RETRACTABLE TECHNOLOGIES, INC. \$13,906 ASPIRE BAKERIES LLC \$13,906 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,49	CONMED CORPORATION	\$19,014
THE COCA-COLA COMPANY \$18,784 SOMERSET PHARMA LLC \$18,757 MEDIGEN MEDICAL PRODUCTS, LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,738 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,104 DIVERSEY, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KCCH FOODS \$15,542 AMBU INC. \$15,336 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,683 ANCHOR PACKAGING \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC.	VAPOTHERM, INC.	\$18,963
SOMERSET PHARMA LLC \$18,757 MEDEGEN MEDICAL PRODUCTS, LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,738 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,104 DIVERSEY, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KCH FOODS \$15,542 AMBU INC. \$15,376 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIAL INC. \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SAPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SAPIRE BAKERIES LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC.	O&M HALYARD, INC.	\$18,875
MEDEGEN MEDICAL PRODUCTS, LLC \$17,949 CAMPBELL FOODSERVICE COMPANY \$17,738 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,104 DIVERSEY, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KOCH FOODS \$15,542 AMBU INC. \$15,376 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 KERECIS LLC \$14,444 SILENTIA INC. \$14,372 RETRACTABLE TECHNOLOGIES, INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 ASPIRE BAKERIES LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$13,906 ASPIRE BAKERIES LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,945 MXR IMAGING, INC. \$11,754 MYS CRITICAL CARE, LLC \$11,473 ZANNOZ INC. \$11,754 SANDOZ INC. \$11,754 STERICYCLE, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,450 UV. L. GORE & ASSOCIATES, INC. \$11,450 UV. L. GORE & ASSOCIATES, INC. \$11,450 UV. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$11,450	THE COCA-COLA COMPANY	\$18,784
CAMPBELL FOODSERVICE COMPANY \$17,738 AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,104 DIVERSEY, INC. \$16,822 REOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KOCH FOODS \$15,542 AMBU INC. \$15,373 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,592 FEDERAL EXPRESS CORPORATION \$14,592 KERECIS LLC \$14,444 SILENTIA INC. \$14,372 RETRACTABLE TECHNOLOGIES, INC. \$13,702 PILGRIM'S PRIDE CORPORATION \$13,3702 PILGRIM'S PRIDE CORPORATION \$13,490 ASPIRE BAKERIES LLC \$13,490 ASPIRE BAKERIES LLC \$13,490 ASPIRE BAKERIES LLC \$13,490 ASPIRE BAKERIES LLC \$13,490 MICHARDIA INC. \$12,945	SOMERSET PHARMA LLC	\$18,757
AZURITY PHARMACEUTICALS, INC. \$17,661 BAUSCH & LOMB AMERICAS INC. \$17,104 DIVERSEY, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,872 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KOCH FOODS \$15,542 AMBU INC. \$15,336 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,911 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 ASPIRE BAKERIES LLC \$13,702 ASPIRE BAKERIES LLC \$13,906 ASPIRE BAKERIES LLC \$13,906 ASPIRE BAKERIES LLC \$13,907 ASPIRE BAKERIES LLC \$13,907 NESTLE PROFESSIONAL NORTH AMERICA \$12,915 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,773 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154	MEDEGEN MEDICAL PRODUCTS, LLC	\$17,949
BAUSCH & LOMB AMERICAS INC. \$17,104 DIVERSEY, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,773 KOCH FOODS \$15,542 AMBU INC. \$15,376 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$14,342 RETRACTABLE TECHNOLOGIES, INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,945 MXR IMAGING, INC. \$12,945 MXE GORIE & ASSOCIATE AMERICA \$11,754 SANDOZ INC. \$11,754 AVANOS MEDICAL, INC. \$11,754	CAMPBELL FOODSERVICE COMPANY	\$17,738
DIVERSEY, INC. \$16,822 NEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KCCH FOODS \$15,542 AMBU INC. \$15,542 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$13,702 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,945 MXR IMAGING, INC. \$12,951 NESTLE PROFESSIONAL NORTH AMERICA \$11,754 WG CRITICAL CARE, LLC \$11,754 DJO GLOBAL, INC. \$11,757 AVANOS MEDICAL, INC. \$11,579	AZURITY PHARMACEUTICALS, INC.	\$17,661
NEOGENOMICS LABORATORIES, INC. \$16,572 Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KOCH FOODS \$15,542 AMBU INC. \$15,376 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,945 MXR IMAGING, INC. \$12,945 MSETILE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$10,900	BAUSCH & LOMB AMERICAS INC.	\$17,104
Z-MEDICA, LLC \$16,331 KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KOCH FOODS \$15,542 AMBU INC. \$15,376 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 20LL MEDICAL CORPORATION \$14,690 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,945 MXR IMAGING, INC. \$12,945 MSTLE PROFESSIONAL NORTH AMERICA \$11,973 DIO GLOBAL, INC. \$11,973 AVANOS MEDICAL, INC. \$11,754 SANDOZ INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$10,900	DIVERSEY, INC.	\$16,822
KLS MARTIN LP \$15,779 NOVO SURGICAL, INC. \$15,733 KOCH FOODS \$15,542 AMBU INC. \$15,376 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERCIS LLC \$14,444 SILENTIA INC. \$13,302 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,945 MXR IMAGING, INC. \$12,945 MY GCRITICAL CARE, LLC \$11,754 DIO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,754 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$10,900	NEOGENOMICS LABORATORIES, INC.	\$16,572
NOVO SURGICAL, INC. \$15,733 KOCH FOODS \$15,542 AMBU INC. \$15,376 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$14,372 RETRACTABLE TECHNOLOGIES, INC. \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 ARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,945 MXR IMAGING, INC. \$12,945 MXR IMAGING, INC. \$11,754 SANDOZ INC. \$11,757 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$11,154	Z-MEDICA, LLC	\$16,331
KOCH FOODS \$15,542 AMBU INC. \$15,376 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,915 WG CRITICAL CARE, LLC \$11,754 SANDOZ INC. \$11,754 SANDOZ INC. \$11,754 SANDOZ INC. \$11,80 W. L. GORE & ASSOCIATES, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$10,900	KLS MARTIN LP	\$15,779
AMBU INC. \$15,376 HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,915 WG CRITICAL CARE, LLC \$11,973 DIO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,754 VANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	NOVO SURGICAL, INC.	\$15,733
HOVERTECH INTERNATIONAL \$15,261 BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$14,372 RETRACTABLE TECHNOLOGIES, INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	KOCH FOODS	\$15,542
BSN MEDICAL, INC. \$15,011 PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$13,702 RETRACTABLE TECHNOLOGIES, INC. \$13,702 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	AMBU INC.	\$15,376
PROGRESSIVE MEDICAL, INC. \$14,690 ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$14,372 RETRACTABLE TECHNOLOGIES, INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,973 SANDOZ INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	HOVERTECH INTERNATIONAL	\$15,261
ZOLL MEDICAL CORPORATION \$14,683 ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$14,372 RETRACTABLE TECHNOLOGIES, INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	BSN MEDICAL, INC.	\$15,011
ANCHOR PACKAGING \$14,591 FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$14,372 RETRACTABLE TECHNOLOGIES, INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,945 MXR IMAGING, INC. \$12,145 WG CRITICAL CARE, LLC \$11,754 SANDOZ INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,090	PROGRESSIVE MEDICAL, INC.	\$14,690
FEDERAL EXPRESS CORPORATION \$14,582 KERECIS LLC \$14,444 SILENTIA INC. \$13,702 RETRACTABLE TECHNOLOGIES, INC. \$13,702 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	ZOLL MEDICAL CORPORATION	\$14,683
KERECIS LLC \$14,444 SILENTIA INC. \$14,372 RETRACTABLE TECHNOLOGIES, INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	ANCHOR PACKAGING	\$14,591
SILENTIA INC. \$14,372 RETRACTABLE TECHNOLOGIES, INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,480 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	FEDERAL EXPRESS CORPORATION	\$14,582
RETRACTABLE TECHNOLOGIES, INC. \$13,906 ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	KERECIS LLC	\$14,444
ASPIRE BAKERIES LLC \$13,702 PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	SILENTIA INC.	\$14,372
PILGRIM'S PRIDE CORPORATION \$13,530 SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	RETRACTABLE TECHNOLOGIES, INC.	\$13,906
SARA LEE FROZEN BAKERY, LLC \$13,497 ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	ASPIRE BAKERIES LLC	\$13,702
ASPEN SURGICAL PRODUCTS, INC. \$12,945 MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	PILGRIM'S PRIDE CORPORATION	\$13,530
MXR IMAGING, INC. \$12,901 NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	SARA LEE FROZEN BAKERY, LLC	\$13,497
NESTLE PROFESSIONAL NORTH AMERICA \$12,145 WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	ASPEN SURGICAL PRODUCTS, INC.	\$12,945
WG CRITICAL CARE, LLC \$11,973 DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	MXR IMAGING, INC.	\$12,901
DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	NESTLE PROFESSIONAL NORTH AMERICA	\$12,145
DJO GLOBAL, INC. \$11,754 SANDOZ INC. \$11,579 AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	WG CRITICAL CARE, LLC	\$11,973
AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	DJO GLOBAL, INC.	
AVANOS MEDICAL, INC. \$11,480 W. L. GORE & ASSOCIATES, INC. \$11,154 STERICYCLE, INC. \$10,900	SANDOZ INC.	\$11,579
STERICYCLE, INC. \$10,900	AVANOS MEDICAL, INC.	
STERICYCLE, INC. \$10,900	W. L. GORE & ASSOCIATES, INC.	\$11,154
SPECGX LLC \$10,810	STERICYCLE, INC.	\$10,900
	SPECGX LLC	\$10,810

HARRIS HEALTH PREMIER Q4 SPEND FY2024	
SUPPLIER	Q4 SPEND FY2024
KRUEGER INTERNATIONAL, INC.	\$10,714
BIOTISSUE HOLDINGS INC.	\$10,536
AMNEAL PHARMACEUTICALS LLC	\$10,514
BASIC AMERICAN FOODS	\$10,479
LITTLE RAPIDS HOLDING CORPORATION DBA GRAHAM MEDICAL	\$10,392
KNOUSE FOODS CO-OP INC	\$10,278
HORMEL HEALTHLABS, INC.	\$9,965
PRECISION DOSE, INC.	\$9,918
MANNINGTON MILLS INC.	\$9,761
EUGIA US LLC	\$9,681
WELLS DAIRY, INC.	\$9,532
INTERSURGICAL INCORPORATED	\$9,510
MONDELEZ INTERNATIONAL, INC.	\$9,423
BRACCO DIAGNOSTICS INC.	\$9,196
BRISTOL MYERS SQUIBB US PHARM	\$8,885
DANONE NORTH AMERICA	\$8,557
J.R. SIMPLOT COMPANY	\$8,455
WK KELLOGG SALES LLC	\$8,344
SHASTA FOODSERVICE	\$8,224
HOWMEDICA OSTEONICS CORP. DBA STRYKER SPINE	\$8,218
CAMBRO MANUFACTURING COMPANY	\$8,177
LIFENET HEALTH	\$8,133
SWISSLOG HEALTHCARE	\$7,800
STRATUS PHARMACEUTICALS, INC.	\$7,644
UPSHER-SMITH LABORATORIES, LLC	\$7,300
TRILLIANT SURGICAL, LLC	\$7,248
FUJIFILM HEALTHCARE AMERICAS CORPORATION	\$6,888
ALCON VISION, LLC	\$6,827
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	\$6,671
PAR STERILE PRODUCTS, LLC	\$6,661
KEDRION BIOPHARMA INC.	\$6,640
HUB PHARMACEUTICALS, LLC	\$6,555
CUSTOM CULINARY, INC.	\$6,426
BELIMED, INC.	\$6,278
CAMFIL USA, INC	\$6,206
NOVOLEX HOLDINGS, LLC	\$6,183
NOVARTIS PHARMACEUTICALS CORPORATION	\$6,130
CARDINAL HEALTH 414, LLC	\$6,065
WERFEN USA, LLC	\$5,963
CANVIIY, LLC.	\$5,928
FERNDALE LABORATORIES, INC.	\$5,854
RICHARD WOLF MEDICAL INSTRUMENTS CORP.	\$5,803
PELSTAR, LLC DBA HEALTH O METER	\$5,685
PHILIPS DS NORTH AMERICA LLC	\$5,672
STELLEX/CF BUYER (US) LLC	\$5,617
PHARMA LOGISTICS	\$5,420
OHIO MEDICAL, LLC	\$5,384
OTHO WILDICAL, LLC	\$5,384


SUPPLIER QUEST DIAGNOSTICS INCORPORATED ENERGIZER BATTERY COMPANY \$5,27 STEELCASE INC. \$5,23 B&G FOODS, INC. \$5,17 XGEN PHARMACEUTICALS DJB, INC. \$5,03 TZ MEDICAL, INC. \$4,95 PAR PHARMACEUTICAL, INC. CYGNUS MEDICAL L.L.C. \$4,76 TETRA MEDICAL SUPPLY CORP. URGO MEDICAL NORTH AMERICA LANDAUER, INC. \$4,49 UCB PHARMA, INC. \$4,49 UCB PHARMA, INC. MEAD JOHNSON & COMPANY, LLC JOHNSONVILLE, LLC \$4,49 IOHNSONVILLE, LLC \$4,49 IOHNSONVILLE, LLC \$4,40 IOHNSONVILLE, INC. \$4,00 IOHNSONVILLE, INC. IO
ENERGIZER BATTERY COMPANY \$5,27 STEELCASE INC. \$5,23 B&G FOODS, INC. \$5,17 XGEN PHARMACEUTICALS DJB, INC. \$5,03 TZ MEDICAL, INC. \$4,95 PAR PHARMACEUTICAL, INC. \$4,86 CYGNUS MEDICAL L.L.C. \$4,76 TETRA MEDICAL SUPPLY CORP. \$4,75 URGO MEDICAL NORTH AMERICA \$4,47 LANDAUER, INC. \$4,69 ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,08 MGC DIAGNOSTICS CORPORATION \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
STEELCASE INC. \$5,23 B&G FOODS, INC. \$5,17 XGEN PHARMACEUTICALS DJB, INC. \$5,03 TZ MEDICAL, INC. \$4,95 PAR PHARMACEUTICAL, INC. \$4,86 CYGNUS MEDICAL L.L.C. \$4,76 TETRA MEDICAL SUPPLY CORP. \$4,75 URGO MEDICAL NORTH AMERICA \$4,74 LANDAUER, INC. \$4,69 ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
B&G FOODS, INC. \$5,17 XGEN PHARMACEUTICALS DJB, INC. \$5,03 TZ MEDICAL, INC. \$4,95 PAR PHARMACEUTICAL, INC. \$4,86 CYGNUS MEDICAL L.L.C. \$4,76 TETRA MEDICAL SUPPLY CORP. \$4,75 URGO MEDICAL NORTH AMERICA \$4,74 LANDAUER, INC. \$4,69 ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
XGEN PHARMACEUTICALS DJB, INC. \$5,03 TZ MEDICAL, INC. \$4,95 PAR PHARMACEUTICAL, INC. \$4,86 CYGNUS MEDICAL L.L.C. \$4,76 TETRA MEDICAL SUPPLY CORP. \$4,75 URGO MEDICAL NORTH AMERICA \$4,74 LANDAUER, INC. \$4,69 ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
TZ MEDICAL, INC. \$4,95 PAR PHARMACEUTICAL, INC. \$4,86 CYGNUS MEDICAL L.L.C. \$4,76 TETRA MEDICAL SUPPLY CORP. \$4,75 URGO MEDICAL NORTH AMERICA \$4,74 LANDAUER, INC. \$4,69 ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
TZ MEDICAL, INC. \$4,95 PAR PHARMACEUTICAL, INC. \$4,86 CYGNUS MEDICAL L.L.C. \$4,76 TETRA MEDICAL SUPPLY CORP. \$4,75 URGO MEDICAL NORTH AMERICA \$4,74 LANDAUER, INC. \$4,69 ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
CYGNUS MEDICAL L.L.C. \$4,76 TETRA MEDICAL SUPPLY CORP. \$4,75 URGO MEDICAL NORTH AMERICA \$4,74 LANDAUER, INC. \$4,69 ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
TETRA MEDICAL SUPPLY CORP. \$4,75 URGO MEDICAL NORTH AMERICA \$4,74 LANDAUER, INC. \$4,69 ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
URGO MEDICAL NORTH AMERICA \$4,74 LANDAUER, INC. \$4,69 ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
LANDAUER, INC. \$4,69 ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
ERBE USA, INC. \$4,49 UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
UCB PHARMA, INC. \$4,49 MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
MEAD JOHNSON & COMPANY, LLC \$4,49 JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
JOHNSONVILLE, LLC \$4,48 NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
NORDIC PHARMA, INC. \$4,42 AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
AERO US INC. DBA AEROGEN \$4,40 FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
FREEDOM MEDICAL, INC. \$4,27 CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
CONTEC, INC. \$4,10 BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
BLUETRITON BRANDS, INC. \$4,08 MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
MGC DIAGNOSTICS CORPORATION \$4,04 RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
RISING PHARMACEUTICALS, INC. \$4,03 PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
PEDIGO PRODUCTS INC \$3,98 MICROGENICS CORPORATION \$3,92
MICROGENICS CORPORATION \$3,92
TARRY MEDICAL PRODUCTS DBA DANDLELION MEDICAL \$3,88
GOJO INDUSTRIES, INC. \$3,83
CHOBANI LLC \$3,72
SMITH & NEPHEW INC - ENDOSCOPY DIVISION \$3,71
THE WINSFORD COMPANY, LLC DBA THE HARLOFF COMPANY, INC. \$3,71
HOLLISTER INCORPORATED \$3,65
ABBOTT NUTRITION \$3,62
SCHWAN'S FOOD SERVICE, INC. \$3,55
RESER'S FINE FOODS, INC. \$3,47
CHICKEN OF THE SEA INTERNATIONAL \$3,39
SUGAR FOODS LLC \$3,26
CONMED LINVATEC \$3,19
KELLANOVA \$3,19
CIVCO MEDICAL SOLUTIONS \$3,14
CARL ZEISS MEDITEC USA, INC. \$3,06
BIOVENTUS LLC \$3,04
CIPLA USA, INC \$2,99
J & J SNACK FOODS CORP \$2,99
XIROMED, LLC \$2,97
RICH PRODUCTS CORPORATION \$2,94
ULTRAVIOLET DEVICES, INC. \$2,90
HOFFMASTER GROUP, INC. \$2,84
ALBA BIOSCIENCE, INC. \$2,81

HARRIS HEALTH PREMIER Q4 SPEND FY2024	
SUPPLIER	Q4 SPEND FY2024
PADAGIS US LLC	\$2,810
MEITHEAL PHARMACEUTICALS, INC.	\$2,755
R D PLASTICS COMPANY, INC.	\$2,743
SWEET STREET DESSERTS, INC.	\$2,697
LAND O'LAKES, INC.	\$2,674
GREINER BIO-ONE NORTH AMERICA, INC.	\$2,659
INMAR RX SOLUTIONS, INC.	\$2,639
SEBELA PHARMACEUTICALS INC	\$2,621
ALADDIN TEMP-RITE	\$2,611
ASAHI INTECC USA, INC.	\$2,600
BPI LABS, LLC	\$2,538
MEDICAL COMPONENTS, INC.	\$2,530
PROCTER & GAMBLE DISTRIBUTING LLC	\$2,528
OLE MEXICAN FOODS, INC.	\$2,522
CASE MEDICAL, INC.	\$2,477
GRACE MEDICAL, INC.	\$2,446
PFIZER (BRAND)	\$2,373
GENDOSE PHARMACEUTICALS	\$2,285
MARS FOOD US, LLC	\$2,275
OBP SURGICAL CORPORATION	\$2,250
VENTURA FOODS, LLC	\$2,245
LABCONCO CORPORATION	\$2,245
INTERMETRO INDUSTRIES CORPORATION	\$2,186
CONCORDANCE HEALTHCARE SOLUTIONS LLC	\$2,180
CINTAS CORPORATION NO. 2	\$2,037
	\$2,037
GREENSTONE LLC	
ENABLECV, INC.	\$1,979
TELA BIO, INC.	\$1,934
BEUTLICH PHARMACEUTICALS, LLC	\$1,934
HERSHEY	\$1,913
ANI PHARMACEUTICALS	\$1,912
HALEON US INC.	\$1,891
HYDROFERA, LLC	\$1,881
MCCORMICK & COMPANY, INC.	\$1,814
MERCURY MEDICAL	\$1,782
RHODES PHARMACEUTICALS	\$1,769
HARTMANN USA, INC.	\$1,689
APOTEX CORP.	\$1,650
PITNEY BOWES INC.	\$1,626
LUPIN PHARMACEUTICALS, INC.	\$1,577
LEADIANT BIOSCIENCES, INC.	\$1,524
NISSHA MEDICAL TECHNOLOGIES	\$1,506
MCKESSON PACKAGING	\$1,459
HORIZON ORGANIC DAIRY, LLC	\$1,444
TOLMAR, INC	\$1,375
LACTALIS AMERICAN GROUP, INC.	\$1,355
UNICHEM PHARMACEUTICALS USA INC	\$1,353

HARRIS HEALTH PREMIER Q4 SPEND FY2024	
SUPPLIER	Q4 SPEND FY2024
ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES	\$1,326
GUERBET LLC	\$1,300
BRECKENRIDGE PHARMACEUTICAL INC.	\$1,276
GLENMARK PHARMACEUTICALS INC., USA	\$1,255
INTERNATIONAL BIOMEDICAL, LTD.	\$1,254
KATENA PRODUCTS, INC. DBA CORZA OPHTHALMOLOGY	\$1,239
KIKKOMAN SALES USA, INC	\$1,220
SMITHFIELD FOODS, INC.	\$1,212
PRASCO LABORATORIES	\$1,113
NOVADOZ PHARMACEUTICALS LLC	\$1,106
STRYKER SUSTAINABILITY SOLUTIONS, INC.	\$1,079
HANDGARDS, INC.	\$1,059
EDENBRIDGE PHARMACEUTICALS LLC	\$1,044
SANOFI PASTEUR	\$1,030
NOVOLEX HERITAGE BAG, LLC	\$1,029
TARO PHARMACEUTICALS USA, INC.	\$987
OUT OF THE SHELL, LLC DBA YANGS 5TH TASTE	\$977
MEGAMEX FOODS, LLC	\$971
PERDUE FOODS LLC	\$965
MERISANT US, INC.	\$962
CONTINENTAL MILLS, INC. DBA THE KRUSTEAZ COMPANY	\$956
DAISY BRAND	\$938
CONOPCO, INC DBA UNILEVER NA FOODSOLUTIONS	\$889
MYCO MEDICAL SUPPLIES INC.	\$884
KEN'S FOODS, INC.	\$854
ACIST MEDICAL SYSTEMS, INC.	\$846
CMP PHARMA, INC.	\$812
CARDIOVASCULAR SYSTEMS, INC.	\$800
STERNO PRODUCTS	\$777
ORASURE TECHNOLOGIES, INC.	\$775
MYLAN SPECIALTY L.P.	\$763
INPRO CORPORATION	\$748
OCEAN SPRAY	\$729
HARDY DIAGNOSTICS	\$716
NESTLE USA, INC.	\$712
HEARTLAND FOOD PRODUCTS GROUP	\$712
MCI FOODS INC	\$702
BROOKWOOD FARMS, INC.	\$693
DARLINGTON SNACKS	\$669
BIONIX, LLC	\$622
MHC MEDICAL PRODUCTS, LLC	\$609
GREENFIELD GLOBAL USA INC.	\$597
MYLAN PHARMACEUTICALS INC.	\$596
KERMA MEDICAL PRODUCTS, INC.	\$579
HAEMONETICS CORPORATION	\$576
PULMODYNE	\$569
SIEMENS HEALTHCARE DIAGNOSTICS INC.	\$563
	,

SUPPLIER 04 SPEND FY2024 AMD MEDICOM INC. \$553 ALLEN MEDICAL SYSTEMS, INC. \$538 MIZUHO ORTHOPEDIC SYSTEMS, INC. \$538 SOLCO HEALTHCARE US, LLC \$493 CARRIER ENTERPRISE, LLC \$492 IMPOSSIBLE FOODS INC. \$490 KING CHEESECAKE COMPANY, INC. \$474 LANNETT COMPANY, INC. \$474 LANNETT COMPANY, INC. \$434 AUROBINDO PHARMA USA, INC. \$438 BARILLA AMERICA INC. \$414 BIONPHARMA, INC. \$404 NATCO PHARMA USA, LLC \$403 ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$394 TAGIF PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$226 BEYOND MEAT, INC. \$292 MEDITITION, INC. \$286 HERITAGE PHARMACEUTICALS INC \$235 ALVOGEN, INC. \$235 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$226 FERRIS MFG, CORP.	HARRIS HEALTH PREMIER Q4 SPEND FY2024	
ALLEN MEDICAL SYSTEMS, INC. \$538 MIZUHO ORTHOPEDIC SYSTEMS, INC. \$492 CARRIER ENTERPRISE, LLC \$493 CARRIER ENTERPRISE, LLC \$490 CARRIER ENTERPRISE, LLC \$490 KING CHEESECAKE COMPANY, INC. \$490 MICROTEK MEDICAL, INC. \$444 LANNETT COMPANY, INC. \$444 DURACELL INDUSTRIBLO OPERATIONS, INC. \$438 AUROBINDO PHARMA USA, INC. \$414 BIONPHARMA, INC. \$414 BIONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$403 CACCORD HEALTHCARE INC \$404 NATCO PHARMA USA LLC \$403 CACCORD HEALTHCARE INC \$404 NATCO PHARMA USA LLC \$403 TAGI PHARMA \$371 THE HERTZ CORPORATION \$385 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$283 ALVOGEN, INC. \$244 MEDICURE PHARMA, INC. \$240 MEDICURE PHARMA, INC. \$241 MEDICURE PHARMA, INC. \$242 MEDICURE PHARMA, INC. \$240 MEDICURE PHARMA, INC. \$240 MEDICURE PHARMA, INC. \$241 MEDICURE PHARMA, INC. \$242 MEDICURE PHARMA, INC. \$242 MEDICURE PHARMA, INC. \$245 FERRIS MFG. CORP. \$221 FURMANO FOODS, INC. \$3189 PATRIOT PHARMACEUTICALS LLC MINONO NORDISK PHARMACEUTICALS LLC MINONO NORDISK PHARMACEUTICALS, INC. \$3194 DYMA BRANDS, INC. \$315 SLATE RUN PHARMACEUTICALS LLC MONON ORDISK PHARMACEUTICALS INC. \$315 SLATE RUN PHARMACEUTICALS LLC MONON ORDISK PHARMACEUTICALS INC. \$315 SLATE RUN PHARMACEUTICALS LLC MONON ORDISK PHARMACEUTICALS INC. \$315 SLATE RUN PHARMACEUTICALS LLC MONON ORDISK PHARMACEUTICALS INC. \$315 SLATE RUN PHARMACEUTICALS LLC MONON ORDISK PHARMACEUTICALS INC. \$315 SLATE RUN PHARMACEUTICALS USA KING & PRINCE SEAFOOD CORPORATION \$312 NONON ORDISK PHARMACEUTICALS USA KING & PRINCE SEAFOOD CORPORATION \$312 NONON ORDISK PHARMACEUTICALS, LLC \$312 THE SHERWIN-WILLIALMS COMPANY \$312 NONAGHAM MEDICAL CORPORATION \$312 NONAGHAM MEDICAL CORPORATION \$312 NONAGHAM MEDICAL CORPORATION \$312 NONAGHAM MEDICAL CORPORATION \$312 MERSELER US. JA. MEDICAL, LLC \$3131		Q4 SPEND FY2024
MIZUHO ORTHOPEDIC SYSTEMS, INC. \$535 SOLCO HEALTHCARE US, LLC \$493 CARRIER BETREPRISE, LLC \$492 IMPOSSIBLE FOODS INC. \$490 KING CHEESECAKE COMPANY, INC. \$494 MICROTEK MEDICAL, INC. \$444 LANNETT COMPANY, INC. \$444 DURACELL INDUSTRIBL OPERATIONS, INC. \$438 AUROBINDO PHARMA USA, INC. \$436 BABRILLA AMERICA INC. \$444 BONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$403 ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$490 KENTEC MEDICAL, INC. \$490 KENTEC MEDICAL, INC. \$490 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$226 BEYOND MEAT, INC. \$292 MEDITITION, INC. \$292 HERITAGE PHARMACEUTICALS INC \$223 HERITAGE PHARMA, INC. \$223 FERRIS MFG. CORP. \$221 KETTLE CU	AMD MEDICOM INC.	\$553
SOLCO HEALTHCARE US, LLC \$493 CARRIER ENTERPRISE, LLC \$492 IMPOSSIBLE FOODS INC. \$490 KING CHEESECAKE COMPANY, INC. \$490 MICROTEK MEDICAL, INC. \$474 LANNETT COMPANY, INC. \$448 DURACELL INDUSTRIAL OPERATIONS, INC. \$438 AUROBINDO PHARMA USA, INC. \$436 BARILLA AMERICA INC. \$414 BIONPHARMA, INC. \$403 ACCORD HEALTHCARE INC \$403 ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$394 KENTEC MEDICAL, INC. \$393 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDITITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALYOGEN, INC. \$240 MEDICURE PHARMA, INC. \$234 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURNANO FOODS, INC. \$120 SIMPLYTHICK, LLC \$	ALLEN MEDICAL SYSTEMS, INC.	\$538
CARRIER ENTERPRISE, LLC \$492 IMPOSSIBLE FOODS INC. \$490 KING CHEESECAKE COMPANY, INC. \$474 MICROTEK MEDICAL, INC. \$474 LANNETT COMPANY, INC. \$444 DURACELL INDUSTRIAL OPERATIONS, INC. \$436 BARILLA AMERICA INC. \$436 BARILLA AMERICA INC. \$414 BIONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$403 ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 BEYOND MEAT, INC. \$292 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$228 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MIFG. CORP. \$221 KETLE CUISINE \$210	MIZUHO ORTHOPEDIC SYSTEMS, INC.	\$535
IMPOSSIBLE FOODS INC. \$490 KING CHEESECAKE COMPANY, INC. \$490 MICROTEK MEDICAL, INC. \$474 LANNETT COMPANY, INC. \$448 DURACELL INDUSTRIAL OPERATIONS, INC. \$438 AUROBINDO PHARMA USA, INC. \$438 BARILLA AMERICA INC. \$414 BIONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$403 ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$282 MEDTRITION, INC. \$282 MEDICURE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$225 FERRIS MEG. CORP. \$221 KETILE CUISINE \$210 FURMANO FOODS, INC. \$180 SIMPLYTHICK, LLC \$189	SOLCO HEALTHCARE US, LLC	\$493
KING CHEESECAKE COMPANY, INC. \$490 MICROTEK MEDICAL, INC. \$474 LANNETT COMPANY, INC. \$444 DURACELL INDUSTRIAL OPERATIONS, INC. \$438 AUROBINDO PHARMA USA, INC. \$414 BONPHARMA, INC. \$414 BIONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$402 ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDITITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURNANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$157 JOHNSON & JOHNSON CONSUMER INC.	CARRIER ENTERPRISE, LLC	\$492
MICROTEK MEDICAL, INC. \$444 LANNETT COMPANY, INC. \$448 DURACELL INDUSTRIAL OPERATIONS, INC. \$438 AUROBINDO PHARMA USA, INC. \$436 BARILLA AMERICA INC. \$404 BIONPHARMA, INC. \$402 NATCO PHARMA USA LLC \$403 ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$352 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDITITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$225 JOERNS HEALTHCARE, LLC \$246 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$218 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$157 JOHNSON & JOHNSON CONSUMER INC. \$157 FERRERO USA INC. \$157	IMPOSSIBLE FOODS INC.	\$490
LANNETT COMPANY, INC. \$444 DURACELL INDUSTRIAL OPERATIONS, INC. \$438 AUROBINDO PHARMA USA, INC. \$414 BARILLA AMERICA INC. \$414 BIONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$403 ACCORD HEALTHCARE INC \$403 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$256 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$224 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$225 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$120 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. <t< td=""><td>KING CHEESECAKE COMPANY, INC.</td><td>\$490</td></t<>	KING CHEESECAKE COMPANY, INC.	\$490
DURACELL INDUSTRIAL OPERATIONS, INC. \$438 AUROBINDO PHARMA USA, INC. \$436 BARILLA AMERICA INC. \$404 BIONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$402 ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTITITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYHIICK, LLC \$180 MCCAIN FOODS USA, INC. \$157 JOHNSON & JOHNSON CONSUMER INC. \$157 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$157 SLATE RUN PHARMACEUTICALS, INC. \$157 OYMA BRANDS, INC.	MICROTEK MEDICAL, INC.	\$474
AUROBINDO PHARMA USA, INC. \$436 BARILLA AMERICA INC. \$414 BIONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$403 ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$292 MEDTRITION, INC. \$292 MEDTRITION, INC. \$293 HERITAGE PHARMACEUTICALS INC \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$253 ALVOGEN, INC. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$321 FURMANO FOODS, INC. \$321 FURMANO FOODS, INC. \$322 SIMPLYTHICK, LLC \$338 MCCAIN FOODS USA, INC. \$157 JOHNSON & JOHNSON CONSUMER INC. \$157 NOVO NORDISK PHARMACEUTICALS INC \$157 NOVO NORDISK PHARMACEUTICALS INC \$157 NOVO NORDISK PHARMACEUTICALS INC. \$158 CAMBER PHARMACEUTICALS INC. \$159 CAMBER PHARMACEUTICALS INC. \$151 NOVO NORDISK PHARMACEUTICALS INC. \$151 NOVO NORDISK PHARMACEUTICALS INC. \$152 CAMBER PHARMACEUTICALS INC. \$153 CAMBER PHARMACEUTICALS INC. \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$130 MONAGHAN MEDICAL CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$132 MEXISTER SEARCH, LLC \$113	LANNETT COMPANY, INC.	\$444
BARILLA AMERICA INC. \$444 BIONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$403 ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUSINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$157 JOHNSON & JOHNSON CONSUMER INC. \$157 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS SINC \$155 POST CONSUMER BRANDS \$136<	DURACELL INDUSTRIAL OPERATIONS, INC.	\$438
BIONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$403 ACCORD HEALTHCARE INC \$3402 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$996 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOENNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$220 FURMANO FOODS, INC. \$120 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$15 JOHNSON & JOHNSON CONSUMER INC. \$157 JOHNSON RAMAMACEUTICALS, INC. \$157 SLATE RUN PHARMACEUTICALS INC. \$155 SLATE RUN PHARMACEUTICALS INC. \$155 SLATE RUN PHARMACEUTICALS INC. \$155 OYMA BRANDS, INC.	AUROBINDO PHARMA USA, INC.	\$436
BIONPHARMA, INC. \$404 NATCO PHARMA USA LLC \$403 ACCORD HEALTHCARE INC \$3402 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$996 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOENNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$220 FURMANO FOODS, INC. \$120 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$15 JOHNSON & JOHNSON CONSUMER INC. \$157 JOHNSON RAMAMACEUTICALS, INC. \$157 SLATE RUN PHARMACEUTICALS INC. \$155 SLATE RUN PHARMACEUTICALS INC. \$155 SLATE RUN PHARMACEUTICALS INC. \$155 OYMA BRANDS, INC.	BARILLA AMERICA INC.	\$414
ACCORD HEALTHCARE INC \$402 KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 MCCAIN FOODS USA, INC. \$189 MCCAIN FOODS USA, INC. \$167 JOHNSON & JOHNSON CONSUMER INC. \$155 SLATE RUN PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS INC \$136 MCSAIN PHARMACEUTICALS INC \$155 SLATE RUN PHARMACEUTICALS INC. \$154 MOST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$122 NEXUS PHARMACEUTICALS, LLC \$124 METREX RESEARCH, LLC \$111 METREX RESEARCH, LLC \$111 METREX RESEARCH, LLC \$111 METREX RESEARCH, LLC \$111	BIONPHARMA, INC.	
KENTEC MEDICAL, INC. \$394 TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$189 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS INC \$155 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$122 NEXUS PHARMACEUTICALS, LLC	NATCO PHARMA USA LLC	\$403
TAGI PHARMA \$371 THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$180 MCCAIN FOODS USA, INC. \$120 JOHNSON & JOHNSON CONSUMER INC. \$150 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$157 SLATE RUN PHARMACEUTICALS INC. \$155 CAMBER PHARMACEUTICALS INC. \$155 CAMBER PHARMACEUTICALS INC. \$154 POST CONSUMER BRANDS \$136 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATI	ACCORD HEALTHCARE INC	\$402
THE HERTZ CORPORATION \$355 ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$2282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$189 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$157 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$157 CAMBER PHARMACEUTICALS INC \$158 POST CONSUMER BRANDS \$133 DYMA BRANDS, INC. \$154 POST CONSUMER BRANDS \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDI	KENTEC MEDICAL, INC.	\$394
ECO-PRODUCTS, INC. \$326 KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$2246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$155 CAMBER PHARMACEUTICALS INC \$136 TWI PHARMACEUTICALS USA \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$122 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$113	TAGI PHARMA	\$371
KIND, LLC \$296 BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$221 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$122 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 <td< td=""><td>THE HERTZ CORPORATION</td><td>\$355</td></td<>	THE HERTZ CORPORATION	\$355
BEYOND MEAT, INC. \$292 MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS INC \$155 SLATE RUN PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$113	ECO-PRODUCTS, INC.	\$326
MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$157 SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$133 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113 <td>KIND, LLC</td> <td>\$296</td>	KIND, LLC	\$296
MEDTRITION, INC. \$282 HERITAGE PHARMACEUTICALS INC \$253 ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$157 SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$133 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113 <td>BEYOND MEAT, INC.</td> <td>\$292</td>	BEYOND MEAT, INC.	\$292
ALVOGEN, INC. \$246 JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS INC \$155 SLATE RUN PHARMACEUTICALS INC \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113		\$282
JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	HERITAGE PHARMACEUTICALS INC	\$253
JOERNS HEALTHCARE, LLC \$240 MEDICURE PHARMA, INC. \$235 FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	ALVOGEN, INC.	· · · · · · · · · · · · · · · · · · ·
FERRIS MFG. CORP. \$221 KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113		
KETTLE CUISINE \$210 FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$114	MEDICURE PHARMA, INC.	\$235
FURMANO FOODS, INC. \$202 SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	FERRIS MFG. CORP.	\$221
SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS INC \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	KETTLE CUISINE	\$210
SIMPLYTHICK, LLC \$189 PATRIOT PHARMACEUTICALS LLC \$180 MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS INC \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	FURMANO FOODS, INC.	
PATRIOT PHARMACEUTICALS LLC MCCAIN FOODS USA, INC. JOHNSON & JOHNSON CONSUMER INC. FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	SIMPLYTHICK, LLC	·
MCCAIN FOODS USA, INC. \$174 JOHNSON & JOHNSON CONSUMER INC. \$167 FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS INC \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113		
FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	MCCAIN FOODS USA, INC.	
FERRERO USA INC. \$157 NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	JOHNSON & JOHNSON CONSUMER INC.	\$167
NOVO NORDISK PHARMACEUTICALS, INC. \$155 SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	FERRERO USA INC.	
SLATE RUN PHARMACEUTICALS \$155 CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	NOVO NORDISK PHARMACEUTICALS, INC.	
CAMBER PHARMACEUTICALS INC \$154 POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	SLATE RUN PHARMACEUTICALS	
POST CONSUMER BRANDS \$139 DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	CAMBER PHARMACEUTICALS INC	
DYMA BRANDS, INC. \$136 TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	POST CONSUMER BRANDS	
TWI PHARMACEUTICALS USA \$135 KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	DYMA BRANDS, INC.	
KING & PRINCE SEAFOOD CORPORATION \$132 MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	·	· · · · · · · · · · · · · · · · · · ·
MONAGHAN MEDICAL CORPORATION \$129 NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	KING & PRINCE SEAFOOD CORPORATION	
NEXUS PHARMACEUTICALS, LLC \$124 THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	MONAGHAN MEDICAL CORPORATION	
THE SHERWIN-WILLIAMS COMPANY \$120 BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113		
BRASSELER U.S.A. MEDICAL, LLC \$114 METREX RESEARCH, LLC \$113	·	· · · · · · · · · · · · · · · · · · ·
METREX RESEARCH, LLC \$113		
	·	· · · · · · · · · · · · · · · · · · ·

HARRIS HEALTH PREMIER Q4 SPEND FY2	024
SUPPLIER	Q4 SPEND FY2024
GERI-CARE PHARMACEUTICALS CORP.	\$109
DAVIDS COOKIES	\$99
HR PHARMACEUTICALS, INC. DBA HR HEALTHCARE	\$95
PAR-WAY TRYSON COMPANY	\$77
RUIZ FOODS, INC.	\$73
MARKETLAB, INC.	\$66
T MARZETTI COMPANY	\$63
RC BIGELOW, INC.	\$54
RAULAND-BORG CORPORATION	\$50
ADVAGEN PHARMA LTD.	\$50
LIFESTAR PHARMA LLC	\$50
INHARVEST, INC.	\$47
INGENUS PHARMACEUTICALS, LLC	\$46
ROLAND FOODS, LLC	\$39
ORGANON USA, INC.	\$38
WORLD CENTRIC	\$36
LOGIQUIP L.L.C.	\$36
MEDEFIL, INC.	\$36
BLACKHIVE CORP	\$34
LYONS MAGNUS	\$34
KVK-TECH, INC.	\$30
BRANDING IRON HOLDINGS, INC	\$27
ACTION HEALTH	\$13
SOL-MILLENNIUM MEDICAL INC	\$10
GRAND TOTAL	\$65,339,329



HARRIS HEALTH PREMIER Q4 SPEND FY2024						
Premier Contract Category	Q4 Spend FY2024					
Patient Care	\$15,084,859					
Surgical & Imaging	\$13,110,014					
Pharmacy	\$10,777,085					
Services	\$10,114,073					
Food & Nutrition	\$4,689,020					
Laboratory	\$3,832,940					
Distribution	\$3,465,367					
Facilities	\$2,644,999					
IT/ Telecom	\$1,620,972					
Grand Total	\$65,339,329					

BOARD OF TRUSTEES

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Consideration of Approval of Contract Recommendations
(Items C1 through C2 of the Contract Matrix)

- C1. Request for additional funding related to and Interlocal Agreement for services provided by The University of Texas Health Science Center at Houston to Harris Health
 - Contractor: The University of Texas Health Science Center at Houston (UTHSC)
 - Project Owner: Dr. Amy Smith
 - Term: August 1, 2024 March 21, 2025
 - Amount: Additional \$1,500,000.00

In July 2024, Harris Health's agreement with UTHSC was amended to increase the number of available beds at UTHSC dedicated to Harris Health patients due to projected increased demand, and to align the rates with HHSC self-pay rates of \$700 per bed day.

As a result of these changes, Harris Health administration is requesting Board approval to allocate an additional \$1.5 million to cover the increased costs through the remainder of the purchase order period to fund outstanding invoices.

- C2. Consideration of approval of a non-exclusive temporary license agreement between the Board of Regents of The University of Texas System and Harris Health "licensee" for the use and benefit of the Pickens Shuttle Stop at the University of Texas M.D. Anderson Cancer Center.
 - Contractor: Board of Regents of The University of Texas System
 - Project Owner: Mr. Christopher Okezie and Mr. Jon Hallaway
 - Term: Effective date of the executed contract December 31, 2029
 - Amount: \$15,119.57

The agreement requires Harris Health to cover an apportioned share of cleaning and maintenance costs for the Pickens Shuttle Stop, which is located adjacent to TMC Garage 17 and will allow Harris Health shuttle buses to continue to use the Pickens Shuttle Stop for the convenience of Harris Health employees traveling to and from TMC Garage 17 and Ben Taub Hospital.

Licensee shall pay MD Anderson the license fee set forth in the schedule below:

- o Effective Date 12/31/25: \$2,847.84
- 0 01/01/26 12/31/26: \$2,933.28
- 0 01/01/27 12/31/27: \$3,021.27
- 0 01/01/28 12/31/28: \$3,111.91
- 0 01/01/29 12/31/29: \$3,205.27

Contract Agenda Item(s) for the Harris County Hospital District dba Harris Health, Board of Trustees Report Contract Matrix: February 27, 2025

No.	Contractor	Description/Justification	Action, Basis of Recommendation	Term	Project Owner	Amount
C1	The University of Texas Health Science Center at Houston (UTHSC)	Consideration of approval to allocate an additional \$1.5 Million in Funding for inpatient, psychiatric services provided by The University of Texas Health Science Center at Houston to Harris Health patients when Harris Health lacks sufficient resources to provide the immediate inpatient, psychiatric services.	Additional Funding for an Interlocal Agreement	August 1, 2024 through March 21, 2025	Dr. Amy Smith	\$ 1,500,000.00
C2	Board of Regents of The University of Texas System	Consideration of approval of a non-exclusive temporary license agreement between the Board of Regents of The University of Texas System and the Harris County Hospital District d/b/a Harris Health "licensee" for the use and benefit of the Pickens Shuttle Stop at the University of Texas M.D. Anderson Cancer Center.	Non-Exclusive Temporary License Agreement	Effective Date of the Executed Contract through December 31, 2029	Christopher Okezie and Jon Hallaway	\$ 15,119.57
					TOTAL AMOUNT:	\$ 1,515,119.57

Page 1 of 1 2/20/2025 3:54 PM

BOARD OF TRUSTEES

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025


Consideration of Acceptance of the Harris Health January 2025 Financial Report
Subject to Audit

Attached for your review and consideration is the January 2025 Financial Report.

Administration recommends that the Board accept the financial report for the period ended January 31, 2025, subject to final audit.

Victoria Nikitin

EVP - Chief Financial Officer



Financial Statements

As of January 31, 2025 Subject to Audit



Table of Contents

HARRISHEALTH

Financial Highlights Review.	3
FINANCIAL STATEMENTS	
Income Statement.	4
Balance Sheet	5
Cash Flow Summary	6
Performance Ratios.	7
KEY STATISTICAL INDICATORS	
Statistical Highlights	9
Statistical Highlights Graphs	10 - 21

Financial Highlights Review HARRISHEALTH

As of January 31, 2025

Operating income for the month ended January 31, 2025 was \$23.1 million compared to budgeted income of \$4.5 million.

Total net revenue for the month ended January 31, 2025 of \$184.7 million was \$16.3 million or 9.7% more than budget. Net patient revenue and ad valorem taxes were \$14.1 million and \$3.8 million, respectively, more than budget. Medicaid Supplemental programs were \$2.2 million more than expected primarily due to timing.

As of January 31, 2025, total expenses of \$217.7 million were \$0.2 million or 0.07% less than budget. Total services had a favorable variance of \$4.2 million driven mostly by lower purchased services, offset by emergency facilities closure paid time off due to Winter Storm Enzo.

Through the month ended January 31, 2025, total patient days and average daily census increased 2.8% compared to budget. Inpatient case mix index, a measure of patient acuity, and length of stay were 2.0% and 16.8% higher, respectively, than budget. Emergency room visits were 3.6% less than budget. Total clinic visits, including telehealth, were 3.5% lower compared to budget. Births were down 6.9%.

Total cash receipts for the month were \$706.6 million. The System has \$1,578.4 million in unrestricted cash, cash equivalents and investments, representing 241.0 days cash on hand. Harris Health System has \$135.4 million in net accounts receivable, representing 63.8 days of outstanding patient accounts receivable at January 31, 2025. The January balance sheet reflects a combined net receivable position of \$160.0 million under the various Medicaid Supplemental programs. The current portion of ad valorem taxes receivable is \$381.5 million, which is offset by ad valorem tax collections as received. Accounts payable and accrued liabilities include \$703.9 million in deferred ad valorem tax revenues that are released as ad valorem tax revenue is recognized. As of January 31, 2025, \$561.5 million in ad valorem tax collections were received and \$87.3 million in current ad valorem tax revenue was recognized.

Income Statement

HARRISHEALTH

As of January 31, 2025 and 2024 (in \$ Millions)

	MONTH-TO-MONTH				YEAR-TO-DATE								
	CURRENT		CURI	RENT	PERCENT		CURRENT	(CURRENT	PERCENT	PRIOR		PERCENT
		/EAR	BUD	GET	VARIANCE	_	YEAR		BUDGET	VARIANCE		YEAR	VARIANCE
REVENUE													
Net Patient Revenue	\$	77.9	\$	63.9	22.0%		\$ 261.0	\$	250.6	4.1%	\$	252.3	3.5%
Medicaid Supplemental Programs		56.1		53.9	4.1%		210.5		215.7	-2.4%		223.5	-5.8%
Other Operating Revenue		12.2		12.2	0.0%	_	46.9		48.4	-3.0%		43.4	8.1%
Total Operating Revenue	\$	146.3	\$	130.0	12.5%		\$ 518.5	\$	514.7	0.7%	\$	519.2	-0.1%
Net Ad Valorem Taxes		88.9		85.1	4.5%		338.2		340.3	-0.6%		300.8	12.4%
Net Tobacco Settlement Revenue		-		-	0.0%		-		-	0.0%		-	0.0%
Capital Gifts & Grants		-		0.8	0.0%		-		3.3	-100.0%		-	0.0%
Interest Income & Other		5.7		6.5	-11.1%		21.5		25.9	-16.8%		20.1	7.0%
Total Nonoperating Revenue	\$	94.6	\$	92.4	2.4%		\$ 359.7	\$	369.5	-2.6%	\$	320.9	12.1%
Total Net Revenue	\$	240.9	\$	222.3	8.3%		\$ 878.2	\$	884.2	-0.7%	\$	840.1	4.5%
<u>EXPENSE</u>													
Salaries and Wages	\$	93.6	\$	87.6	-6.9%		\$ 337.9	\$	337.7	-0.1%	\$	312.9	-8.0%
Employee Benefits		28.8		27.7	-4.2%		104.8		110.7	5.3%		110.2	5.0%
Total Labor Cost	\$	122.5	\$	115.2	-6.3%		\$ 442.7	\$	448.3	1.3%	\$	423.2	-4.6%
Supply Expenses		25.0		29.8	16.0%		105.6		116.8	9.6%		97.5	-8.3%
Physician Services		37.2		38.7	4.0%		150.2		155.0	3.1%		138.9	-8.1%
Purchased Services		24.0		26.7	10.1%		100.2		115.5	13.2%		86.9	-15.4%
Depreciation & Interest		9.0		7.4	-21.7%		35.4		29.8	-18.7%		34.5	-2.6%
Total Operating Expense	\$	217.7	\$	217.9	0.1%	_	\$ 834.1	\$	865.4	3.6%	\$	780.9	-6.8%
Operating Income (Loss)	\$	23.1	\$	4.5		-	\$ 44.1	\$	18.8		\$	59.2	
Total Margin %		9.6%		2.0%		=	5.0%		2.1%			7.0%	

Balance Sheet

HARRISHEALTH

January 2025 and 2024 (in \$ Millions)

	CURRENT YEAR		PRIOR YEAR		
CURRENT ASSETS					
Cash, Cash Equivalents and Short Term Investments	\$	1,578.4	\$	1,426.7	
Net Patient Accounts Receivable		135.4		180.2	
Net Ad Valorem Taxes, Current Portion		381.5		415.8	
Other Current Assets		264.1		347.9	
Total Current Assets	\$	2,359.5	\$	2,370.5	
CAPITAL ASSETS					
Plant, Property, & Equipment, Net of Accumulated Depreciation	\$	563.7	\$	540.1	
Construction in Progress		297.8		147.0	
Right of Use Assets		34.0		41.6	
Total Capital Assets	\$	895.4	\$	728.7	
ASSETS LIMITED AS TO USE & RESTRICTED ASSETS					
Debt Service & Capital Asset Funds	\$	35.6	\$	41.5	
LPPF Restricted Cash		132.8		141.9	
Capital Gift Proceeds		54.5		55.6	
Other - Restricted		1.0		1.0	
Total Assets Limited As to Use & Restricted Assets	\$	224.0	\$	240.0	
Other Assets		40.5		50.0	
Deferred Outflows of Resources		182.3		234.8	
Total Assets & Deferred Outflows of Resources	\$	3,701.8	\$	3,624.0	
CURRENT LIABILITIES					
Accounts Payable and Accrued Liabilities	\$	306.3	\$	330.5	
Employee Compensation & Related Liabilities		148.7		154.8	
Deferred Revenue - Ad Valorem		703.9		606.0	
Estimated Third-Party Payor Settlements		30.7		23.0	
Current Portion Long-Term Debt and Capital Leases		36.4		36.7	
Total Current Liabilities	\$	1,226.0	\$	1,151.1	
Long-Term Debt		277.0		297.8	
Net Pension & Post Employment Benefits Liability		683.4		780.2	
Other Long-Term Liabilities		8.1		7.0	
Deferred Inflows of Resources		110.4		115.3	
Total Liabilities	\$	2,304.7	\$	2,351.4	
Total Net Assets	\$	1,397.0	\$	1,272.6	
Total Liabilities & Net Assets	\$	3,701.8	\$	3,624.0	

Cash Flow Summary

HARRISHEALTH

As of January 31, 2025 and 2024 (in \$ Millions)

	MONTH-TO-MONTH					YEAR-TO-DATE			
	CURRENT PRIOR			CURRENT		PRIOR			
	YEAR YEAR			YEAR	YEAR		YEAR		
<u>CASH RECEIPTS</u>									
Collections on Patient Accounts	\$	77.3	\$	70.3	\$	282.9	\$	281.1	
Medicaid Supplemental Programs		63.1		(29.9)		72.4		382.7	
Net Ad Valorem Taxes		561.5		366.8		657.3		481.1	
Tobacco Settlement		-		-		-		-	
Other Revenue		4.8		32.4		34.6		74.0	
Total Cash Receipts	\$	706.6	\$	439.6	\$	1,047.2	\$	1,219.0	
CASH DISBURSEMENTS									
Salaries, Wages and Benefits	\$	143.7	\$	92.9	\$	444.4	\$	422.9	
Supplies		29.9		22.9		126.2		102.3	
Physician Services		36.4		33.0		142.1		132.6	
Purchased Services		0.0		19.8		103.2		87.3	
Capital Expenditures		32.6		12.5		121.8		53.8	
Debt and Interest Payments		0.3		0.2		1.1		1.1	
Other Uses		(6.3)		12.6		(6.6)		4.9	
Total Cash Disbursements	\$	236.6	\$	194.0	\$	932.2	\$	805.0	
Net Change	\$	470.0	\$	245.7	\$	115.0	\$	414.0	
Unrestricted cash, cash equivalents and investments - Beginning of year					\$	1,463.4			
					\$	1,465.4			
Net Change Untrestricted cash, cash equivalents and investments - End of period					\$	1,578.4	•		
onnesuncted cash, cash equivalents and investments - End of period						1,370.4	•		

Performance Ratios

HARRISHEALTH

As of January 31, 2025 and 2024 (in \$ Millions)

	MONTH-TO-MONTH			YEAR-TO-DATE						
	CURRENT			URRENT	IT CURRENT			URRENT	PRIOR	
	YEAR		В	UDGET	YEAR		BUDGET			YEAR
OPERATING HEALTH INDICATORS										
Operating Margin %		9.6%		2.0%		5.0%		2.1%		7.0%
Run Rate per Day (In\$ Millions)	\$	6.8	\$	6.8	\$	6.5	\$	6.8	\$	6.1
Salary, Wages & Benefit per APD	\$	2,772	\$	2,663	\$	2,477	\$	2,563	\$	2,432
Supply Cost per APD	\$	567	\$	689	\$	591	\$	668	\$	561
Physician Services per APD	\$	842	\$	896	\$	840	\$	886	\$	798
Total Expense per APD	\$	4,929	\$	5,036	\$	4,667	\$	4,948	\$	4,489
Overtime as a % of Total Salaries		5.2%		3.0%		3.8%		3.1%		3.3%
Contract as a % of Total Salaries		2.5%		2.8%		3.2%		2.8%		4.8%
Full-time Equivalent Employees		10,662		10,775		10,502		10,707		10,322
FINANCIAL HEALTH INDICATORS										
Quick Ratio						1.9				2.0
Unrestricted Cash (In \$ Millions)					\$	1,578.4	\$	1,746.7	\$	1,426.7
Days Cash on Hand						241.0		256.3		232.8
Days Revenue in Accounts Receivable						63.8		76.3		87.8
Days in Accounts Payable						44.6				82.2
Capital Expenditures/Depreciation & Amortization						383.1%				189.4%
Average Age of Plant(years)						9.8				10.3

Harris Health Key Indicators




Statistical Highlights


HARRISHEALTH

As of January 31, 2025 and 2024

	MONTH-TO-MONTH				YEAR-TO-DATE				
	CURRENT	CURRENT	PERCENT	CURRENT	CURRENT	PERCENT	PRIOR	PERCENT	
	QUARTER	BUDGET	CHANGE	YEAR	BUDGET	CHANGE	YEAR	CHANGE	
Adjusted Patient Days	44,175	43,145	2.4%	178,718	175,868	1.6%	173,974	2.7%	
Outpatient % of Adjusted Volume	61.6%	60.8%	1.2%	62.7%	61.5%	2.0%	61.3%	2.4%	
Primary Care Clinic Visits	41,045	43,153	-4.9%	178,263	176,180	1.2%	171,056	4.2%	
Specialty Clinic Visits	19,015	19,413	-2.1%	82,329	79,160	4.0%	78,201	5.3%	
Telehealth Clinic Visits	9,689	9,678	0.1%	39,594	39,188	1.0%	37,812	4.7%	
Total Clinic Visits	69,749	72,244	-3.5%	300,186	294,528	1.9%	287,069	4.6%	
Emergency Room Visits - Outpatient	11,463	11,808	-2.9%	46,976	46,416	1.2%	45,198	3.9%	
Emergency Room Visits - Admitted	1,777	1,925	-7.7%	7,043	7,420	-5.1%	7,180	-1.9%	
Total Emergency Room Visits	13,240	13,733	-3.6%	54,019	53,836	0.3%	52,378	3.1%	
Surgery Cases - Outpatient	892	1,025	-13.0%	3,833	3,811	0.6%	3,711	3.3%	
Surgery Cases - Inpatient	870	887	-1.9%	3,625	3,416	6.1%	3,234	12.1%	
Total Surgery Cases	1,762	1,912	-7.8%	7,458	7,227	3.2%	6,945	7.4%	
Total Outpatient Visits	117,930	119,986	-1.7%	505,050	485,957	3.9%	471,001	7.2%	
Inpatient Cases (Discharges)	2,375	2,763	-14.0%	10,227	10,795	-5.3%	10,585	-3.4%	
Outpatient Observation Cases	983	938	4.8%	3,989	3,528	13.1%	3,762	6.0%	
Total Cases Occupying Patient Beds	3,358	3,701	-9.3%	14,216	14,323	-0.7%	14,347	-0.9%	
Births	482	518	-6.9%	1,961	1,875	4.6%	1,768	10.9%	
Inpatient Days	16,962	16,894	0.4%	66,602	67,737	-1.7%	67,368	-1.1%	
Outpatient Observation Days	3,672	3,170	15.8%	14,646	11,647	25.7%	12,722	15.1%	
Total Patient Days	20,634	20,064	2.8%	81,248	79,384	2.3%	80,090	1.4%	
Average Daily Census	665.6	647.2	2.8%	660.5	645.4	2.3%	651.1	1.4%	
Average Operating Beds	701	700	0.1%	702	700	0.3%	696	0.9%	
Bed Occupancy %	95.0%	92.5%	2.7%	94.1%	92.2%	2.1%	93.6%	0.6%	
Inpatient Average Length of Stay	7.14	6.11	16.8%	6.51	6.27	3.8%	6.36	2.3%	
Inpatient Case Mix Index (CMI)	1.746	1.712	2.0%	1.707	1.712	-0.3%	1.682	1.5%	
Payor Mix (% of Charges)									
Charity & Self Pay	41.2%	43.4%	-5.0%	41.8%	43.4%	-3.5%	44.8%	-6.6%	
Medicaid & Medicaid Managed	20.5%	19.4%	5.8%	20.0%	19.4%	3.1%	19.9%	0.6%	
Medicare & Medicare Managed	11.6%	11.4%	1.6%	11.1%	11.4%	-2.8%	11.8%	-6.1%	
Commercial & Other	26.6%	25.8%	3.3%	27.0%	25.8%	4.9%	23.5%	15.1%	
Total Unduplicated Patients - Rolling 12				246,191			246,821	-0.3%	
Total New Patient - Rolling 12				89,728			88,761	1.1%	


Statistical Highlights
January FY 2025








Emergency Visits - CM Actual Budget Prior Year 13,240 13,733 13,461













	Statistical Highlights January FY 2025										
Sur	gery Cases - (<u>CM</u>	Surge	ery Cases	- YTD	<u>Cli</u>	nic Visits -	<u>CM</u>	Clinic Visits - YTD		
Actual	J	Prior Year	Actual	Budget	Prior Year	Actual	Budget	Prior Year	Actual	Budget	Prior Year
1,762	1,912	1,720	7,458	7,227	6,945	69,749	72,244	69,849	300,186	294,528	287,069
Surgery Cases - Current Month						Clir	nic Visits -	Current N	Month		
2,500 -						100,000					
2,000 -		-				80,000 -					
1,500 -	242		341	24	8	60,000	9,689		9,678	77	,707
1,000 -	505		543	49	99	40,000 -	19,015		19,413		3,982
500 -	1,015		1,028	9:	73	20,000 -	41,045		43,153	41	L,160
0						o _		La Carlo	THE REPORT OF THE PART WHEN THE REPORT OF THE PART AND TH		
	ACTUAL 2025	BU	JDGET 2025	PRIOF	YEAR		ACTUAL 202	5	BUDGET 2025	PRI	OR YEAR
■В	Ben Taub 🔲 Lynde	on B. Johnson	■Ambulatory	Surgical Cente	r (ASC)		Primary Care	Clinics Spec	ialty Clinics 🔲	Telehealth Clinic V	'isits
	Sı	ırgery (Cases - YTD)				Clinic \	/isits - YTD)	
10,000 ¬	30	argery C	a3C3 - 11D	•		400,000 ¬		Cillic	13103 - 112	•	
8,000 -						320,000					
6,000	1,102		1,095	1,0	96	240,000 -	39,594	芸	39,188	37	,812
	2,231		2,190	1,9	064		82,329		79,160	78	3,201
4,000						160,000 -	470.262	25 25 25 25 25 25 25 25 25 25 25 25 25 2	176 100		
2,000 -	4,125		3,942	3,8	885	80,000 -	178,263		176,180	· 17	1,056
0 —	ACTUAL 2025	В	UDGET 2025	PRIOF	RYEAR	0 —	ACTUAL 202	5	BUDGET 2025	PRIC	DR YEAR

■ Primary Care Clinics ■ Specialty Clinics ■ Telehealth Clinic Visits

■ Lyndon B. Johnson ■ Ambulatory Surgical Center (ASC)

Ben Taub







Statistical Highlights - Cases Occupying Beds
January FY 2025


BT Cases Occupying Beds - CM								
Actual	Budget	Prior Year						
1,962	2,278	2,070						


BT Cases Occupying Beds - YTD								
Actual	Budget	Prior Year						
8.295	8.591	8.547						





LBJ Cases Occupying Beds - YTD								
Actual	Budget	Prior Year						
5,863	5,669	5,800						














Statistical Highlights - Emergency Room Visits
January FY 2025


BT Emergency Visits - CM			BT Emergency Visits - YTD		
Actual	Budget	Prior Year	Actual	Budget	Prior Year
6,772	7,236	6,874	27,411	28,217	27,582





LBJ Emergency Visits - YTD					
Actual	Budget	Prior Year			
26,608	25,619	24,796			























BOARD OF TRUSTEES

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Consideration of Approval to Acquire McGee, Troost, and LBJ Hospital Loop Streets in exchange for Consideration and the Conveyance of Easements to the City of Houston

Administration recommends Board of Trustees approval of the acquisition of real property and the conveyance of easements to the City of Houston as follows:

Harris Health shall acquire from the City of Houston:

- 1) ± 18,600 square feet of McGee Street, from Lockwood Drive east to LBJ Hospital Loop;
- 2) ± 15,000 square feet of Troost Street, from Lockwood Drive east to LBJ Hospital Loop; and
- 3) ±24,000 square feet of LBJ Hospital Loop, between McGee Street and Troost St

Harris Health will convey to the City of Houston:

- 1) A ±3,327 square foot right of way easement on Lockwood Drive between Kelly Street and McGee Street;
- 2) Two 20-foot-wide storm sewer easements; and
- A ±375 square foot water meter easement,

All real property to be acquired and/or conveyed through this approval is out of the Kashmere Gardens Park Partial Replat No. 2 and Extension, Harris & Wilson Survey, Abstract No. 32. Parcels SY24-065A through SY24-065C, AY24-136, LY24-118, LY24-119, and KY24-164.

Harris Health has provisionally accepted the City of Houston's request for additional consideration in the amount of \$320,508.00 as the appraised value for the acquired properties, subject to completion of the transaction requirements and approval of the Houston City Council, Harris Health Board of Trustees and Harris County Commissioner's Court.

SVP – Facilities Construction &

Systems Engineering

Sr. EVP/Chief Operating Officer



December 12, 2024

Chuck Davis C.L. Davis & Company 1500 Winding Way Friendswood, Texas 77546

Offer Letter

Subject: Abandonment and sale of: 1) ±18,600 square feet of McGee Street, from Lockwood Drive east to LBJ Hospital Loop, 2) ±15,000 square feet of Troost Street, from Lockwood Drive east to LBJ Hospital Loop, and 3) ±24,000 square feet of LBJ Hospital Loop, between McGee Street and Troost Street, in exchange for the conveyance to the City of: 1) ±3,327 square feet of Lockwood Drive right of way easement between Kelly Street and McGee Street, 2) two 20 foot-wide storm sewer easements, and 3) a ±375 square feet water meter easement, all out of the Kashmere Gardens Park Partial Replat No. 2 and Extension, Harris & Wilson Survey, Abstract No. 32. Parcels SY24-065A through SY24-065C, AY24-136, LY24-118, LY24-119, and KY24-164

Dear Mr. Davis:

This letter is the City's offer to conclude the captioned transaction for a consideration of \$320,508.00 subject to your completion of the outstanding transaction requirements and City Council approval.

Please provide the following required documents within fifteen days from the date of this letter:

- 1. A letter from Harris Health System accepting the City's offer.
- 2. A cashier's check payable to the City of Houston for the \$316,608.00 total balance of consideration. We will hold these funds with the \$3,900.00 nonrefundable City appraisal fee deposit.
- 3. A letter of no objection from each of the privately-owned utility companies.
- 4. Proof Item 4 of the Contact Letter dated May 7, 2024 (Attachment 1) is completed.
- 5. A Certificate of Final Completion as proof the requirements in Item 7 of the Contact Letter dated May 7, 2024, are completed.

Should you not be able to accept the offer within the fifteen-day period and are unable to do so no later than thirty days from the date of this letter, this offer will be considered withdrawn, and the file will be canceled without further communication To pursue the transaction thereafter might require either: (1) you to initiate the process anew OR (2) an appraisal update. If, at the City's sole discretion, the latter alternative is chosen, you will be required to submit a written request and an additional nonrefundable deposit equal to the cost of updating the appraisal. This additional nonrefundable deposit will not be applied toward the consideration. The City's updated offer will be for the higher of the original appraised value or the updated appraised value.

PO Box 1562 | Houston, Texas 77251-1562 | HoustonPublicWorks.org

Upon your completing these requirements, we will request our Legal Department to prepare the conveyance instruments.

Attached for your information are copies of the approved field notes and Drawing No. 78162.

Should you have any questions, please contact Eboni Taylor, Real Estate Analyst, Real Estate Services – Asset Management, at (832) 395-3139. All correspondence should reference the captioned parcel for prompt handling.

Sincerely,

DocuSigned by:

DocuSi

Addie L. Jackson, Esq Assistant Director – Real Estate Services Capital Projects Houston Public Works

ALJ:WSB:et

File: ab\sy24-065clsc.doc

ec: Patrick Casey, Harris Health System



May 7, 2024

Mr. Chuck Davis C.L. Davis and Company 1500 Winding Way Friendswood, Texas 77546

Contact Letter

Subject: Abandonment and sale of: 1) ±18,600 square feet of McGee Street, from Lockwood Drive east to LBJ Hospital Loop, 2) ±15,000 square feet of Troost Street, from Lockwood Drive east to LBJ Hospital Loop, and 3) ±24,000 square feet of LBJ Hospital Loop, between McGee Street and Troost Street, in exchange for the conveyance to the City of: 1) ±3,327 square feet of Lockwood Drive right of way easement between Kelly Street and McGee Street, 2) two 20 foot-wide storm sewer easements, and 3) a ±375 square feet water meter easement, all out of the Kashmere Gardens Park Partial Replat No. 2 and Extension, Harris & Wilson Survey, Abstract No. 32. **Parcels SY24-065A through SY24-065C, AY24-136, LY24-118, LY24-119, and KY24-164**

Dear Mr. Davis:

The Joint Referral Committee (JRC) has reviewed and approved your request for the abandonment and sale of the subject property interests, subject to your completion of the requirements necessary to proceed with the transaction and final approval thereafter by City Council. We ask that you signify your acknowledgment and acceptance of these requirements by signing and returning to our office the attached "Acknowledgment and Acceptance Statement" (Attachment 1) within 10 business days from the date of this letter. You may also choose not to accept the requirements or proceed with the transaction.

This letter is your notice of the requirements to proceed with the request. As you begin work on the requirements below, use this Contact Letter as needed for permits, plan and profile review or any other City process that requires evidence you are fulfilling the requirements to complete a JRC transaction.

Should you choose to proceed, you must complete these requirements within 30 days from the date of this letter. An extension may be granted based upon your written request stating the business need for the extension. The requirements to proceed with the transaction are listed below and should be pursued simultaneously. Processing one requirement at a time will prolong the time needed to complete this transaction.

- 1. You must submit a \$3,900.00 nonrefundable deposit by cashier's check payable to the City of Houston as follows:
 - (a) \$900.00, an amount representing the \$300.00 minimum fee required for the conveyance of a public land interest for each of the three abandonment parcels ($3 \times 300 = 900.00$) and

PO Box 1562 | Houston, Texas 77251-1562 | HoustonPublicWorks.org
Capital Projects | Customer Account Services | Houston Permitting Center | Houston Water | Transportation & Drainage Operations



(b) \$3,000.00, an amount equal to the City's estimated appraisal fees.

Should the appraisal fees be greater than estimated, we will contact you about the additional required deposit amount. If the transaction is concluded, the deposit will be applied toward the consideration. Otherwise, the City will retain the deposit to cover its operating expenses.

2. You must submit a survey map and field notes of the abandonment and sale and conveyance parcels labeled as Parcels SY24-065A through SY24-065C (requested streets) and conveyance parcels labeled as LY24-118, LY24-119 (storm easements), and KY24-164 (water meter easement) and AY24-136 (right-of-way easement) to Eboni Taylor at eboni.taylor@houstontx.gov. Please refer to the parcel maps (Attachment 2). The survey map(s) and field notes must be signed and sealed by the surveyor responsible for the map(s) and field notes. All maps must be submitted in PDF format and a minimum size of 11"X17". For more information, please contact the Survey Section at (832) 395-2382 and/or refer to the attached JRC Approval – Survey Checklist (Attachment 3).

Upon receipt of the required deposit as listed in Item 1 and the approved electronic survey map and field notes of the affected property as listed in Item 2, we will request the appraisal. You should continue processing the other requirements enumerated in this letter while the appraisal is being completed.

- 3. You must obtain a letter of no objection from each of the privately-owned utility companies for the streets being abandoned and sold. Please see the attached list of the privately-owned utility companies (Attachment 4). A plat or clear description of the property should accompany your written request.
- 4. You must convert the streetlights from the City of Houston's ownership to CenterPoint Energy. This item must be completed at no cost to the City. For specific instructions concerning this requirement, you may contact Judith Burgos with Transportation and Drainage Operations at (832) 395-3001. Keep Real Estate Services informed of the activity undertaken to complete the requirement.
- 5. You must submit an original Statement of Ownership Letter from an attorney-at-law. The letter must include a copy of the documents conveying title to the property owner. Attached is a sample letter (Attachment 5) to assist you in complying with this requirement. If there are liens on the property to the conveyance parcels, the letter must disclose the lienholders and include copies of the lien instruments. Our Legal Department will prepare the conveyance deed, and should it be necessary, subordination agreements for the lienholders to execute. Harris County Hospital District must be the sole abutting property owner to all the tracts abutting the requested streets. Private property owners can not be denied public right-of-way access.
- 6. You must submit business documents when conveying a property interest to the City. Please see the attached list of required business documents (Attachment 6).
- 7. You must separately permit the following utility construction items as marked on the GIMS map (Attachment 7):

Sanitary

(a) Cut, plug and abandon the 8-inch sanitary sewer and sanitary sewer manholes (MH# IB047014) located at McGee and LBJ Loop and (MH# IB047014A) located at McGee Street and Lockwood Drive from the sanitary sewer manhole (MH# IB047013) located

PO Box 1562 | Houston, Texas 77251-1562 | HoustonPublicWorks.org
Capital Projects | Customer Account Services | Houston Permitting Center | Houston Water | Transportation & Drainage Operations



- at Lockwood Drive and McGee Street approximately 333 feet east to its terminus or converted to private sewer from manhole (MH# IB047014A) east to its terminus.
- (b) Cut, plug and abandon the 8-inch sanitary sewer and sanitary sewer manholes (MH# IB047008A, MH# IB047008, MH# IB047009, MH# IB047010B, MH# IB047010A, MH# IB047010) at Troost Street from the sanitary sewer manhole (MH# IB047007) at Lockwood Drive approximately 1,163 feet east to its terminus or converted to private use and a private manhole will need to be installed at the intersection of Lockwood Drive and Troost Street. Any existing connection on the sanitary sewer to be abandoned must be relocated to the 8-inch sanitary sewer to remain in Lockwood Drive.

Water

- (c) Cut, plug and abandon the 8-inch water line from the 12-inch water main in Lockwood Drive, approximately 393 feet east to its terminus in McGee Street and approximately 459 feet in LBJ Loop from McGee Street to Troost Street. Since the water meter can not be abandoned, it must be relocated contiguous in Lockwood Drive within a 15 by 25 foot-wide water meter easement. The rest will be converted to private water line after the water meter. All existing water line lead connections must be reconnected to a feasible active water line.
- (d) Relocate all fire hydrants in proposed abandon right-of-way (McGee Street, LBJ Hospital Loop, Troost Street) to the Lockwood Drive in compliance with the Infrastructure Design Manual (IDM). Any existing connection on the water line to be abandoned, must be relocated to the 12-inch water main to remain in Lockwood Drive. The cut, plug, and abandonment of the water main must meet and be in accordance to provide water circulation following looping requirements per COH IDM to avoid and eliminate deadend water lines.

Storm

- (e) Convey two 20 foot-wide storm sewer easements for the five (5) storm inlets at the intersection of Lockwood Drive and McGee Street and at the intersection of Lockwood Drive and Troost Street. The City will maintain 24/7 full access to the storm sewer utilities. The rest will be converted to private service or needs to be abandoned.
- (f) The foregoing items must be completed as stated unless conditions on the ground or City standards require modifications to the items.

The forgoing items must be completed at no cost to the City and under the proper permits obtained separately and exclusively for public rights-of-way and easements independent of private development.

For specific instructions concerning these requirements, you may contact Gilbert Portillo in the Office of the City Engineer at (832) 394-9546.

- (g) Keep Real Estate Services informed of the activities undertaken to satisfy these requirements.
- (h) Provide Eboni Taylor with copies of the permits documenting the construction approvals.



8. You must:

- (a) Prepare a **separate set of drawings** that show the public utilities (sanitary sewer, water, storm) that are being abandoned, relocated, and/or constructed as part of this JRC transaction **independent of any overall project drawings.**
- (b) Submit the drawings to the Office of the City Engineer for plan review and approval.
- (c) Attach a copy of this letter to the plan set when it is submitted for plan review.
- (d) A copy of the approved plans and permit must be submitted to Eboni Taylor before the transaction can be concluded.
- (e) Provide a copy of a **Certificate of Final Completion** (Attachment 8) completed by your Project Manager and reviewed and approved by City personnel. For specific instructions concerning this requirement, you may contact Richard Smith at 832-395-2322.
- You must submit a separate cashier's check in the amount of \$50,689.76 payable to the City of Houston for the depreciated value of water lines, sanitary sewer lines and manholes that are being abandoned.
- 10. You must submit a separate cashier's check in the amount of \$8,480.00 payable to the City of Houston for the depreciated value of the storm sewer lines that are being abandoned.

Once the subject abandonment and conveyance parcels have been surveyed and appraised, an Offer Letter will be forwarded to you that will include the requirement to pay the balance of consideration and listing any outstanding items from the requirements above. Once you have completed the requirements listed in this letter and the Offer Letter, Real Estate Services will process a Request for Council Action (RCA) requesting City Council approval of an ordinance effecting the final abandonment and sale of the City's property interests.

Should you have any questions, please contact Eboni Taylor, Real Estate Analyst, Real Estate Services-Asset Management, at (832) 395-3139.

Sincerely,



Addie L. Jackson, Esq. Assistant Director - Real Estate Services Capital Projects Houston Public Works

ALJ:WSB:et ab\sy24-065clsc.doc

8 Attachments

- 1. Acknowledgment and Acceptance Statement
- 2. Parcels Maps
- 3. Survey Checklist
- 4. List of Private Utility Companies
- 5. Sample Statement of Ownership Letter
- 6 Business Documents
- 7. GIMS Map


PO Box 1562 | Houston, Texas 77251-1562 | HoustonPublicWorks.org

Capital Projects | Customer Account Services | Houston Permitting Center | Houston Water | Transportation & Drainage Operations



8. Certificate of Final Completion

ec: Patrick Casey, Harris County Hospital District
Survey Section
Richard Smith
Gilbert Portillo
Judith Burgos
Geoff Butler
Deidre VanLangren



PARCEL SY24-065A PORTION OF McGEE STREET METES AND BOUNDS DESCRIPTION 0.4281 ACRE BEING OUT OF KASHMERE GARDENS PARK SECTION HARRIS AND WILSON SURVEY, ABSTRACT NO. 32 HOUSTON, HARRIS COUNTY, TEXAS

All that certain 0.4821 acre (18,836 square feet) being a portion of McGee Street (60' wide) as dedicated by Kashmere Gardens Park Section according to the plat thereof as filed in Volume 15, Page 18, Harris County Map Records, Harris and Wilson Survey, Abstract No. 32, Houston, Harris County, Texas, said portion of McGee Street being between the east right-of-way line of Lockwood Drive (100' wide) and extending east to its terminus being the west line of Unrestricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 2 and Extension according to the plat thereof as filed in Film Code Number 652012 Harris County Map Records and being more particularly described by metes and bounds as follows (Bearings and coordinates based on Texas Coordinate System of 1983, South Central Zone No. 4204. Distances shown are surface and can be converted to grid by multiplying by a combined scale factor of 0.99990022);

Commencing at Harris County Floodplain Reference Mark No. 080210 having published grid coordinates of N: 13,861,698.31, E: 3,138,048.38, and from which Harris County Floodplain Reference Mark No. 080100 bears S 59° 07' 59" E – 2,058.68' for reference; Thence S 88° 59' 29" W – 1,565.87' to a found 1/2" iron rod marking the northwest corner of said Unrestricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 2 and Extension from which a found 1/2" iron rod bears N 86° 23' 02" W – 0.65' for reference; Thence the following (3) courses with the west line of said Kashmere Gardens Partial Replat No. 2 and Extension; Thence S 02° 30' 22" E – 135.99' (called 135.90') to a found 1/2" iron rod for corner from which a found 5/8" iron rod with cap (stamped RPLS 4400) bears N 78° 01' 05" W – 0.21' for reference; Thence N 87° 19' 14" E – 59.86' (called 60.00') to a found 5/8" iron rod for corner; Thence S 02° 34' 30" E – 200.04' (called 199.90') to a found 5/8" iron rod with cap (stamped RPLS 4400) marking the southeast corner of Lot 1816, Block 76 of said Kashmere Gardens Park Section and marking a point on the existing north right-of-way line of said McGee Street and marking the POINT OF BEGINNING of herein described tract having grid coordinates of N: 13,861,338.04, E: 3,136,557.72;

- 1. Thence S 02° 34' 30" E 59.87' continuing with the west line of said Kashmere Gardens Partial Replat No. 2 and Extension to set "X" cut in concrete for corner;
- 2. Thence S 87° 19' 14" W 60.39' with the south right-of-way line of said McGee Street to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner and marking the intersection of the south right-of-way line of said McGee Street and the east right-of-way line of LBJ Hospital Loop (60' wide);

00-11-999 McGee SY24-065A M&B.doc

- 3. Thence S 87° 23' 38" W 60.00' to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) marking the northeast corner of Lot 1849, Block 77 of said Kashmere Gardens Park Section and marking the intersection of the south right-of-way line of said McGee Street and the west right-of-way line of LBJ Hospital Loop and from which a found 5/8" iron rod with cap (stamped Town & Country) bears S 01° 35' 10" W 0.26' for reference;
- 4. Thence S 87° 25' 12" W 174.90' with the common south right-of-way line of said McGee Street and the north line of Lot 1849, Block 77 of said Kashmere Gardens Park Section to a found 5/8" iron rod with cap (stamped EIC Surveying Co.) for corner and marking the north end of a cut-back corner located at the intersection of the south right-of-way line of said McGee Street and the east right-of-way line of said Lockwood Drive as dedicated by that certain right-of-way deed filed in the Official Records of Real Property of Harris County at Clerk's File Number S-170858 and Film Code Number 510-47-2206;
- 5. Thence S 42° 28' 19" W 21.21' with said cut-back corner to a found 5/8" iron rod with cap (stamped EIC Surveying Co.) for corner marking the south end of said cut-back corner;
- 6. Thence N 02° 31' 41" W 14.46' to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner:
- 7. Thence N 01° 29' 35" E 70.75' to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) marking a point on a cut-back line located at the intersection of said Lockwood Drive and north right-of-way line of said McGee Street, as dedicated that certain deed filed in the Official Records of Real Property of Harris County at Clerk's File Number M-930776 and Film Code Number 195-61-2130:
- 8. Thence S 47° 31' 41" E 14.19' with said cut-back corner to a point for corner (unable to set due to power pole);
- 9. Thence N 87° 25' 12" E 295.25' with the north right-of-way line of said McGee Street and the south line of Lots 1814, 1815 and 1816, Block 76 of said Kashmere Gardens Park Section to the POINT OF BEGINNING and containing 0.4281 acre (18,648 square feet) of land more or less.

This metes and bounds description is accompanied by a separate plat, drawing or exhibit per Texas Board of Professional Land Surveyor's "General Rules of Procedures and Practices" Section 663.19(9).

Compiled by:

C.L. Davis & Company Firm No. 10082000

Job Number: 11-999 McGee SY24-065A M&B.doc

07-12-2024



PARCEL SY24-065B PORTION OF TROOST STREET METES AND BOUNDS DESCRIPTION 0.3492 ACRE BEING OUT OF KASHMERE GARDENS PARK SECTION HARRIS AND WILSON SURVEY, ABSTRACT NO. 32 HOUSTON, HARRIS COUNTY, TEXAS

All that certain 0.3492 acre (15,210 square feet) being a portion of Troost Street (60' wide) as dedicated by Kashmere Gardens Park Section according to the plat thereof as filed in Volume 15, Page 18, Harris County Map Records, Harris and Wilson Survey, Abstract No. 32, Houston, Harris County, Texas, said portion of Troost Street being between the east right-of-way line of Lockwood Drive (100' wide) and extending east to its terminus being the west line of Unrestricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 2 and Extension according to the plat thereof as filed in Film Code Number 652012 Harris County Map Records and being more particularly described by metes and bounds as follows (Bearings and coordinates based on Texas Coordinate System of 1983, South Central Zone No. 4204. Distances shown are surface and can be converted to grid by multiplying by a combined scale factor of 0.99990022);

Commencing at Harris County Floodplain Reference Mark No. 080210 having published grid coordinates of N: 13,861,698.31, E: 3,138,048.38, and from which Harris County Floodplain Reference Mark No. 080100 bears S 59° 07' 59" E - 2,058.68' for reference; Thence S 88° 59' 29" W - 1,565.87' to a found 1/2" iron rod marking the northwest corner of said Unrestricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 2 and Extension from which a found 1/2" iron rod bears N 86° 23' 02" W - 0.65' for reference; Thence the following (3) courses with the west line of said Kashmere Gardens Partial Replat No. 2 and Extension; Thence S 02° 30' 22" E - 135.99' (called 135.90') to a found 1/2" iron rod for corner and from which a found 5/8" iron rod with cap (stamped RPLS 4400) be N 78° 01' 05" W -0.21' for reference; Thence N 87° 19' 14" E - 59.86' (called 60.00') to a found 5/8" iron rod for corner; Thence S 02° 34' 30" E - 200.04' (called 199.90') to a found 5/8" iron rod with cap (stamped RPLS 4400) marking the southeast corner of Lot 1816, Block 76 of said Kashmere Gardens Park Section and marking a point on the existing north right-of-way line of said McGee Street (60' wide); Thence S 02° 34' 30" E - 59.87' continuing with the west line of said Kashmere Gardens Partial Replat No. 2 and Extension to set "X" cut in concrete for corner; Thence S 87° 19' 14" W - 60.39' with the south right-of-way line of said McGee Street to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner and marking the intersection of the south right-of-way line of said McGee Street and the east right-of-way line of LBJ Hospital Loop (60' wide); Thence S 02° 30' 22" E - 400.24' with the common east right-ofway line of said LBJ Hospital Loop and the west line of said Kashmere Gardens Partial Replat No. 2 and Extension to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) marking the POINT OF BEGINNING of herein described tract having grid coordinates of N: 13,860,875.60, E: 3,136,517.59;

1. Thence S 02° 30' 22" E - 60.00' with the west line of said Unrestricted Reserve "A", Block 1 Kashmere Gardens Park Partial Replat No. 2 and Extension to a found 5/8" iron rod for corner and marking the southeast corner of said Troost Street;

00-11-999 Troost SY24-065B M&B.doc

- 2. Thence S 87° 28' 19" W 234.73' with the common south right-of-way line of said Troost Street and the north line of Restricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 3 according to the plat thereof as filed in Film Code Number 666028 Harris County Map Records to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner and marking the north end of a cut-back corner located at the intersection of the south right-of-way line of said Troost Street and the east right-of-way line of said Lockwood Drive as dedicated by that certain right-of-way deed filed in the Official Records of Real Property of Harris County at Clerk's File Number P-203168 and Film Code Number 104-52-0643;
- 3. Thence S 42° 28' 19" W 21.21' with said cut-back corner to a set "X" cut in concrete for corner marking the south end of said cut-back corner and from which a found 5/8" iron rod bears N 24° 51' 54" W 0.49' for reference;
- 4. Thence N 02° 31' 41" W 90.00' to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner and marking the north end of a cut-back corner located at the intersection of the north right-of-way line of said Troost Street and the east right-of-way line of said Lockwood Drive as dedicated by that certain right-of-way deed filed in the Official Records of Real Property of Harris County at Clerk's File Number N-033193 and Film Code Number 027-19-1557;
- 5. Thence S 47° 31' 41" E-21.21' with said cut-back corner to a point (unable to set) for corner and marking the south end of said cut-back corner;
- 6. Thence N 87° 28' 19" E 174.75' with the common north right-of-way line of said Troost Street and the south line of Lot 1855, Block 77 of said Kashmere Gardens Park Section to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner and marking the southeast corner of said Lot 1855 and marking the intersection of the north right-of-way line of said Troost Street and the west right-of-way line LBJ Hospital Loop;
- 7. Thence N 87° 28' 19" E-60.00' to the POINT OF BEGINNING and containing 0.3492 acre (15,210 square feet) of land more or less.

This metes and bounds description is accompanied by a separate plat, drawing or exhibit per Texas Board of Professional Land Surveyor's "General Rules of Procedures and Practices" Section 663.19(9).

Compiled by:

C.L. Davis & Company Firm No. 10082000

Job Number: 11-999 Troost SY24-065B M&B.doc

07-12-2024



PARCEL SY24-065C LBJ HOSPITAL LOOP METES AND BOUNDS DESCRIPTION 0.5512 ACRE BEING OUT OF KASHMERE GARDENS PARK SECTION HARRIS AND WILSON SURVEY, ABSTRACT NO. 32 HOUSTON, HARRIS COUNTY, TEXAS

All that certain 0.5512 acre (24,011 square feet) being all of LBJ Hospital Loop (60' wide) as established by that certain called Street Right-of-Way Easement Parcel No. AY9-552 as described in a deed dated 01-09-2013 from Harris County Hospital District to The City of Houston as filed in the Official Records of Real Property of Harris County at Clerk's File Number 20130026417 and Film Code Number 085-52-1967 located between McGee Street (60' wide) and Troost Street (60' wide) as dedicated by Kashmere Gardens Park Section according to the plat thereof as filed in Volume 15, Page 18, Harris County Map Records, Harris and Wilson Survey, Abstract No. 32, Houston, Harris County, Texas and being more particularly described by metes and bounds as follows (Bearings and coordinates based on Texas Coordinate System of 1983, South Central Zone No. 4204. Distances shown are surface and can be converted to grid by multiplying by a combined scale factor of 0.99990022);

Commencing at Harris County Floodplain Reference Mark No. 080210 having published grid coordinates of N: 13,861,698.31, E: 3,138,048.38, and from which Harris County Floodplain Reference Mark No. 080100 bears S 59° 07' 59" E - 2,058.68' for reference; Thence S 88° 59' 29" W = 1,565.87' to a found 1/2" iron rod marking the northwest corner of Unrestricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 2 and Extension according to the plat thereof as filed in Film Code Number 652012 Harris County Map Records and from which a found 1/2" iron rod bears N 86° 23' 02" W - 0.65' for reference; Thence the following (3) courses with the west line of said Kashmere Gardens Partial Replat No. 2 and Extension; Thence S 02° 30' 22" E-135.99' (called 135.90') to a found 1/2" iron rod for corner and from which a found 5/8" iron rod with cap (stamped RPLS 4400) bears N 78° 01' 05" W -0.21' for reference; Thence N 87° 19' 14" E - 59.86' (called 60.00') to a found 5/8" iron rod for corner; Thence S 02° 34' 30" E-200.04' (called 199.90') to a found 5/8" iron rod with cap (stamped RPLS 4400) marking the southeast corner of Lot 1816, Block 76 of said Kashmere Gardens Park Section and marking a point on the existing north right-of-way line of said McGee Street (60' wide); Thence S 02° 34' 30" E - 59.87' continuing with the west line of said Kashmere Gardens Partial Replat No. 2 and Extension to set "X" cut in concrete for corner; Thence S 87° 19' 14" W = 60.39' with the south right-of-way line of said McGee Street to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) marking the intersection of the south right-of-way line of said McGee Street and the east right-of-way line of LBJ Hospital Loop (60' wide) and marking the POINT OF BEGINNING of herein described tract having grid coordinates of N: 13,861,275.41, E: 3,136,500.09;

00-11-999 LBJ Hospital Loop SY24-065C M&B.doc

- 1. Thence S 02° 30' 22" E 400.24' with the common east right-of-way line of said LBJ Hospital Loop and the west line of said Kashmere Gardens Partial Replat No. 2 and Extension to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner;
- 2. Thence S 87° 28' 19" W 60.00' to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner and marking the southeast corner of Lot 1855, Block 77 of said Kashmere Gardens Park Section and marking the intersection of the north right-of-way line of said Troost Street and the west right-of-way line LBJ Hospital Loop;
- 3. Thence N 02° 30' 21" W 400.15' with the common west right-of-way line of said LBJ Hospital Loop and east line Lots 1849 through 1855 Block 77 of said Kashmere Gardens Park Section to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) from which a found 5/8" iron rod with cap (stamped Town & Country) bears S 01° 35' 10" W 0.26' for reference;
- 4. Thence N 87° 23' 38" E-60.00' to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) to the POINT OF BEGINNING and containing 0.5512 acre (24,011 square feet) of land more or less.

This metes and bounds description is accompanied by a separate plat, drawing or exhibit per Texas Board of Professional Land Surveyor's "General Rules of Procedures and Practices" Section 663.19(9).

Compiled by: C.L. Davis & Company Firm No. 10082000

Job Number: 11-999 LBJ Hospital Loop SY24-065C M&B.doc

07-12-2024



PARCEL AY24-136
RIGHT-OF-WAY EASEMENT
METES AND BOUNDS DESCRIPTION
0.0762 ACRE BEING OUT OF
LOTS 1810 – 1814, BLOCK 76
KASHMERE GARDENS PARK SECTION
HARRIS AND WILSON SURVEY, ABSTRACT NO. 32
HOUSTON, HARRIS COUNTY, TEXAS

All that certain 0.0762 acre (3,321 square feet) being out of Lots 1810 – 1814, Block 76 Kashmere Gardens Park Section according to the plat thereof as filed in Volume 15, Page 18, Harris County Map Records, Harris and Wilson Survey, Abstract No. 32, Houston, Harris County, Texas, and being more particularly described by metes and bounds as follows (Bearings and coordinates based on Texas Coordinate System of 1983, South Central Zone No. 4204. Distances shown are surface and can be converted to grid by multiplying by a combined scale factor of 0.99990022);

Commencing at Harris County Floodplain Reference Mark No. 080210 having published grid coordinates of N: 13,861,698.31, E: 3,138,048.38, and from which Harris County Floodplain Reference Mark No. 080100 bears S 59° 07' 59" E – 2,058.68' for reference; Thence S 88° 59' 29" W – 1,565.87' to a found 1/2" iron rod marking the northwest corner of said Unrestricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 2 and Extension according to the plat thereof as filed in Film Code Number 652012 Harris County Map Records, from which a found 1/2" iron rod bears N 86° 23' 02" W – 0.65' for reference; Thence S 87° 26' 00" W – 230.27' with the south right-of-way line of Kelley Street (150' wide) to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner; Thence S 02° 31' 41" E – 55.99' to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner, from which a found 1/2" iron rod bears N 80° 39' 50" E – 0.41' for reference; Thence S 87° 28' 19" W – 5.00' to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) marking the POINT OF BEGINNING of herein described tract having grid coordinates of N: 13,861,604.44, E: 3,136,250.46;

Thence the following (2) courses with the proposed east right-of-way line of Lockwood Drive;

- 1. Thence S 02° 31' 41" E 127.15' to a set 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner;
- 2. Thence S 01° 29' 35" W 143.16' to a set 5/8" iron rod for corner;

Thence the following (2) courses with the west right-of-way line of Lockwood Drive (150' wide) as established by that certain easement for street and road purposes as filed in the Official Records of Real Property of Harris County at Clerk's File Number M-930776 and Film Code Number 195-61-2130;

00-11-999 R-W ESMT- AY24-136 M&B.doc

- 3. Thence N 47° 31' 41" W-7.02' to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner;
- 4. Thence N 02° 31' 41" W 265.00' to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner, from which a found 5/8" iron rod with cap (unreadable) bears S 05° 38' 18" W 0.37' for reference;
- 5. Thence N 87° 28' 19" E 15.00' to the POINT OF BEGINNING and containing 0.0762 acre (3,321 square feet) of land more or less.

This metes and bounds description is accompanied by a separate plat, drawing or exhibit per Texas Board of Professional Land Surveyor's "General Rules of Procedures and Practices" Section 663.19(9).

Compiled by:

C.L. Davis & Company Firm No. 10082000

Job Number: 11-999 RIGHT-OF-WAY ESMT- AY24-136 M&B.doc 07-12-2024



PARCEL LY24-118 STORM SEWER EASEMENT METES AND BOUNDS DESCRIPTION 0.0344 ACRE BEING OUT OF KASHMERE GARDENS PARK SECTION HARRIS AND WILSON SURVEY, ABSTRACT NO. 32 HOUSTON, HARRIS COUNTY, TEXAS

All that certain 0.0344 acre (1,500 square feet) being out of Troost Street (60' wide) as dedicated by Kashmere Gardens Park Section according to the plat thereof as filed in Volume 15, Page 18, Harris County Map Records, Harris and Wilson Survey, Abstract No. 32, Houston, Harris County, Texas, said Troost Street being between the east right-of-way line of Lockwood Drive (100' wide) and extending east to its terminus being the west line of Unrestricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 2 and Extension according to the plat thereof as filed in Film Code Number 652012 Harris County Map Records and being more particularly described by metes and bounds as follows (Bearings and coordinates based on Texas Coordinate System of 1983, South Central Zone No. 4204. Distances shown are surface and can be converted to grid by multiplying by a combined scale factor of 0.99990022);

Commencing at Harris County Floodplain Reference Mark No. 080210 having published grid coordinates of N: 13,861,698.31, E: 3,138,048.38, and from which Harris County Floodplain Reference Mark No. 080100 bears S 59° 07' 59" E - 2,058.68' for reference; Thence S 88° 59' 29" W - 1,565.87' to a found 1/2" iron rod marking the northwest corner of said Unrestricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 2 and Extension. from which a found 1/2" iron rod bears N 86° 23' 02" W - 0.65' for reference; Thence S 87° 26' 00" W – 230.27' with the south right-of-way line of Kelley Street (150' wide) to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner; Thence S 02° 31' 41" E - 55.99' to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner, from which a found 1/2" iron rod bears N 80° 39' 50" E - 0.41' for reference; Thence S 87° 28' 19" W - 20.00' to a found 5/8" iron rod (stamped C.L. DAVIS-RPLS 4464) for corner, from which a found 5/8" iron rod with cap (unreadable) bears S 05° 38' 18" W-0.37' for reference; Thence S 02° 31' 41" E – 725.00' with the west right-of-way line of Lockwood Drive (150' wide) to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner and marking the north end of a cut-back corner located at the intersection of the north right-of-way line of said Troost Street and the east right-of-way line of said Lockwood Drive as dedicated by that certain right-of-way deed filed in the Official Records of Real Property of Harris County at Clerk's File Number N-033193 and Film Code Number 027-19-1557: Thence S 47° 31' 41" E – 21.21' with said cut-back corner to a point (unable to set) marking the south end of said cut-back corner and the POINT OF BEGINNING of herein described tract having grid coordinates of N: 13,860,865.24, E: 3,136,283.09;

1. Thence N 87° 28' 19" E – 20.00' with the common north right-of-way line of said Troost Street and the south line of Lot 1855, Block 77 of said Kashmere Gardens Park Section to a point for corner;

00-11-999 Storm Sewer Esmt. LY24-118 M&B.doc

- 2. Thence S 02° 31' 41" E 60.00' to a point for corner on the south right-of -way line if said Troost Street and the north line of Restricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 3 according to the plat thereof filed in Film Code No. 666028 Harris County Map Records;
- 3. Thence S 87° 28' 19" W 20.00' with the common south right-of-way line of said Troost Street and the north line of said Restricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 3 to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner and marking the north end of a cut-back corner located at the intersection of the south right-of-way line of said Troost Street and the east right-of-way line of said Lockwood Drive as dedicated by that certain right-of-way deed filed in the Official Records of Real Property of Harris County at Clerk's File Number P-203168 and Film Code Number 104-52-0643;
- 4. Thence N 02° 31' 41" W -11.17' to a point for corner;
- 5. Thence S 87° 28' 19" W 15.00' to a point for corner;
- 6. Thence N 02° 31' 41" W 20.00' to a point for corner;
- 7. Thence N 87° 28' 19" E 15.00' to a point for corner;
- 8. Thence N 02° 31' 41" W 28.83' to the POINT OF BEGINNING and containing 0.0344 acre (1,500 square feet) of land more or less.

This metes and bounds description is accompanied by a separate plat, drawing or exhibit per Texas Board of Professional Land Surveyor's "General Rules of Procedures and Practices" Section 663.19(9).

Compiled by:

C.L. Davis & Company Firm No. 10082000

Job Number: 00-11-999 Storm Sewer Esmt. LY24-118 M&B.doc

07-12-2024



PARCEL KY24-164 WATER METER EASEMENT METES AND BOUNDS DESCRIPTION 0.0086 ACRE BEING OUT OF KASHMERE GARDENS PARK SECTION HARRIS AND WILSON SURVEY, ABSTRACT NO. 32 HOUSTON, HARRIS COUNTY, TEXAS

All that certain 0.0086 acre (1.500 square feet) being out of Troost Street (60' wide) as dedicated by Kashmere Gardens Park Section and Lot 1855, Block 77 Kashmere Gardens Park Section according to the plat thereof as filed in Volume 15, Page 18, Harris County Map Records, Harris and Wilson Survey, Abstract No. 32, Houston, Harris County, Texas, and being more particularly described by metes and bounds as follows (Bearings and coordinates based on Texas Coordinate System of 1983, South Central Zone No. 4204. Distances shown are surface and can be converted to grid by multiplying by a combined scale factor of 0.99990022);

Commencing at Harris County Floodplain Reference Mark No. 080210 having published grid coordinates of N: 13,861,698.31, E: 3,138,048.38, and from which Harris County Floodplain Reference Mark No. 080100 bears S 59° 07' 59" E – 2,058.68' for reference; Thence S 88° 59' 29" W – 1,565.87' to a found 1/2" iron rod marking the northwest corner of said Unrestricted Reserve "A", Block 1, Kashmere Gardens Park Partial Replat No. 2 and Extension, from which a found 1/2" iron rod bears N 86° 23' 02" W – 0.65' for reference; Thence S 87° 26' 00" W – 230.27' with the south right-of-way line of Kelley Street (150' wide) to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner; Thence S 02° 31' 41" E – 55.99' to a found 5/8" iron rod with cap (stamped C.L. DAVIS-RPLS 4464) for corner, from which a found 1/2" iron rod bears N 80° 39' 50" E – 0.41' for reference; Thence S 87° 28' 19" W – 20.00' to a found 5/8" iron rod (stamped C.L. DAVIS-RPLS 4464) for corner, from which a found 5/8" iron rod with cap (unreadable) bears S 05° 38' 18" W – 0.37' for reference; Thence S 02° 31' 41" E – 716.99' with the west right-of-way line of Lockwood Drive (150' wide) to the POINT OF BEGINNING of herein described tract having grid coordinates of N: 13,860,887.56, E: 3,,136,267.09;

- 1. Thence N 87° 28' 19" E 25.00' to a point for corner;
- 2. Thence S 02° 31' 41" E -15.00' to a point for corner;
- 3. Thence S 87° 28' 19" W 25.00' to a point for corner;
- 4. Thence N 02° 31' 41" W 15.00' with the west right-of-way line of said Lockwood Drive to the POINT OF BEGINNING and containing 0.0086 acre (375 square feet) of land more or less.

00-11-999 Water Meter Esmt. KY24-164 M&B.doc

This metes and bounds description is accompanied by a separate plat, drawing or exhibit per Texas Board of Professional Land Surveyor's "General Rules of Procedures and Practices" Section 663.19(9).

Compiled by: C.L. Davis & Company Firm No. 10082000 Job Number: 11-999 KY24-164 M&B.doc 07-12-2024



00-11-999 Water Meter Esmt. KY24-164 M&B.doc

docusign.

Certificate Of Completion

Envelope Id: A0EB99EA-0290-41B3-BD4E-8F1A4955DA3F

Subject: Complete with Docusign: SY24-065 CUIC 20_10321 Offer Letter.pdf

Source Envelope:

Document Pages: 20 Signatures: 1 Certificate Pages: 5 Initials: 0 AutoNav: Enabled

Envelopeld Stamping: Enabled

Time Zone: (UTC-06:00) Central Time (US & Canada)

Envelope Originator: Deirdre Walker 611 Walker St. HITS

Status: Completed

Houston, TX 77002

Deirdre.Walker@houstontx.gov IP Address: 50.58.210.12

Sent: 12/12/2024 1:52:26 PM

Viewed: 12/12/2024 5:00:59 PM

Signed: 12/12/2024 5:08:09 PM

Sent: 12/12/2024 5:08:12 PM

Timestamp

Record Tracking

Status: Original Holder: Deirdre Walker Location: DocuSign

12/12/2024 1:51:00 PM Deirdre.Walker@houstontx.gov

Security Appliance Status: Connected Pool: FedRamp

Storage Appliance Status: Connected Pool: City of Houston IT Services Location: DocuSign

Signer Events Signature **Timestamp** DocuSigned by:

al Jackson

5F1D621925F944C

Signature Adoption: Pre-selected Style

Using IP Address: 50.58.210.12

AL Jackson addie.jackson@houstontx.gov Asst. Director, Real Estate City of Houston

Not Offered via DocuSign

In Person Signer Events

Security Level: Email, Account Authentication

(None)

Electronic Record and Signature Disclosure:

Signature Editor Delivery Events Status Timestamp

Agent Delivery Events Status Timestamp

Timestamp Intermediary Delivery Events Status

Certified Delivery Events Status Timestamp

Carbon Copy Events **Status Timestamp**

eboni taylor

eboni.taylor@houstontx.gov

Security Level: Email, Account Authentication

(None)

Electronic Record and Signature Disclosure:

Accepted: 10/24/2024 9:36:53 AM ID: 42af93be-d8cf-4f27-bcd5-b12fa9845b4b

COPIED Viewed: 12/13/2024 9:38:21 AM

Witness Events **Signature Timestamp Notary Events Signature Timestamp Envelope Summary Events Status Timestamps Envelope Sent** Hashed/Encrypted 12/12/2024 1:52:26 PM Certified Delivered Security Checked 12/12/2024 5:00:59 PM Signing Complete Security Checked 12/12/2024 5:08:09 PM

Envelope Summary Events	Status	Timestamps
Completed	Security Checked	12/12/2024 5:08:12 PM
Payment Events	Status	Timestamps

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, City of Houston - Information Technology (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact City of Houston - Information Technology:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To advise City of Houston - Information Technology of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from City of Houston - Information Technology

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with City of Houston - Information Technology

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to docusign@houstontx.gov and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify City of Houston Information Technology as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by City of Houston Information Technology during the course of your relationship with City of Houston Information Technology.

BOARD OF TRUSTEES

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Consideration of Approval of the Revised Harris Health 2025 Board of Trustees Calendar

Sara Thomas

Chief Legal Officer/Division Director Harris County Attorney's Office Harris Health

HARRISHEALTH

Board of Trustees 2025 Board Calendar

	M	ARC	JARY H 27 24, 1	, 20	25	S	EPT	EMB	28, 2 ER 2 R 23,	5, 20	025			DO	C AT	QM	A GOVERNING BODY (9:45-10:1 Y 20, 2025 AUGUST 21,													COMPLIANCE & AUDIT COM						MITTEE (10:15-11:45 AM) PTEMBER 11, 2025							
MAY 22, 2025 DECEMBER 11, 2025															AY 15		-						•	25					AY 08, 2025 NOVEMBER 13, 2025														
JUNE 26, 2025 SPECIAL CALL BOARD														GOVERNANCE COMMITTEE (1:15 PM-2:15 PM) FEBRUARY 27, 2025 AUGUST 28, 2025													JOINT CONFERENCE COMMITTEE (12:00 PM-1:00 PM) JANUARY 09, 2025(virtual) SEPTEMBER 11, 2025 (virtual)																
NOVEMBER 13, 2025 (HRSA)												AP	RIL 2 NE 2	4, 2	025 OCTO				CTOBER 23, 2025								MARCH 13, 2025 (virtual) NOVEMBER 13, 202 MAY 08, 2025 (virtual)																
SPECIAL EVENTS														QUALITY COMMITTEE (12:15-1:45 PM)																													
2025 THT Conference (June 12-14, 2025)												FE	BRUA	ARY	77, 2025 JUNE 10, 2025 11, 2025 AUGUST 12, 2025 , 2025 SEPTEMBER 09, 2025						25																						
	В	JDG	ET V	VOR	KSH	OP (1	L:00 I	PM-3	:00 P	M)				ΑP	RIL 0	8, 2	025			0	сто	BER	07, 2	2025																			
	Αl	JGU	IST 0	1, 20)25									M	4Y 06	5, 20	25			Ν	OVE	MBE	R 11	., 202	25																		
		J <i>A</i>	ANU	ARY					FEE	BRU	ARY					N	IARCH				AP			APRI	L					MAY													
S	M	Т	W	TH	F	S	S	M	Т	W	TH	F	S	S	M	Т	W	TH	F	S	S	M	Т	W	TH	F	S	S	M	Т	W	TH	F	S	S	M	Т	W	TH	F			
			1	2	3	4							1							1			1	2	3	4	5					1	2	3	1	2	3	4	5	6			
5	6	7	8	9	10	11	2	3	4	5	6	7	8	2	3	4	5	6	7	8	6	7	8	9	10	11	12	4	5	6	7	8	9	10	8	9	10	11	12	13			
12	13	14	15	16	17	18	9		11				15	9	10			13		15						18							16		15			18					
19						25	16	17	18	19	20	21	22	16	17			20							24	25	26	18	19	20	21	22	23	24	22	23	24	25	2 6	27			
26	27	28	29	30	31		23	24	25	26	2 7	28		23	24	25	26	27	28	29	27	28	29	30				25	26	27	28	29	30	31	29	30							
															30 31																												
JULY AUGUST														SEP	PTEMBER						OCTOBER							NOVEMBER							DE	СЕМЕ	BER						
S	M	Т	W	TH	F	S	S	M	Т	W	TH	F	S	S	M	Т	W	TH	F	S	S	M	Т	W	TH	F	S	S	M	Т	W	TH	F	S	S	M	Т	W	TH	F			
		1	2	3	4	5						1	2		1	2	3	4	5	6				1	2	3	4							1		1	2	3	4	5			
6	7	8	9	10	11	12	3	4	5	6	7	8	9	7	8	9	10	11	12	13	5	6	7	8	9	10	11	2	3	4	5	6	7	8	7	8	9	10	11	12			
13	14	15	16	17	18	19	10		_		14		16	14				18		20						17		9					14		14	15	16	17	18	19			
20	21	22	23	24	25	26	17	18	19	20	2 1	22	23	21	22	23	24	25	26	27	19	20	21	22	23	24	25	16	17	18	19	20	21	22	21	22	23	24	25	26			
27	28	29	30	31			24	25	26	27	28	29	30	28	29	30					26	27	28	29	30	31		23	24	25	26	27	28	29	28	29	30	31					
							31			L																		30								<u> </u>							
HARRIS HEALTH HOLIDAY CLOSLIRES:							01/0	1/2!	5 (New	/ Year'	s Day)		05/	05/26/25 (Memorial Day) 07/04/25 (Inc 06/19/25 (Juneteenth) 09/01/25 (La										ce Day	()								12/25/25 (Christmas) 01/01/26 (New Year's Day)										
	Н	ARI	ris f	EAL.	гн н	OLIL	PAY	CLO	SUKE	:5:			5 (MLK						_					0/0-	10-							_											

Board Approved: 12.12.24 | Revised: 12.16.24, 01.13.25, 01.22.25; 02.27.25

BOARD OF TRUSTEES

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

<u>Updates Regarding Pending State and Federal Legislative and Policy Issues</u>
<u>Impacting Harris Health</u>

R. King Hillier

SVP, Public Policy & Government Relations



February 27, 2025 Board of Trustees Monthly Report

Federal Update

<u>Proposed Reconciliation Packages:</u> With a slim 1 seat majority in the House and 53 seats in the Senate, congressional Republicans have almost no margin for error until April 1, when Florida will hold two special elections to fill vacated seats in the House. These special elections will presumably give Speaker Johnson the votes he needs to pass the Trump agenda in the House without any Democratic votes. The Senate will rely upon the filibuster proof budget reconciliation process, which requires only a simple majority rather than 60 votes for passage.

We are hopeful the reconciliation bill(s) will include extensions for the ACA DSH cuts, telehealth, and hospital-at-home. Each of these bills/issues enjoys broad bipartisan support. DPP, ACA Market Place EPTCs, and site-neutral facility fees will be part of a broader conversation related to health provisions.

Following the release of the Senate's budget resolution text, the House has now introduced its own budget resolution, which incorporates the debt limit into the broader fiscal framework. Attached are the House budget resolution, corresponding funding tables and section-by-section. The Senate Budget Committee passed its budget out of committee by a vote of 11-10 on Wednesday, while the House Budget Committee passed its budget out of committee by a vote of 21-16 on Thursday.

For health care committees of jurisdiction, the House budget resolution instructs:

- Energy & Commerce (E&C): Submit legislative changes to reduce the deficit by at least \$880 billion for FYs 2025–2034 (Much of which could come from Medicaid cuts/reform – see policy statements within the text.)
- Ways & Means (W&Ms): Submit legislative changes that increase the deficit by no more than \$4.5 trillion for FYs 2025–2034.

Budget Process & Outlook

Although the fiscal year began on October 1, the government is still operating under a temporary funding measure that expires on March 14. With time running out, negotiations remain deadlocked over how to finalize the 12 outstanding appropriations bills. Potential outcomes include:

- Reaching agreement on funding levels for each bill,
- Enacting a full-year continuing resolution, or
- Risking a government shutdown.

As the FY25 process unfolds, the Administration will also need to propose its FY26 budget. When there is a newly installed President, this release is typically delayed. The proposal is widely expected to include significant cuts to social programs.



Budget Reconciliation

A second key budgetary item is the aforementioned budget reconciliation bill—a package of spending and revenue changes that, if properly structured, can pass the Senate with just 51 votes. The House and Senate have had a difficult time agreeing on how to proceed with this legislation and it remains to be seen how they will reconcile efforts.

The attached chart distinguishes the differences between competing budget resolutions. The primary division among the proposals is whether to pursue two separate reconciliation bills—an approach backed by several Senators, as well as the House Freedom Caucus—or a single comprehensive package, favored by House Leadership. Notably, the House leadership's proposal, unveiled earlier today, swiftly faced opposition from the House Freedom Caucus. They are demanding deeper spending reductions—at least \$500 billion more—as well as stricter work requirements for Medicaid, food assistance programs, and other safety net initiatives. This fracture in approach could delay the House markup timeline.

<u>Make America Healthy Again:</u> Following the confirmation of the HHS Secretary Robert F. Kennedy Jr. on Feb. 13, President Trump signed an executive order establishing *The President's Commission to Make America Healthy Again*, with Kennedy serving as chair. Please find the EO attached.

State Update

<u>Gov. Greg Abbott Emergency Items:</u> Gov. Greg Abbott declared seven issues as emergency items in his State of the State address, meaning lawmakers may vote on legislation pertaining to these issues within the first 60 days of session.

Gov. Abbott's seven declared emergency items are:

- 1. Property Tax Relief
- 2. Texas-Size Investment in Water
- 3. Increasing Teacher Pay
- 4. Expanding Career Training
- 5. School Choice
- 6. Bail Reform
- 7. Dan Establishing the Texas Cyber Command

<u>Lt. Gov. Patrick Announces Session Priorities:</u> Lt. Gov. Dan Patrick released a list of 25 bills he's designated as 89th Regular Session priorities. He will soon release the remainder of his list for an eventual total of 40 priority pieces of legislation.

The list of priority bills thus far are as follows:

- Senate Bill 1 Senate's Budget for Texas
- Senate Bill 2 Providing School Choice
- Senate Bill 3 Banning THC in Texas
- Senate Bill 4 Increasing the Homestead Exemption to \$140,000 (\$150,000 for seniors/disabled)



- Senate Bill 5 Combatting Alzheimer's Establishing DPRIT (Dementia Prevention & Research Institute of Texas)
- Senate Bill 6 Increasing Texas' Electric Grid Reliability
- Senate Bill 7 Increasing Investments in Texas' Water Supply
- Senate Bill 8 Requiring Local Law Enforcement to Assist the Federal Government's Deportation Efforts
- Senate Bill 9 Reforming Bail Keeping Violent Criminals Off Our Streets
- Senate Bill 10 Placing the Ten Commandments in School
- Senate Bill 11 Protecting the Freedom to Pray in School
- Senate Bill 12 Establishing a Parental Bill of Rights in Public Education
- Senate Bill 13 Guarding Against Inappropriate Books in Public Schools
- Senate Bill 14 Texas DOGE Improving Government Efficiency
- Senate Bill 15 Removing Barriers to Affordable Housing
- Senate Bill 16 Stopping Non-Citizens from Voting
- Senate Bill 17 Stopping Foreign Adversaries' Land Grabs
- Senate Bill 18 Stopping Drag Time Story Hour
- Senate Bill 19 Stopping Taxpayer Dollars for Lobbyists
- Senate Bill 20 Stopping AI Child Pornography
- Senate Bill 21 Establishing the Texas Bitcoin Reserve
- Senate Bill 22 Establishing Texas as America's Film Capital
- Senate Bill 23 Removing the Cap on the Rainy Day Fund to Secure Texas' Long-term
 Financial Future
- Senate Bill 24 Educating Texas Students on the Horrors of Communism
- Senate Bill 25 Making Texas Healthy Again

<u>DEI and M/WBE Contracting:</u> State lawmakers have filed numerous pieces of legislation on Diversity, Equity, and Inclusion, but one that bears watching in particular is House Bill 167 by Rep. Carl Tepper of Lubbock.

This 15-page bill broadly prohibits DEI personnel or activity within state and local governmental entities, with some limited exceptions. Moreover, it prohibits governmental entities from allowing contractors preferential treatment based on "race, color, ethnicity, sex, gender identity, or sexual orientation."

All told there are at least seven bills that have thus far been filed prohibiting or restricting DEI in some way, though lawmakers are likely to file more before the bill filing deadline in March.

Although it is too soon to know which of these will move through the legislative process, or to what degree, the conventional wisdom is some language prohibiting or restricting DEI is likely to become law by the time lawmakers leave Austin.

Many industries are watching legislation on this matter. Governor Abbott did state in his State of the State address that **ANY** entity that receives **ANY** state funds shall not have a DEI program. Unsure how that relates to M/WBE programs. It is a wait and see situation.



Other than Rep. Tepper's HB 167, other bills prohibiting or restricting DEI are:

- House Bill 436 by Rep. Terri Leo-Wilson
- House Bill 1521 by Rep. Stan Gerdes / Senate Bill 689 by Sen. Bryan Hughes
- House Bill 2311 by Rep. Brian Harrison
- House Bill 2339 by Rep. Brian Harrison
- Senate Bill 946 by Sen. Bryan Hughes

Ad Valorem Taxation & Debt / Certificates of Obligation: Though more bills are likely to be filed, at present there are just under 200 pieces of legislation directly or indirectly impacting, to various degrees, the ability of hospital districts to levy and collect ad valorem taxes as well as their ability to issue and service debt.

Among the ever-growing list of bills to watch, several—in light of who the bill author is—warrant heightened attention.

As introduced, Senate Bill 749 by Sen. Louis Kolkhorst would lower hospital districts' voter-approval tax rate by applying a multiple of 1.035—versus the current 1.08—to the maintenance and operations (M&O) tax rate component.

Moreover, this bill revises current statute on calculating the unused increment rate for hospital districts by setting it to zero till 2028. This change would further reduce the voter-approval tax rate for hospital districts and limit the amount of discretion they currently have in this regard.

House Bill 1453 by Rep. Carl Tepper would strip hospital districts' ability to issue certificates of obligation in addition to placing additional hurdles on units of local government that would still retain this ability.

Finally—even though it only impacts school district taxes—Senate Bill 4 / Senate Joint Resolution 2 by Sen. Paul Bettencourt bears watching, as these were designated priorities by the Lt. Gov.

SB 4 / SJR 2 seek to increase the independent school district resident homestead exemption from \$100,000 to \$140,000 (\$150,000 for seniors/disabled).

Indeed, as SB 4 / SJR 2 enjoy emergency status, they have already passed out of the Senate and will soon be received by the House.

89th Texas Legislature Committee Assignments: Both the state House and Senate have announced committee assignments for the 89th Texas Legislature.

Relative to last session, House committees experienced substantial change pursuant to several factors, including a new Speaker, a large number of new members, and significant rule changes.

Though many committees can marginally impact Harris Health, the House committees—and subcommittees—of jurisdiction most relevant to Harris Health in the Texas House are chaired by:

- Rep. Greg Bonnen Appropriations
- Rep. Giovanni Capriglione Delivery of Government Efficiency
- Rep. Lacey Hull Human Services



- Rep. Jay Dean Insurance
- Rep. Cecil Bell Intergovernmental Affairs
 - o Rep. David Spiller S/C on County & Regional Government
- Rep. Gary VanDeaver Public Health
 - o Rep. James Frank S/C on Disease Prevention & Women's & Children's Health
- Rep. Angie Chen Button Trade, Workforce & Economic Development
 - o Rep. Oscar Longoria S/C on Workforce
- Rep. Morgan Meyer Ways & Means
 - o Rep. Chris Turner S/C on Property Tax Appraisals

Committee assignments in the Texas Senate were far more static relative to last session. The Senate committees of jurisdiction most relevant to Harris Health in the Texas Senate are chaired by:

- Sen. Joan Huffman Finance
- Sen. Lois Kolkhorst Health & Human Services
- Sen. Paul Bettencourt Local Government



SECTION-BY-SECTION DESCRIPTION

The fiscal year 2025 concurrent resolution on the budget establishes an overall budgetary framework. As required under the Congressional Budget Act of 1974 (Budget Act), this concurrent resolution includes aggregate levels of new budget authority, outlays, revenues, the amount by which revenues should be changed, the surplus or deficit, new budget authority and outlays for each major functional category, debt held by the public, and debt subject to the statutory limit. This concurrent resolution also sets appropriate budgetary levels for fiscal years 2026 through 2034.

This concurrent resolution also includes rulemaking provisions necessary to enforce the budget resolution, procedures for adjusting the budget resolution, provisions to accommodate legislation not assumed in the budget resolution, and certain policy assumptions underlying the budget resolution.

Section 1. Concurrent Resolution on the Budget for Fiscal Year 2025.

Subsection (a) establishes the budget for fiscal year 2025 and each of the nine ensuing fiscal years, 2026 through 2034, at the levels that appear subsequently in the resolution, replacing all prior concurrent resolutions on the budget. Section 301(a) of the Budget Act requires the budget resolution to establish budgetary levels for the fiscal year for which such resolution is adopted and for at least each of the four ensuing fiscal years.

Subsection (b) sets out the table of contents of the budget resolution.

TITLE I - RECOMMENDED LEVELS AND AMOUNTS

Section 101. Recommended Levels and Amounts.

Section 101, as required by section 301 of the Budget Act, establishes the recommended levels for revenue, the amount by which revenue should be changed, total new budget authority, total outlays, surpluses or deficits, debt subject to the statutory limit, and debt held by the public.

While the revenue level operates as a floor against which all revenue legislation is measured, the recommended levels of new budget authority and outlays serve as a ceiling for spending legislation. The surplus or deficit levels include only on-budget outlays and revenue.

Most outlays and receipts related to the Social Security program and United States Postal Service are not included because both accounts are statutorily off-budget.

Debt subject to the limit reflects the gross Federal debt, but excludes debt issued by the Federal Financing Bank or by non-Treasury agencies. Debt held by the public is the amount of debt issued and held by entities or individuals other than the U.S. Government and includes Treasury debt held by the Federal Reserve system.

Section 102. Major Functional Categories.

Section 102, as required by section 301(a) of the Budget Act, establishes the budgetary levels for each major functional category for fiscal year 2025 and for fiscal years 2026 through 2034.

These major functional categories include:

o50 National Defense

150 International Affairs

250 General Science, Space, and Technology

270 Energy

300 Natural Resources and Environment

350 Agriculture

370 Commerce and Housing Credit

400 Transportation

450 Community and Regional Development

500 Education, Training, Employment, and Social Services

550 Health

570 Medicare

600 Income Security

650 Social Security

700 Veterans Benefits and Services

750 Administration of Justice

800 General Government

900 Net Interest

920 Allowances

930 Government-Wide Savings and Adjustments

950 Undistributed Offsetting Receipts

TITLE II – BUDGET ENFORCEMENT IN THE HOUSE OF REPRESENTATIVES

Section 201. Point of Order Against Increasing Long-Term Direct Spending.

Subsection (a) establishes a point of order against the consideration of any measure, or amendment thereto or conference report thereon, that increases long—term net direct spending by more than \$2.5 billion in any of the four 10—fiscal year periods after the budget window.

Subsection (b) requires the Congressional Budget Office (CBO), to the extent practicable, to prepare an estimate of whether a measure reported by a committee, other than an appropriation measure, or amendment thereto or conference report thereon, would cause a net increase in direct spending in excess of \$2.5 billion in any of the four consecutive 10–fiscal year periods beginning with the first fiscal year that is 10 fiscal years after the current fiscal year.

Subsection (c) states that application of this section in the House shall not apply to any measure, or amendment thereto or conference report thereon, for which the Chair of the House Committee on the Budget adjusts the allocations, aggregates, or other budgetary levels in this concurrent resolution.

Subsection (d) affirms the authority of the Chair of the House Committee on the Budget to determine the estimates that are used to enforce this section.

Section 202. Limitation on Changes in Certain Mandatory Programs.

Section 202 strengthens the enforcement of the Committee on Appropriations' 302(a) allocation and 302(b) suballocations by limiting the amount Congress can use mandatory savings to meet the overall limit on discretionary spending.

Subsection (a) defines the term "change in mandatory programs" (CHIMPs) as a provision that: (1) would have been estimated as affecting direct spending or receipts under section 252 of the Balanced Budget and Emergency Deficit Control Act of 1985 (as in effect prior to September 30, 2002) if such provision were included in legislation other than appropriations acts; and (2) results in a net decrease in budget authority in the budget year but does not result in a net decrease in outlays over the period of the current year, budget year, and all fiscal years covered under the most recently agreed to budget resolution.

Subsection (b) establishes a point of order against any provision in a bill or joint resolution, making appropriations for a full fiscal year that proposes a change in mandatory programs, or amendment thereto or conference report thereon, that, if enacted, would cause the absolute value of all such changes in mandatory programs enacted in relation to a full fiscal year to be more than \$15 billion for fiscal year 2025.

Subsection (c) stipulates that, for purposes of this section, budgetary levels shall be determined based on estimates provided by the Chair of the House Committee on the Budget.

Section 203. Limitation on Advance Appropriations.

Section 203 establishes a limit on advance appropriations, defined as budget authority that first becomes effective following fiscal year 2025.

Subsection (a) establishes a general rule that prohibits the consideration of any general appropriation bill or bill or joint resolution continuing appropriations, or amendment thereto or conference report thereon, from providing advance appropriations.

Subsection (b) provides exceptions to the general rule for three separate lists of accounts included in the report accompanying this concurrent resolution – one for miscellaneous accounts identified under the heading "Accounts Identified for Advance Appropriations" in an aggregate amount not to exceed \$28.852 billion in new budget authority, one for veterans accounts under the heading "Veterans Accounts Identified for Advance Appropriations", and one for Indian health accounts under the heading "Indian Health Accounts Identified for Advance Appropriations" in an aggregate amount not to exceed the total budget authority provided for such accounts for fiscal year 2025 in bills or joint resolutions making appropriations for fiscal year 2025.

Subsection (c) defines an "advance appropriation" as any new discretionary budget authority provided in a general appropriation bill or bill or joint resolution continuing appropriations for fiscal year 2025, or any amendment thereto or conference report thereon, that first becomes available following fiscal year 2025.

Section 204. Estimates of Debt Service Costs.

Section 204 stipulates that the Chair of the House Committee on the Budget may direct CBO to include an estimate of debt service costs (if any) resulting from carrying out legislation in any estimate prepared pursuant to section 402 of the Budget Act. These estimates are advisory and will not be used to determine whether a measure complies with the limits established in the budget resolution and other budget rules. This requirement is not intended to apply to the authorization of discretionary programs nor to appropriation bills or joint resolutions but is intended to apply to changes in the authorization level of appropriated entitlements.

Section 205. Fair-Value Credit Estimates.

Subsection (a) directs CBO, at the request of the Chair Committee of the Budget, to include a supplemental fair-value estimate in its cost estimate for any legislation modifying or establishing a loan or loan guarantee program.

Subsection (b) requires CBO to include estimates of loan and loan guarantee programs on a fair-value and credit reform basis in its *The Budget and Economic Outlook* to the extent practicable.

Subsection (c) permits the Chair of the House Committee on the Budget to use the supplemental fair-value estimates provided pursuant to subsection (a) in determining whether legislation complies with the Budget Act and other budget rules.

4

Section 206. Adjustments for Improved Control of Budgetary Resources.

Subsection (a) permits the Chair of the House Committee on the Budget to adjust the budget resolution to accommodate legislation that subjects an existing mandatory spending program to annual appropriations. The Chair would increase the 302(a) allocation to the Committee on Appropriations by the amount of the new discretionary program and reduce the 302(a) allocation of the authorizing committee that reported the legislation. An adjustment would be made upon the enactment of the legislation.

Subsection (b) authorizes the Chair to make the adjustments under subsection (a) and affirms the Chair's authority to determine the estimates used to execute this section.

Section 207. Limitation on Transfers from the General Fund of the Treasury to the Highway Trust Fund.

Section 207 stipulates that legislation that transfers funds from the general fund of the Treasury to the Highway Trust Fund will count as new budget authority and outlays in the fiscal year the transfer occurs for purposes of budget enforcement.

Section 208. Budgetary Treatment of Administrative Expenses.

Subsection (a) provides that the administrative expenses of the Social Security Administration and the United States Postal Service are reflected in the allocation to the Committee on Appropriations even though both are technically off-budget. This language is necessary to ensure the Committee on Appropriations retains control over administrative expenses for these agencies through the annual appropriations process. This budgetary treatment is based on the long-term practice of the House and Senate Committees on the Budget.

Subsection (b) requires administrative expenses to be included in the cost estimates for the relevant appropriation measure, which are used to determine if a measure exceeds the budget resolution's spending limits.

Section 209. Application and Effect of Changes in Allocations and Aggregates.

Subsection (a) specifies the procedure for adjusting the levels established by the budget resolution under the reserve funds and other special procedures in this concurrent resolution. It provides that the adjustments apply while the legislation is under consideration and take effect upon enactment of the legislation. The Chair of the House Committee on the Budget must submit any adjustments to the budget resolution for printing in the Congressional Record.

Subsection (b) clarifies that the adjusted levels in the budget resolution are fully enforceable under the Budget Act and other budget rules.

Subsection (c) stipulates that the Chair of the House Committee on the Budget is the ultimate arbiter of the cost estimates for legislation used to enforce the budget resolution and budget rules.

Subsection (d) clarifies that legislation for which an adjustment to the budget resolution is made, such as those in the reserve funds in Title III, is not subject to the point of order set forth in clause 10 of rule XXI of the Rules of the House Representatives, commonly referred to as the House Cut-As-You-Go rule.

Section 210. Adjustments to Reflect Changes in Concepts and Definitions.

Section 210 authorizes the Chair of the House Committee on the Budget to adjust the appropriate budgetary levels of this concurrent resolution for any change in budgetary concepts and definitions in accordance with section 251(b)(1) of the Balanced Budget and Emergency Deficit Control Act of 1985.

Section 211. Adjustment for Changes in the Baseline.

Section 211 authorizes the Chair of the House Committee on the Budget to adjust the applicable budgetary levels in this concurrent resolution to reflect changes from CBO's update to its baseline for fiscal years 2025 to 2034.

Section 212. Exercise of Rulemaking Powers.

Section 212 affirms the adoption of this concurrent resolution is an exercise of the rulemaking power of the House of Representatives and that the House of Representatives has the constitutional right to change these rules.

TITLE III - RESERVE FUNDS IN THE HOUSE OF REPRESENTATIVES

Title III establishes four reserve funds, which are special procedures that provide the committee reporting specific legislation flexibility as to the timing and composition of offsets in the legislation.

Section 301. Deficit Neutral Reserve Fund for Investments in National Infrastructure.

Section 301 permits the Chair of the House Committee on the Budget to adjust the allocations, aggregates, and other appropriate levels in the budget resolution for legislation that invests in national infrastructure if such a measure would not increase the deficit for the period of fiscal years 2025 through 2034.

Section 302. Reserve Fund for Pro-Growth Tax Policies.

Section 302 permits the Chair of the House Committee on the Budget to adjust the allocations, aggregates, and other appropriate levels in the budget resolution for legislation reported by the Committee on Ways and Means that advances pro-growth tax reforms and simplifies the tax code.

Section 303. Deficit Neutral Reserve Fund for Medical Innovation.

Section 303 permits the Chair of the House Committee on the Budget to adjust the allocations, aggregates, and other appropriate levels in the budget resolution for legislation related to promoting

American medical innovation if such a measure would not increase the deficit for the period of fiscal years 2025 through 2034.

Section 304. Reserve Fund for Trade Agreements.

Section 304 permits the Chair of the House Committee on the Budget to adjust the allocations, aggregates, and other appropriate levels in the budget resolution for legislation reported by the Committee on Ways and Means that modifies tariffs on imports or implements trade agreements.

TITLE IV – POLICY STATEMENTS IN THE HOUSE OF REPRESENTATIVES

Section 401. Policy Statement on Economic Growth.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution to pursue policies that embrace the free market and promote economic growth through reducing federal spending and deficits; expanding American energy production by eliminating excessive burdens and barriers placed on energy producers; lowering taxes that discourage work, savings, and investment; deregulating the economy and enacting reforms to restrict future bureaucratic red tape; eliminating barriers to work that keep Americans on the sidelines; expanding free and fair trade; and restructuring health care to focus on patients and cures instead of administrative control.

Section 402. Policy Statement on Unauthorized Appropriations.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution that the House should enact legislation establishing a schedule for reauthorizing all Federal programs on a staggered basis with declining spending limits for each year a program is not reauthorized. Congress would be prohibited from funding programs above specified levels. These limits would gradually decrease the longer a program remained unauthorized. The policy further states that this new rule should be strictly enforced.

Section 403. Policy Statement on Improper Payments.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution to lower improper payment rates by \$1 trillion over the next decade by working closely with authorizing committees throughout the budget process to: require all Federal programs to annually report improper payment rates; streamline the processes and mechanisms through which information is shared between Federal agencies; task Federal agencies to implement technologies to identify patterns indicative of fraudulent activities or errors, and enhance eligibility verification processes to ensure that only qualified receipts

receive benefits; incentivize States and Federal agencies to comply with anti-fraud rules; and hold programs and agencies accountable for continued or prolonged failure to prevent and mitigate improper payments.

Section 404. Policy Statement on Budget Gimmick Reform.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution that the House should pursue reforms to the budget and appropriations process that eliminate the use of budget gimmicks, to ensure greater transparency, accountability, and fiscal discipline; specific mechanisms should be implemented to correct the current fiscal path and safeguard the Nation's economic future, such as the use of budgetary caps, stricter criteria for emergency spending, the prohibition of "bad CHIMPs," and the requirement to direct savings towards deficit reduction; the House supports efforts to engage in discussions that refine and enact these reforms to restore fiscal responsibility; and that by pursuing reform, the House reaffirms its commitment to fiscal responsibility and the elimination of practices that obscure the Federal budget's true condition.

Section 405. Policy Statement on Higher Education and the American Workforce.

Subsection (a) sets out findings on higher education.

Subsection (b) states it is the policy of this concurrent resolution to promote college affordability, access, and success by reserving Federal financial aid for those most in need and streamlining grant and loan programs to help students and families more easily assess their options for financing post-secondary education; removing regulatory barriers to reduce costs, increase access, and allow for innovative teaching models; increasing accountability for colleges and universities and ensuring students and taxpayers receive a return on investment; and championing policies that achieve these goals, including H.R. 6951, the College Cost Reduction Act.

Subsection (c) sets out findings on the American workforce.

Subsection (d) states it is the policy of this concurrent resolution to promote and advocate policies that benefit all American workers and businesses by further streamlining and consolidating Federal workforce development programs; empowering States with the flexibility to tailor funding and programs to the specific needs of their workforce and employers; and protecting employee freedom, promoting union accountability, supporting independent contractors, updating the Fair Labor Standards Act, and strengthening retirement security for workers and families.

Section 406. Policy Statement on Medicare.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution to support bipartisan solutions to save Medicare for those in or near retirement and strengthen the program's

solvency for future beneficiaries.

Section 407. Policy Statement on Promoting Patient-Centered Health Care Reform.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution that Americans deserve affordable, accessible, and personalized health care coverage that best fits their needs; Congress should enact policies that increase competition and transparency in health care markets by targeting the incentives that drive consolidation, including bipartisan legislation to equalize payments between hospital outpatient departments and independent physician offices; the American health care system should encourage research, development, and innovation in the medical sector, rather than stymic growth through overregulation; States should determine the parameters of acceptable private insurance plans based on the needs of their populations and retain control over other health care coverage standards; reforms should protect patients with pre-existing conditions and create greater parity between benefits offered through employers and those offered independently; States should have greater flexibility in determining their Medicaid programs and State Children's Health Insurance Programs; and States should have the flexibility to implement medical liability policies to best suit their needs.

Section 408. Policy Statement on Medical Innovation.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution that Congress should foster investment in health care innovation and maintain the Nation's world leadership status in medical science by encouraging competition; continue to support the critical work of medical innovators throughout the country through preserving free market incentives to conduct life-saving research and development; and unleash the power of private-sector medical innovation by removing regulatory obstacles and rejecting centralized government price controls for innovative cures and therapies that impede the development and adoption of new medical technology and pharmaceuticals and increase costs for patients.

Section 409. Policy Statement on Medicaid Work Requirements.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution that Congress should enact legislation, similar to the provisions in the House-passed Limit, Save, Grow Act of 2023 (H.R. 2811), that encourages able-bodied adults without dependents to work, actively seek work, participate in a job-training program, or do community service in order to receive Medicaid benefits; legislation implementing Medicaid work requirements could require able-bodied adults without dependents to work, engage in community service, or participate in a work training program for at least 80 hours per month to remain eligible for Medicaid; States should be given flexibility to determine the specific parameters of qualifying program participation and work-

equivalent experience; States should perform regular case checks to ensure taxpayer dollars are appropriately spent; and the Government Accountability Office or the U.S. Department of Health and Human Services Inspector General should annually audit State Medicaid programs to ensure proper reporting and prevent waste, fraud, and abuse.

Section 410. Policy Statement on Combating the Opioid Epidemic.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution that combatting opioid abuse using available budgetary resources remains a high priority; the House, in a bipartisan manner, should continue to examine the Federal response to the opioid abuse epidemic and support essential activities to reduce and prevent substance abuse; the Federal Government should secure the U.S. southern border to reduce the flow of fentanyl and other opioids into the Nation; the House should examine the specific threat posed by fentanyl and fentanyl analogues and support initiatives to reduce the supply of fentanyl in the U.S. and mitigate its deadly impact on American lives; the House should engage in oversight efforts to ensure taxpayer dollars intended to combat opioid abuse are spent appropriately and efficiently; and the House should collaborate with State, local, and tribal entities to develop a comprehensive strategy for addressing the opioid addiction crisis.

Section 411. Policy Statement on Border Security.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution to implement the policies set forth in H.R. 2, the Secure the Border Act of 2023; that it is imperative for Congress to dedicate appropriate resources to the Department of Homeland Security to deter and prevent illegal immigration, secure the border, and effectively control the entry and exit of all people; and that enforcing our borders and the rule of law should be a top priority for Congress.

Section 412. Policy Statement on the Supplemental Nutrition Assistance Program.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution that the House Committee on Agriculture should look for opportunities to strengthen measures related to employment, integrity, and health; and that benefit recipients and the American taxpayer deserve a program that provides for those in need while emphasizing pathways out of poverty.

Section 413. Policy Statement on Agriculture.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution that the House Committee on Agriculture should improve and strengthen the Farm Safety Net.

Section 414. Policy Statement on Bipartisan Fiscal Commission.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution that the House recommends the creation of a bipartisan fiscal commission, consistent with H.R. 5779, as ordered reported by the House Committee on the Budget.

Section 415. Policy Statement on Government Deregulation.

Subsection (a) sets out findings.

Subsection (b) states it is the policy of this concurrent resolution that Congress should examine ways to relieve the burdens of overregulation throughout the Federal Government; House Republicans remain at the ready to promote initiatives that will reduce government bureaucracy, restore Article I congressional power, enhance federalism, and increase economic prosperity through deregulation; ensure that once harmful and costly regulations are repealed, they cannot be reimposed; develop policies with authorizing committees that will demonstrate the contributions to economic growth and reducing government spending embodied in legislation like the Regulations from the Executive in Need of Scrutiny (REINS) Act; and reestablish the role of Congress in checking executive branch overreach in the future.



02/13/25

EXECUTIVE ORDER

ESTABLISHING THE PRESIDENT'S MAKE AMERICA HEALTHY AGAIN COMMISSION

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered:

Section 1. Purpose. American life expectancy significantly lags behind other developed countries, with pre COVID-19 United States life expectancy averaging 78.8 years and comparable countries averaging 82.6 years. This equates to 1.25 billion fewer life years for the United States population. Six in 10 Americans have at least one chronic disease, and four in 10 have two or more chronic diseases. An estimated one in five United States adults lives with a mental illness.

These realities become even more painful when contrasted with nations around the globe. Across 204 countries and territories, the United States had the highest age-standardized incidence rate of cancer in 2021, nearly double the next-highest rate. Further, from 1990-2021, the United States experienced an 88 percent increase in cancer, the largest percentage increase of any country evaluated. In 2021, asthma was more than twice as common in the United States than most of Europe, Asia, or Africa. Autism spectrum disorders had the highest prevalence in high-income countries, including the United States, in 2021. Similarly, autoimmune diseases such as inflammatory bowel disease, psoriasis, and multiple sclerosis are more commonly diagnosed in high-income areas such as Europe and North America.

Overall, the global comparison data demonstrates that the health of Americans is on an alarming trajectory that requires immediate action.

This concern applies urgently to America's children. In 2022, an estimated 30 million children (40.7 percent) had at least one health condition, such as allergies, asthma, or an autoimmune disease. Autism spectrum disorder now affects 1 in 36 children in the United States -- a staggering increase from rates of 1 to 4 out of 10,000 children identified with the condition during the 1980s. Eighteen percent of late adolescents and young adults have fatty liver disease, close to 30 percent of adolescents are prediabetic, and more than 40 percent of adolescents are overweight or obese.

These health burdens have continued to increase alongside the increased prescription of medication. For example, in the case of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder, over 3.4 million children are now on medication for the disorder -- up from 3.2 million children in 2019-2020 -- and the number of children being diagnosed with the condition continues to rise.

This poses a dire threat to the American people and our way of life. Seventy-seven percent of young adults do not qualify for the military based in large part on their health scores. Ninety percent of the Nation's \$4.5 trillion in annual healthcare expenditures is for people with chronic and mental health conditions. In short, Americans of all ages are becoming sicker, beset by illnesses that our medical system is not addressing effectively. These trends harm us, our economy, and our security.

To fully address the growing health crisis in America, we must redirect our national focus, in the public and private sectors, toward understanding and drastically lowering chronic disease rates and ending childhood chronic disease. This includes fresh thinking on nutrition, physical activity, healthy lifestyles, over-reliance on medication and treatments, the effects of new technological habits, environmental impacts, and food and drug quality and safety. We must restore the integrity of the scientific process by protecting expert recommendations from inappropriate influence and increasing transparency regarding existing data. We must ensure our healthcare system promotes health rather than just managing disease.

- Sec. 2. Policy. It shall be the policy of the Federal Government to aggressively combat the critical health challenges facing our citizens, including the rising rates of mental health disorders, obesity, diabetes, and other chronic diseases. To do so, executive departments and agencies (agencies) that address health or healthcare must focus on reversing chronic disease. Under this policy:
- (a) all federally funded health research should empower

 Americans through transparency and open-source data, and should avoid

 or eliminate conflicts of interest that skew outcomes and perpetuate

 distrust;
- (b) the National Institutes of Health and other health-related research funded by the Federal Government should prioritize gold-standard research on the root causes of why Americans are getting sick;
- (c) agencies shall work with farmers to ensure that United States food is the healthiest, most abundant, and most affordable in the world; and
- (d) agencies shall ensure the availability of expanded treatment options and the flexibility for health insurance coverage to provide benefits that support beneficial lifestyle changes and disease prevention.
- Sec. 3. Establishment and Composition of the President's Make

 America Healthy Again Commission. (a) There is hereby

 established the President's Make America Healthy Again Commission

(Commission), chaired by the Secretary of Health and Human Services (Chair), with the Assistant to the President for Domestic Policy serving as Executive Director (Executive Director).

- (b) In addition to the Chair and the Executive Director, the Commission shall include the following officials, or their designees:
 - (i) the Secretary of Agriculture;
 - (ii) the Secretary of Housing and Urban Development;
 - (iii) the Secretary of Education;
 - (iv) the Secretary of Veterans Affairs;
- $\qquad \qquad \text{(v)} \qquad \qquad \text{the Administrator of the Environmental Protection} \\ \text{Agency;}$
 - (vi) the Director of the Office of Management and Budget;
- (vii) the Assistant to the President and Deputy Chief of
 Staff for Policy;
 - (viii) the Director of the National Economic Council;
 - (ix) the Chairman of the Council of Economic Advisers;
- $\qquad \qquad \text{(x)} \qquad \qquad \text{the Director of the Office of Science and Technology} \\ \text{Policy;}$
 - (xi) the Commissioner of Food and Drugs;
- $\hbox{(xii)} \qquad \hbox{the Director for the Centers for Disease Control and } \\ \\ \hbox{Prevention;}$
- $% \left(1\right) =0$ (xiii) the Director of the National Institutes of Health; and
- $\,$ (xiv) other members of my Administration invited to participate, at the discretion of the Chair and the Executive Director.

- Sec. 4. Fighting Childhood Chronic Disease. The initial mission of the Commission shall be to advise and assist the President on how best to exercise his authority to address the childhood chronic disease crisis. Therefore, the Commission shall:
- (a) study the scope of the childhood chronic disease crisis and any potential contributing causes, including the American diet, absorption of toxic material, medical treatments, lifestyle, environmental factors, Government policies, food production techniques, electromagnetic radiation, and corporate influence or cronyism;
- (b) advise and assist the President on informing the American people regarding the childhood chronic disease crisis, using transparent and clear facts; and
- (c) provide to the President Government-wide recommendations on policy and strategy related to addressing the identified contributing causes of and ending the childhood chronic disease crisis.
- Sec. 5. Initial Assessment and Strategy from the Make America

 Healthy Again Commission. (a) Make our Children Healthy Again

 Assessment. Within 100 days of the date of this order, the Commission shall submit to the President, through the Chair and the Executive

 Director, the Make Our Children Healthy Again Assessment, which shall:
- (i) identify and describe childhood chronic disease in America compared to other countries;
- (ii) assess the threat that potential over-utilization of medication, certain food ingredients, certain chemicals, and certain other exposures pose to children with respect to chronic inflammation

or other established mechanisms of disease, using rigorous and transparent data, including international comparisons;

- (iii) assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors, antipsychotics, mood stabilizers, stimulants, and weight-loss drugs;
- (iv) identify and report on best practices for preventing childhood health issues, including through proper nutrition and the promotion of healthy lifestyles;
- (v) evaluate the effectiveness of existing educational programs with regard to nutrition, physical activity, and mental health for children;
- (vi) identify and evaluate existing Federal programs and funding intended to prevent and treat childhood health issues for their scope and effectiveness;
- (vii) ensure transparency of all current data and unpublished analyses related to the childhood chronic disease crisis, consistent with applicable law;
- (viii) evaluate the effectiveness of current Federal Government childhood health data and metrics, including those from the Federal Interagency Forum on Child and Family Statistics and the National Survey of Children's Health;
- (ix) restore the integrity of science, including by eliminating undue industry influence, releasing findings and underlying data to the maximum extent permitted under applicable law, and increasing methodological rigor; and
- (x) establish a framework for transparency and ethics review in industry-funded projects.

- (b) Make our Children Healthy Again Strategy. Within 180 days of the date of this order, the Commission shall submit to the President, through the Chair and the Executive Director, a Make Our Children Healthy Again Strategy (Strategy), based on the findings from the Make Our Children Healthy Again Assessment described in subsection (a) of this section. The Strategy shall address appropriately restructuring the Federal Government's response to the childhood chronic disease crisis, including by ending Federal practices that exacerbate the health crisis or unsuccessfully attempt to address it, and by adding powerful new solutions that will end childhood chronic disease.
- (c) The Chair may hold public hearings, meetings, roundtables, and similar events, as appropriate, and may receive expert input from leaders in public health and Government accountability.
- <u>Sec. 6. Additional Reports.</u> (a) Following the submission to the President of the Strategy, and any final strategy reports thereafter, the Chair and the Executive Director shall recommend to the President updates to the Commission's mission, including desired reports.
- (b) The Commission shall not reconvene, following submission of the Strategy, until an updated mission is submitted to the President through the Executive Director.
- $\underline{\text{Sec. }7}$. $\underline{\text{General Provisions}}$. (a) Nothing in this order shall be construed to impair or otherwise affect:
 - (i) the authority granted by law to an executive department or

agency, or the head thereof; or

- (ii) the functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals.
- (b) This order shall be implemented consistent with applicable law and subject to the availability of appropriations.
- (c) This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.

THE WHITE HOUSE,

February 13, 2025.

To ensure uninterrupted delivery of these emails, please add press@mail.whitehouse.gov to your Address Book and/or Safe Sender list.

The Office of Communications \cdot 1600 Pennsylvania Ave NW \cdot Washington, DC 20500-0005 \cdot USA \cdot 202-456-1111

Privacy Policy | Unsubscribe

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Review and Acceptance of the Following Report for the Healthcare for the Homeless
Program as Required by the United States Department of Health and Human Services
Which Provides Funding to the Harris County Hospital District d/b/a/Harris Health System
to Provide Health Services to Persons Experiencing Homelessness under Section 330(h)
of the Public Health Service Act

Attached for review and acceptance:

• HCHP February 2025 Operational Updates

Administration recommends that the Board accept the Healthcare for the Homeless Program Report as required by the United States Department of Health and Human Services which provides funding to the Harris County Hospital District d/b/a/ Harris Health System to provide health services to persons experiencing homelessness under Section 330 (h) of the Public Health Service Act.

Jennifer Small, AuD, MBA, CCC-A

EVP / Administrator, Ambulatory Care Services

Health Care for the Homeless Monthly Update Report – February 2025

Jennifer Small AuD, MBA, CCC-A, Executive Vice President, Ambulatory Care Services

Tracey Burdine, Director, Health Care for the Homeless Program





Agenda

- Operational Update
 - ➤ Productivity Report
 - ➤ Sliding Fee Scale

HARRISHEALTH

Patients Served

HRSA Unduplicated Patients Target:

7,250

30,496

YTD Unduplicated Patients:
1,073

HRSA Completed Visit Patients
Target:


7,250

30,496

YTD Total Completed Visits:
2,158





Unduplicated Patients



Completed Visits









2025 HCHP Sliding Fee Scale

- We are modifying the Health Care for the Homeless Program Sliding Fee Scale based on the 2025 Federal Poverty Guidelines issued on January 17, 2025.
- The modified Sliding Fee Scale will be effective March 1,2025.
- This sliding fee scale only applies to the Health Care for the Homeless
 Program



2025 Sliding Fee Scale

Health Care for the Homeless Program

Effective March 2025

	HARRIS HEALTH - HEALTH CARE FOR THE HOMELESS PROGRAM - FAP																	
Family																		
Size	HCHP Assist	ance Ca	tegory A	A (100%)	HCHP Assistance Category B (150%)				HCHP Assistance Category C (185%)				HCHP Assistance Category D (200%)				Self-pay	
	Flat F	ee Amo	unt \$	0	Flat Fee Amount \$1				Flat Fee Amount \$2				Flat Fee Amount \$3					
	Min income Ma	Min income Max income FF		PL	Min Income	Max Income	ome FPL		Min Income	Max Income	FI	PL	Min Income	Max Income	FPL	Min Inc	ome	FPL
1	0 \$	1,304	0%	100. 00%	\$ 1,304.01	\$ 1,956	100.01%	150.00%	\$ 1,956.01	\$ 2,413	150.01%	185.00%	\$ 2,413.01	\$ 2,608	185.01% 200	0.00% \$ 2,60	8.01	200.01% and >
2	0 \$	1,763	0%	100. 00%	\$ 1,763.01	\$ 2,644	100.01%	150.00%	\$ 2,644.01	\$ 3,261	150.01%	185.00%	\$ 3,261.01	\$ 3,525	185.01% 200	0.00% \$ 3,52	5.01	200.01% and >
3	0 \$	2,221	0%	100. 00%	\$ 2,221.01	\$ 3,331	100.01%	150.00%	\$ 3,331.01	\$ 4,109	150.01%	185.00%	\$ 4,109.01	\$ 4,442	185.01% 200	0.00% \$ 4,44	2.01	200.01% and >
4	0 \$	2,679	0%	100. 00%	\$ 2,679.01	\$ 4,019	100.01%	150.00%	\$ 4,019.01	\$ 4,956	150.01%	185.00%	\$ 4,956.01	\$ 5,358	185.01% 200	0.00% \$ 5,35	8.01	200.01% and >
Ę	0 \$	3,138	0%	100. 00%	\$ 3,138.01	\$ 4,706	100.01%	150.00%	\$ 4,706.01	\$ 5,804	150.01%	185.00%	\$ 5,804.01	\$ 6,275	185.01% 200	0.00% \$ 6,27	5.01	200.01% and >
6	0 \$	3,596	0%	100. 00%	\$ 3,596.01	\$ 5,394	100.01%	150.00%	\$ 5,394.01	\$ 6,652	150.01%	185.00%	\$ 6,652.01	\$ 7,192	185.01% 200	0.00% \$ 7,19	2.01	200.01% and >
7	0 \$	4,054	0%	100. 00%	\$ 4,054.01	\$ 6,081	100.01%	150.00%	\$ 6,081.01	\$ 7,500	150.01%	185.00%	\$ 7,500.01	\$ 8,108	185.01% 200	0.00% \$ 8,10	8.01	200.01% and >
8	0 \$	4,513	0%	100. 00%	\$ 4,513.01	\$ 6,769	100.01%	150.00%	\$ 6,769.01	\$ 8,348	150.01%	185.00%	\$ 8,348.01	\$ 9,025	185.01% 200	0.00% \$ 9,02	5.01	200.01% and >
9	0 \$	4,971	0%	100. 00%	\$ 4,971.01	\$ 7,456	100.01%	150.00%	\$ 7,456.01	\$ 9,196	150.01%	185.00%	\$ 9,196.01	\$ 9,942	185.01% 200	0.00% \$ 9,94	2.01	200.01% and >
10	0 \$	5,429	0%	100. 00%	\$ 5,429.01	\$ 8,144	100.01%	150.00%	\$ 8,144.01	\$ 10,004	150.01%	185.00%	\$ 10,004.01	\$ 10,858	185.01% 200	0.00% \$ 10,85	8.01	200.01% and >
11	0 \$	5,888	0%	100. 00%	\$ 5,888.01	\$ 8,831	100.01%	150.00%	\$ 8,831.01	\$ 10,892	150.01%	185.00%	\$ 10,892.01	\$ 11,775	185.01% 200	0.00% \$ 11,77	5.01	200.01% and >
12	0 \$	6,346	0%	100. 00%	\$ 6,346.01	\$ 9,519	100.01%	150.00%	\$ 9,519.01	\$ 11,740	150.01%	185.00%	\$ 11,740.01	\$ 12,692	185.01% 200	0.00% \$ 12,69	2.01	200.01% and >
13	0 \$	6,804	0%	100. 00%	\$ 6,804.01	\$ 10,206	100.01%	150.00%	\$ 10,206.01	\$ 12,588	150.01%	185.00%	\$ 12,588.01	\$ 13,608	185.01% 200	0.00% \$ 13,60	8.01	200.01% and >
14	0 \$	7,263	0%	100. 00%	\$ 7,263.01	\$ 10,894	100.01%	150.00%	\$ 10,894.01	\$ 13,436	150.01%	185.00%	\$ 13,436.01	\$ 14,525	185.01% 200	0.00% \$ 14,52	5.01	200.01% and >
15	0 \$	7,721	0%	100. 00%	\$ 7,721.01	\$ 11,581	100.01%	150.00%	\$ 11,581.01	\$ 14,284	150.01%	185.00%	\$ 14,284.01	\$ 15,442	185.01% 200	0.00% \$ 15,44	2.01	200.01% and >

Patient responsibility for categories A = \$0, B = \$1, C = \$2, D = \$3

Poverty level based on 2025 Federal Poverty Guidelines issued 01/2025.

Income figures represent gross monthly income.

This sliding scale applies only to patients of the Health Care for the Homeless Program.



HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Consideration of Approval of the HCHP 2025 Sliding Fee Scale

Attached for review and approval:

• HCHP 2025 Sliding Fee Scale

Administration recommends that the Board approve the Healthcare for the Homeless Program Report as required by the United States Department of Health and Human Services which provides funding to the Harris County Hospital District d/b/a/ Harris Health System to provide health services to persons experiencing homelessness under Section 330 (h) of the Public Health Service Act.

Jennifer Small, AuD, MBA, CCC-A

EVP / Administrator, Ambulatory Care Services

Health Care for the Homeless Program Effective March 2025

HARRIS HEALTH - HEALTH CARE FOR THE HOMELESS PROGRAM - FAP														
Family Size	HCHP Assistance Category A (1	00%)	HCHP Assistance Category B (150%)				HCHP As	sistance Cat	egory C (185%)	HCHP As	ssistance Cat	Self-pay		
	Flat Fee Amount \$0		Flat Fee Amount \$1				F	lat Fee Amοι	ınt \$2	F	lat Fee Amou			
	Min income Max income FP	Ĺ	Min Income	Max Income	FPL	-	Min Income	Max Income	FPL	Min Income	Max Income	FPL	Min Income	FPL
1	0 \$ 1,304 0% 1	100. 00%	\$ 1,304.01	\$ 1,956	100.01%	150.00%	\$ 1,956.01	\$ 2,413	150.01% 185.00%	\$ 2,413.01	\$ 2,608	185.01% 200.00%	\$ 2,608.01	200.01% and >
2	0 \$ 1,763 0% 1	100.00%	\$ 1,763.01	\$ 2,644	100.01%	150.00%	\$ 2,644.01	\$ 3,261	150.01% 185.00%	\$ 3,261.01	\$ 3,525	185.01% 200.00%	\$ 3,525.01	200.01% and >
3	0 \$ 2,221 0% 1	100.00%	\$ 2,221.01	\$ 3,331	100.01%	150.00%	\$ 3,331.01	\$ 4,109	150.01% 185.00%	\$ 4,109.01	\$ 4,442	185.01% 200.00%	\$ 4,442.01	200.01% and >
4	0 \$ 2,679 0% 1	100.00%	\$ 2,679.01	\$ 4,019	100.01%	150.00%	\$ 4,019.01	\$ 4,956	150.01% 185.00%	\$ 4,956.01	\$ 5,358	185.01% 200.00%	\$ 5,358.01	200.01% and >
5	0 \$ 3,138 0% 1	100.00%	\$ 3,138.01	\$ 4,706	100.01%	150.00%	\$ 4,706.01	\$ 5,804	150.01% 185.00%	\$ 5,804.01	\$ 6,275	185.01% 200.00%	\$ 6,275.01	200.01% and >
6	0 \$ 3,596 0% 1	100. 00%	\$ 3,596.01	\$ 5,394	100.01%	150.00%	\$ 5,394.01	\$ 6,652	150.01% 185.00%	\$ 6,652.01	\$ 7,192	185.01% 200.00%	\$ 7,192.01	200.01% and >
7	0 \$ 4,054 0% 1	100. 00%	\$ 4,054.01	\$ 6,081	100.01%	150.00%	\$ 6,081.01	\$ 7,500	150.01% 185.00%	\$ 7,500.01	\$ 8,108	185.01% 200.00%	\$ 8,108.01	200.01% and >
8	0 \$ 4,513 0% 1	100.00%	\$ 4,513.01	\$ 6,769	100.01%	150.00%	\$ 6,769.01	\$ 8,348	150.01% 185.00%	\$ 8,348.01	\$ 9,025	185.01% 200.00%	\$ 9,025.01	200.01% and >
9	0 \$ 4,971 0% 1	100.00%	\$ 4,971.01	\$ 7,456	100.01%	150.00%	\$ 7,456.01	\$ 9,196	150.01% 185.00%	\$ 9,196.01	\$ 9,942	185.01% 200.00%	\$ 9,942.01	200.01% and >
10	0 \$ 5,429 0% 1	100.00%	\$ 5,429.01	\$ 8,144	100.01%	150.00%	\$ 8,144.01	\$ 10,004	150.01% 185.00%	\$ 10,004.01	\$ 10,858	185.01% 200.00%	\$ 10,858.01	200.01% and >
11	0 \$ 5,888 0% 1	100.00%	\$ 5,888.01	\$ 8,831	100.01%	150.00%	\$ 8,831.01	\$ 10,892	150.01% 185.00%	\$ 10,892.01	\$ 11,775	185.01% 200.00%	\$ 11,775.01	200.01% and >
12	0 \$ 6,346 0% 1	100. 00%	\$ 6,346.01	\$ 9,519	100.01%	150.00%	\$ 9,519.01	\$ 11,740	150.01% 185.00%	\$ 11,740.01	\$ 12,692	185.01% 200.00%	\$ 12,692.01	200.01% and >
13	0 \$ 6,804 0% 1	100. 00%	\$ 6,804.01	\$ 10,206	100.01%	150.00%	\$ 10,206.01	\$ 12,588	150.01% 185.00%	\$ 12,588.01	\$ 13,608	185.01% 200.00%	\$ 13,608.01	200.01% and >
14	0 \$ 7,263 0% 1	100. 00%	\$ 7,263.01	\$ 10,894	100.01%	150.00%	\$ 10,894.01	\$ 13,436	150.01% 185.00%	\$ 13,436.01	\$ 14,525	185.01% 200.00%	\$ 14,525.01	200.01% and >
15	0 \$ 7,721 0% 1	100. 00%	\$ 7,721.01	\$ 11,581	100.01%	150.00%	\$ 11,581.01	\$ 14,284	150.01% 185.00%	\$ 14,284.01	\$ 15,442	185.01% 200.00%	\$ 15,442.01	200.01% and >

Patient responsibility for categories A = \$0, B = \$1, C = \$2, D = \$3

Poverty level based on 2025 Federal Poverty Guidelines issued 01/2025.
Income figures represent gross monthly income.
This sliding scale applies only to patients of the Health Care for the Homeless Program.

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Executive Session

Review of the Health Care for the Homeless Program (HCHP) Director's Performance Evaluation, Pursuant to Tex. Gov't Code Ann. §551.085, Including Consideration of Approval of the Performance Evaluation Upon Return to Open Session.

Jennifer Small, AuD, MBA, CCC-A

EVP / Administrator, Ambulatory Care Services

HARRISHEALTH

Meeting of the Board of Trustees

- Pages 308 - 309 Were Intentionally Left Blank -

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Executive Session

Review of the Community Health Choice, Inc. and Community Health Choice Texas, Inc. unaudited, financial performance for the 12-month year ending December 31, 2024, pursuant to Tex. Gov't Code Ann. §551.085.

Anna Mateja

Chief Financial Officer

Community Health Choice, Inc.

Community Health Choice Texas, Inc.

Victoria Nikitin

EVP & Chief Financial Officer

Harris Health

HARRISHEALTH

Meeting of the Board of Trustees

- Pages 311 - 319 Were Intentionally Left Blank -

HARRISHEALTH

Meeting of the Board of Trustees

Thursday, February 27, 2025

Executive Session

Consultation with Attorney Regarding Community Health Choice Litigation Settlement, Pursuant to Tex. Gov't Code Ann. §§551.071, 551.085, and Possible Action Upon Return to Open Session, Including Settlement of Litigation.

Sara Thomas

Chief Legal Officer/Division Director Harris County Attorney's Office Harris Health

HARRISHEALTH

Meeting of the Board of Trustees

- Pages 321 - 322 Were Intentionally Left Blank -